Design, synthesis, conformational study and biological evaluation of structural analogues of native bioactive peptides by Torino, Domenica

  
 
 
 
 
 
 
 
 
 
 
PhD Thesis in Pharmaceutical Sciences 
XXII cycle 
 
 
 
 
Design, synthesis, conformational study and 
biological evaluation of structural analogues 
of native bioactive peptides 
 
 
 
 
Tutors    PhD student 
 
Chiar.mo Prof. Gino LUCENTE       Dr. Domenica TORINO 
Chiar.mo Prof. Enrico MORERA 
 
 
 
2006-2009 
Dipartimento di Chimica 
e Tecnologie del Farmaco 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
To my mother 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Contents 
 
INTRODUCTION 1 
 
Peptides and peptidomimetics 1 
Strategies in the design of peptidomimetics 6 
Subject of present research 7 
References 10 
 
CHAPTER 1 13 
Endomorphins (EMs) and their synthetic analogues 13 
 
1.1 The pain 13 
1.1.1 Endogenous opioid peptides 17 
1.1.2 Opioid receptors 22 
1.2 Stucture-activity   relationship   studies   and   bioactive 
conformation of EMs 26 
1.2.1 Pharmacophoric groups in EMs 27 
1.2.2 Bioactive conformation of EMs 29 
1.3 Adopted structural modification strategies 32 
1.4 Synthesis   and   evaluation   of   new   endomorphin 
analogues modified at the Pro2 residue 33 
1.4.1 Chemistry 37 
1.4.2 Results and conclusions 38 
1.4.3 Experimental section 40 
1.4.3.1 Chemistry. General procedures 41 
1.4.3.2 Synthesis 42 
1.4.3.3 Biological assays 59 
1.5 Synthesis  and  evaluation  of  new  endomorphin-2 
analogues containing (Z)-α,β-dehydrophenilalanine (∆ZPhe) 
residues  60 
1.5.1 Chemistry 63 
1.5.2 Results and discussion 65 
1.5.3 Conclusions 69 
1.5.4 Experimental section 70 
1.5.4.1 Chemistry. General procedures 71 
1.5.4.2 Synthesis 72 
1.5.4.3 X-ray crystallographic data for 8 80 
  
1.5.4.4 Biological Assays 81 
References 82 
 
CHAPTER 2 91 
Chemotactic N-formyl peptides 91 
 
2.1 Chemotaxis 91 
2.1.1 The role of neutrophils in acute inflammation 92 
2.1.2 Formyl peptide receptors (FPRs) 95 
2.2 Structure-activity relationship of fMLF 100 
2.3 Hybrid α/β-peptides: For-Met-Leu-Phe-OMe analogues 
containing geminally disubstituted β2,2- and β3,3-amino acids 
at the central position 104 
2.3.1 Chemistry 107 
2.3.2 Conformational studies 108 
2.3.3 Biological results 111 
2.3.4 Discussion and conclusions 113 
2.3.5 Experimental section 114 
2.3.5.1 Synthesis 115 
2.3.5.2 Biological assays 119 
2.4 Chemotactic tripeptides incorporating at position 2 α-
amino acid residues with unsaturated side chains 122 
2.4.1 Chemistry 125 
2.4.2 Conformational studies 127 
2.4.3 Biological results 133 
2.4.4 Conclusions 135 
2.4.5 Experimental section 137 
2.4.5.1 Chemistry. General procedure 138 
2.4.5.2 Synthesis 139 
2.4.5.3 Biological assays 146 
2.5 X-ray  crystal  structure  and  conformation  of  N-(tert-
butyloxycarbonyl)-L-methionyl-(1-aminocyclo- pent-3-ene-
1-carbonyl)-L-phenylalanine methylester (Boc0-Met1-Cpg2-
Phe3-OMe) 149 
2.5.1 Crystal state conformational analysis 151 
2.5.2 Conclusions 156 
2.5.3 Experimental section 156 
2.5.3.1 X-ray crystallography 156 
 2.5.3.2 Synthesis 158 
2.6 Synthesis and bioactivity of chemotactic tetrapeptides: 
fMLF-OMe analogues incorporating spacer amino acids at 
the lateral positions 159 
2.6.1 Chemistry 162 
2.6.2 Biological results 165 
2.6.3 Conclusions 169 
2.6.4 Experimental section 172 
2.6.4.1 Chemistry. General procedure 173 
2.6.4.2 Synthesis 174 
2.6.4.3 Biological assays 183 
2.7 Novel chemotactic For-Met-Leu-Phe-OMe (fMLF-OMe) 
analogues based on Met residue replacement by 4-amino-
proline scaffold: Synthesis and bioactivity 187 
2.7.1 Chemistry 190 
2.7.2 Biological results 194 
2.7.2.1 Agonism 194 
2.7.2.2 Antagonism 196 
2.7.3 Conclusions 198 
2.7.4 Experimental section 200 
2.7.4.1 Chemistry. General procedure 201 
2.7.4.2 Synthesis 202 
2.7.4.3 Biological assays 214 
References 217 
 
CHAPTER 3 229 
(S)-Aziridine-2-carboxylic acid. A constrained and 
reactive amino acid unit for the synthesis of bioactive 
peptide analogues 229 
 
3.1 Reactivity of aziridine system 229 
3.2 (S)-Aziridine-2-carboxylic acid containing peptides 231 
3.3 On   the   synthesis   of   (S)-Aziridine-2-carboxylic  acid 
containing bioactive peptides 235 
3.3.1 X-ray crystal structure of tripeptide Trt-Azy-Phe-
Phe-NH2 240 
3.4 Conclusions 241 
3.5 Experimental section 242 
  
3.5.1 Chemistry. General procedures 242 
3.5.2 Synthesis 243 
References 250 
 
Papers  
 
Acknowledgments  
       
   
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
INTRODUCTION 
 
Peptides and peptidomimetics 
 
Peptides play an important role in the organism as 
neurotransmitters, neuromodulators, hormones, antibiotics, 
growth promoters and inhibitors, cytokines, antigens, etc. They 
are known to influence essentially all vital physiological 
processes via inter- and intra-cellular communication, and signal 
transduction, mediated through various classes of receptors. The 
study of the peptides has acquired a key role in medicinal 
chemistry and a multitude of biologically active peptides have 
been discovered and characterized during the last decades. 
The main objective of the peptide research is centered on 
elucidation and understanding of the relationships between the 
peptide three-dimensional structure (3D) and its biological 
activity. Since the initial event for the biological response is the 
molecular recognition, it is necessary that a portion of the 
surface of the ligand (pharmacophore), obtained by studying its 
3D structure, can interact with a complementary surface of the 
acceptor/receptor molecule. The pharmacophore can involve 
both a continuous sequence of amino acids (sychnologic 
organization) or amino acid residues separated from each other 
within the primary structure (rhegnylogic organization) but near 
on the surface by the 3D structure of the polypeptide. In either 
cases, the peptide backbone functions as a scaffold for the key 
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side chain groups involved in the interaction and, in some cases, 
also acts as a hydrogen bond donor and/or acceptor in the 
molecular recognition (binding). In all cases, the side chain 
moieties involved directly in the binding are critical for the 
interaction, and their 3D architecture (topography) and 
stereoelectronic properties are needed for an efficient molecular 
recognition.1 
Although native biologically active peptides have a great 
potential for therapeutical applications, their use as drugs is 
limited by different factors: a) low metabolic stability towards 
proteolysis in the grastrointestinal tract and in serum; b) poor 
absorption after oral ingestion, in particular due to their 
relatively high molecular weight and/or the lack of specific 
transport systems; c) rapid excretion through liver and kidneys.2 
Furthermore, a) the peptides generally are relatively small, 
conformationally flexible, molecule. Their interaction with 
different receptors can then cause undesired effects in several 
types of cells and organ systems. Peptide receptors and/or 
isoreceptors are in fact widely distributed in the organisms 
(Figure 1); b) the primary structure and conformation of most 
membrane-bound peptide receptors is still not known and efforts 
to clone these systems have a slow progress; c) the 3D structure 
of peptide ligands, either free or bound to the receptor/acceptor, 
is not generally known.3 
  Introduction 
 
3 
 
Figure 1.  Peptide in conformational equilibrium. 
 
In order to circumvent the above cited limitations, connected 
with the use of peptides as therapeutic agents, peptidomimetics 
also known “Trojan horses”, can help to solve the problem. 
These compounds can be described, at the molecular level, as 
models designed so as to have pharmacophoric stereostructural 
elements able to mimic the correspondent 3D elements of native 
peptides in their 3D space. These structural features can 
improve, with equivalent or superior efficacy, the binding, the 
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biological activity as agonist (or antagonist), and the 
understanding of the structure-activity relationships. In 
comparison with native peptides, peptidomimetics may show 
higher receptor affinity and selectivity, higher metabolic 
stability, better bioavailability and enhanced duration of action. 
 
 
Scheme 1.  Rational approach for peptidomimetics design. 
 
During the past years, considerable progress has been made in 
the development of a rational approach to the design of peptide 
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ligands with specific conformational properties and highly 
potent biological activity (Scheme 1).1 
Once the structure of the native peptide ligands has been 
elucidated, the first phase of this rational approach consists in  
the identification, through single amino acid replacement of the 
key amino acid residues required for receptor recognition. 
Further steps are aimed at the control of molecular flexibility. 
This is generally performed by adopting two different strategies: 
a) introduction of local constraints inside the ligand backbone in 
order to limit the range of the values adopted by ω, ϕ, φ 
torsion angles; b) introduction of global constrain via 
cyclization in order to make a rigid template for all the 
pharmacophoric structural elements. Models with rigid or semi-
rigid conformations are thus produced, and the most active 
structures are selected by studying conformation-activity 
relationships. In the third phase a careful analysis of the 3D 
arrangement of side chains responsible for the activity is made. 
These studies often require complex experiments of NMR 
spectroscopy, X-ray analysis, circular dichroism data and, when 
possible, utilization of computational methods (molecular 
mechanics and molecular dynamics calculations). The results of 
the studies may lead to highly potent, effecacious and selective 
drug candidates which will be eventually the starting point for 
the design of ligands characterized by non-peptide nature 
(Scheme 1). This latter step is the most difficult and consists in 
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finding non-peptidic molecules suitable to replace the native 
crucial structural elements for receptor binding and recognition. 
 
Strategies in the design of peptidomimetics 
 
The design of peptidomimetics is based on different 
approaches. One of this consists in the N- and Cα -methylation 
or in the replacement of L-amino acids with their D-
counterparts.4,5 
Another approach, which increases the metabolic stability of 
biologically active peptides, is based on the introduction of 
amide bond isoster. These mimic the peptide bond and show 
higher stability toward enzymatic hydrolysis. Common 
examples of the class of amide bond surrogates can be found in 
sulphonamido peptides,6 retro-inverso peptides7 and 
azapeptides.8 
Peptide analogs have also been obtained by introducing 
unusual residues, such as β-amino acids,9 Cα,α disubstituted 
amino acids10 or Nα-Cα closed amino acids such as proline,11 or 
hydroxy proline12 and their analogues. 
Turn inducer or helix inducer amino acids, such as 
dehydroamino acids can also be conveniently introduced in the 
backbone. The resulting molecules, which represent valid 
mimics of bioactive peptides, can efficiently interfere in several 
physiological processes. 
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Peptide cyclization, obtained by simple condensation of the 
N- and C-terminus or by connection of functionalized side 
chains, is also an useful approach in designing highly protease-
resistant peptidomimetics. A very efficient method for preparing 
both small and macrocyclic rings is the ring-closing metathesis 
approach based on the use of the Grubb’s catalyst.13 
In order to overcome the low membrane permeability, which 
is a relevant obstacle for the drug bioavailability, suitable 
peptide analogues can be designed. Although the gut-barrier can 
be circumvented via non-oral administration of drugs, the blood-
brain barrier (BBB) represents a problem which greatly reduces 
the time requested for the drug to reach the receptor site. Some 
of these limitations have been solved by masking polar groups 
within the peptide structure or by reducing hydrogen bonding 
potential (peptide lipidization). Other useful approaches are: the 
“prodrug approach” and the “vector-based strategy”.The first is 
based on the coupling of a pharmacologically active moiety to a 
molecule with known transporters or to a lipophilicity enhancer, 
which is cleaved at or near the site of action. The “vector-based 
strategy” may involve the coupling of the peptide drug to a 
molecule that is normally transported through the BBB.14 
 
Subject of present research 
 
Some of the strategies reported above have been adopted in 
the studies performed during my PhD course. In this period the 
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interest was centered on the design and synthesis of analogues 
of biologically active peptides: endomorphins [EMs; Tyr-Pro-
Trp-Phe-NH2 (EM-1) and Tyr-Pro-Phe-Phe-NH2 (EM-2)] and 
chemotactic N-formyl peptides. 
The EMs are highly potent and selective µ-opioid receptor 
agonists and are considered the most effective “endogenous 
analgesics” released in response to pain stimuli. 
The strong analgesic activity of EMs opens up the possibility 
to develop a novel class of painkillers based on their structure. 
Unfortunately, the exogenous application of these opioid 
peptides generally met with failure, owing to their biological 
instability and inability to be transmitted through the blood-
brain barrier (BBB). In order to improve EMs properties as 
potential drugs as well as to better understand the key structural 
and conformational features on which receptor recognition and 
binding are based, a different number of their analogues were 
synthesized and evaluated. 
We focused our attention on two different points: 
a. the Pro at position 2 of EM-1 and EM-2, by replacing 
this residue with amino acids characterized by 
different constraints and structural features; 
b. the Phe at position 3 and/or 4 of EM-2, by replacing 
with an α,β-unsaturated Phe residues. 
Concerning chemotactic N-formyl peptides, they are involved 
in the defence mechanisms against bacterial infections through 
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binding with specific receptors located on neutrophil membrane. 
The interaction triggers, in addition to a rapid movement of the 
phagocytic cells towards the sites of infections (chemotaxis), a 
series of intracellular responses, relevant among which are 
lysosomal enzyme release and superoxide anion production.15-18 
Despite extensive studies, both the essential cellular 
mechanisms controlling the neutrophil migration and the 
structure-activity relationships regulating the N-formyl peptide-
receptor interactions, are not completely understood and are still 
under study.18-20 However, since the discovery of N-formyl-
methionyl peptides as agonists at the neutrophil receptors, the 
potent chemotactic agent N-formyl-Met-Leu-Phe-OH (fMLF) 
and its methyl ester (fMLF-OMe) have been chosen as the 
reference molecules and a variety of structural modifications 
have been performed on these tripeptides for systematic studies 
on biochemical mechanism and structure activity 
relationships.21-25 
The main target of this research was:  
a. to obtain information on structural and 
conformational properties which control biological 
activity; 
b. to design potent and selective ligands by introducing 
unusual amino acids in place of Met or Leu residues; 
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c. to gain information on the consequences deriving 
from the alteration of the native side chain distances, 
through introduction of spacer residues. 
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 CHAPTER 1 
 
Endomorphins (EMs) and their synthetic 
analogues 
 
1.1 The pain 
 
The International Association for the Study of Pain (IASP) 
defines pain as “an unpleasant sensory and emotional experience 
associated with actual or potential tissue damage, or described in 
terms of such damage”. Physiological pain is an important 
survival and protective mechanism designed to warn the animal 
of danger from potentially injurious stimuli from the external 
environment.  
Precisely, the “pain system” should be called the “nociceptive 
system” because pain is a subjective result of nociception. 
Nociception is the encoding and processing of noxious stimuli in 
the nervous system. A noxious stimulus activates nociceptors 
(Aδ and C fibres) in the peripheral nerve (Figure 1). 
Most of the nociceptors are polymodal, responding to 
noxious mechanical stimuli (painful pressure, squeezing or 
cutting of the tissue), noxious thermal stimuli (heat or cold), and 
chemical stimuli. Sensor molecules in the sensory endings of 
nociceptors transduce mechanical, thermal and chemical stimuli 
into a sensor potential, and when the amplitude of the sensor 
potential is sufficiently high, action potentials are triggered and 
conducted by the axon to the dorsal horn of the spinal cord or 
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the brainstem. Nociceptors can also exert efferent functions in 
the tissue by releasing neuropeptides [substance P, calcitonin 
gene-related peptide (CGRP)] from their sensory endings. 
Thereby, they induce vasodilatation, plasma extravasation and 
other effects, e.g. attraction of macrophages or degranulation of 
mast cells. Nociceptors activate synaptically nociceptive dorsal 
horn neurons (Figure 1). The latter are either ascending tract 
neurons or interneurons that are part of segmental motor or 
vegetative reflex pathways. Ascending axons in the 
spinothalamic tract activate the thalamocortical system that 
produces the conscious pain sensation. The pain sensation has a 
sensory discriminative aspect, i.e. the noxious stimulus is 
analysed for its location, duration and intensity. This is produced 
in the lateral thalamocortical system, which consists of relay 
nuclei in the lateral thalamus and the areas SI and SII in the 
postcentral gyrus. A second component of the pain sensation is 
the affective aspect, i.e. the noxious stimulus feels unpleasant 
and causes aversive reactions. This component is produced in 
the medial thalamocortical system, which consists of relay 
nuclei in the central and medial thalamus and the anterior 
cingulate cortex (ACC), the insula, and the prefrontal cortex. 
The spinal cord is under the influence of descending tracts that 
reduce or facilitate the nociceptive processing. Descending 
inhibition is formed by pathways that originate from brainstem 
nuclei (in particular, the periaqueductal grey, nucleus raphe 
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magnus) and descend in the dorsolateral funiculus of the spinal 
cord. This system is able to suppress nociceptive information 
processing via interneurons in the dorsal horn of the spinal 
cord.1 
 
 
Figure 1. Ascending pathways of nociceptive impulses generated by 
peripheral sensory receptors (nociceptors) in response to noxious stimulation. 
 
If persistent, physiological pain may progress to a 
pathological condition. Clinical pain is apparent when 
discomfort and abnormal sensitivity are present and is 
associated with three primary general features. Firstly, pain 
which may be dull, burning, or stabbing that is spontaneous. 
Secondly, pain responses to noxious stimuli are exaggerated 
(hyperalgesia). Thirdly, pain is produced by normally innocuous 
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stimuli (allodynia). Due to the differing pathophysiology, 
clinical pain is separated into inflammatory pain, associated with 
either tissue damage or an acute or chronic inflammatory 
condition, and neuropathic pain, which results from lesions to 
the peripheral or central nervous systems.2 
The current treatment of pain remains highly reliant upon 
non-steroidal anti-inflammatory drugs (NSAIDs) and opioids. 
Chronic inflammatory pain is mainly treated by NSAIDs which 
have poor efficacy, and following chronic treatment can lead to 
serious problems including kidney failure, gastropathy and liver 
damage. For moderate to severe pain, opiates remain the 
preferred approach but many chronic pain conditions are 
refractory to opiate therapy and chronic dosing is associated 
with severe side effects.  
It is possible to distinguish the opiates drugs from opioid. In 
the strict sense, opiates are drugs which are derived from opium 
and include the natural products morphine, codeine, thebaine 
and many semisynthetic congeners derived from them. In the 
wider sense, opiates are morphine-like drugs with non-peptidic 
structures. The old term opiates is now more and more replaced 
by the term opioids which applies to any substance, whether 
endogenous or synthetic, peptidic or non-peptidic, that produces 
morphine-like effects through an action on opioid receptors. 
Opioid systems comprise opiate alkaloids and the families of 
endogenous opioid peptides.3  
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1.1.1 Endogenous opioid peptides 
 
For many centuries opium, the sticky exudates obtained from 
the poppy plant (Papaver somniferum) has been used as an 
effective painkiller. Opium contains a complex mixture of about 
25 alkaloids. The main alkaloid of opium is morphine (Figure 2) 
that was isolated in 1803 by Sertürner and was found to be a 
particularly good analgesic and sedative, far more effective than 
crude opium. 
 
          
Figure 2.  Structure of Morphine. 
 
The rigid structural and stereochemical requirements 
essential for the analgesic action of morphine led to the theory 
that it produces its effect by interacting with a specific receptor 
in the mammalian brain, but the presence of an opiate-like 
system in the brain remained unproven. A particularly 
misleading observation was that the administration of the opioid 
antagonist naloxone to a normal animal produced little effect, 
although the drug was effective in reversing or preventing the 
effects of exogenous opiates.  
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The first physiological evidence suggesting an endogenous 
opioid system was the demonstration that analgesia produced by 
electrical stimulation of certain brain region was reversed by 
naloxone.4-6 Pharmacological evidence for an opiate receptor 
also was building. In 1973, investigators in three laboratories 
demonstrated opiate binding sites in the brain.7-10 This was the 
first use of radioligand binding assays to demonstrate the 
presence of membrane-associated neurotransmitter receptors in 
the brain.  
Based on results of in vivo studies in dogs, Martin and 
colleagues postulated the existence of three main receptor types, 
µ, δ, and κ.11 A fourth member of the opioid peptide receptor 
family, the nociceptine/orphanine FQ (N/FQ) receptor was 
cloned in 1994.12-13  
Three distinct families of classical opioid peptides have been 
identified: the enkefalins (δ-selective), endorphins (non-
selective) and dynorphins (κ-selective). Each family is derived 
from a distinct precursor polypeptide and has a characteristic 
anatomical distribution. These precursors, pre-
proopiomelanocortin, pre-proenkefalin, and pre-prodynorphin, 
are encoding by three corresponding genes (Figure 3).  
Each precursor is subject to complex cleavages and post-
translational modifications resulting in the synthesis of multiple 
active peptides. The opioid peptides share the common amino-
terminal sequence of Tyr-Gly-Gly-Phe- (Met or Leu), which has 
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been called the “opioid motif”. This motif is followed by various 
C-terminal extensions yelding peptides ranging from 5 to 31 
residues (Figure 4). 
 
 
Figure 3.  Peptide precursors. 
 
A novel endogenous opioid peptide was cloned in 1995.14-15 
This peptide has a significant sequence homology to dynorphin 
A, with an identical length of 17 amino acids, identical carboxy-
terminal residues, and a slight modification of amino-terminal 
opioid core (Phe-Gly-Gly-Phe instead of Tyr-Gly-Gly-Phe). The 
removal of hydroxyl phenolic group is sufficient to abolish 
Chapter 1 
 
20 
interactions with the three classical opioid-peptide receptors. 
This peptide was called orphanin FQ (OFQ) by one group of 
researchers and nociceptin (N) by another, because it lowered 
pain threshold under certain conditions. The N/OFQ system 
represents a new neuropeptide system with a high degree of 
sequence identity to the opioid peptides. However, the slight 
change in structure results in a profound alteration in function. 
N/OFQ has behavioural and pain modulatory properties distinct 
from those of the three classical opioid peptides. 
 
 
Figure 4.  Endogenous Opioid Peptides. 
 
It is well established that morphine and related alkaloids elicit 
their analgesic effects when bound to the µ-opioid receptor. 
Intensive studies were undertaken to find a natural agonist for 
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that receptor in the nervous system. Several naturally occurring 
exogenous opioid peptides, which were shown to bind 
preferentially to the µ-receptor were isolated, such as β-
casomorphin (Tyr-Pro-Phe-Pro-Gly-Pro-Ile) from digests of β-
casein,16 its shorter form, morphiceptin (Tyr-Pro-Phe-Pro-
NH2)17-18 and hemorphin-4 (Tyr-Pro-Trp-Thr) from digests of 
haemoglobin.19  
In early 1990 two peptides, Tyr-MIF-1 (Tyr-Pro-Leu-Gly-
NH2) and Tyr-W-MIF-1 (Tyr-Pro-Trp-Gly-NH2) were found in 
the brain,20-22 which displayed high selectivity for the µ-receptor 
sites, but their affinity was relatively low. The group of Zadina 
used Tyr-W-MIF-1 as a parent compound and systematically 
substituted each of the 20 natural amino acids for the Gly in 
position 4 and screened these analogs for binding to the µ-
receptor. A biologically potent sequence, Tyr-Pro-Trp-Phe-NH2 
(Figure 5), was discovered and then identified in the bovine 
brain23 and human cortex.24 This new peptide, which was named 
endomorphin-1 (EM-1), showed remarkable affinity for the µ-
opioid receptor and selectivity of 4000- and 15000-fold for the 
µ-opioid receptor over the δ- and κ-receptors, respectively. EM-
1 was extremely potent in the guinea pig ileum assay, a classical 
test for the µ-opioid receptor agonist activity.23 This peptide also 
had a potent and specific antinociceptive effect in vivo, as shown 
in the tail-flick test.23,24 A second peptide, Tyr-Pro-Phe-Phe-NH2 
(Figure 5), which differed from EM-1 by only one amino acid, 
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was also isolated and named endomorphin-2 (EM-2). EM-2 was 
shown to be almost equally potent with EM-1.23,24 
Endomorphins (EMs) were the first peptides isolated from the 
brain that bind to the µ-opioid receptor with high affinity and 
selectivity and therefore were proposed as the most potent 
endogenous µ-opioid receptor ligands. 
 
 
Figure 5.  Structure of EM-1 and EM-2. 
 
Despite the similar physiological effects, the structure of 
endomorphins is quite distinct from traditional opioid peptides; 
they are only four amino acid long, their N-terminal sequence is 
Tyr-Pro instead of Tyr-Gly-Gly-Phe, and their C-terminus is 
amidated, which seems to be essential for binding to the µ-
opioid receptor. Endomorphins share common structural 
features with morphiceptin, hemorphin, Tyr-MIF-1, and Tyr-W-
MIF-1. 
 
1.1.2 Opioid receptors 
 
Opioid receptors are most abundant in the central nervous 
system (CNS), but have also been localized in many peripheral 
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tissue of the mammalian organism. They belong to the big 
family of G-protein coupled receptors. 
The G-protein coupled receptors (GPCRs) are also known as 
metabotropic receptors or seven-transmembrane-spanning 
(heptaelical) receptors. They are membrane receptors, that span 
the plasma membrane as a bundle of seven alpha helices, with 
an extracellular N-terminal domain of varying length and an 
intracellular C-terminal domain (Figure 6). 
 
 
Figure 6.  G-protein coupled receptor (GPCR). 
 
They are coupled to intracellular effector systems via G-
proteins that interact with the guanine nucleotides GTP and 
GDP. G-proteins are composed of three subunits, α, β and γ. 
Guanine nucleotides bind to the α-subunit, which has enzymic 
activity, catalysing the conversion of GTP to GDP; the β- and γ- 
subunits remain together as a βγ-complex. In the resting state, 
the G-protein exists as an unattached αβγ-trimer, with GDP 
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occupying the site on the α-subunit (Scheme 1). When a GPCRs 
is occupied by an agonist molecule, a conformational change 
occurs, involving the citoplasmic domain of the receptor, 
causing it to acquire high affinity for the αβγ-trimer. 
Association of  αβγ-trimer with the receptor causes the bound 
GDP to dissociate and to be replaced with GTP, which in turn 
causes dissociation of G-protein trimer, releasing α-GTP and 
βγ-subunits (Scheme 1); these are the active forms of the G-
protein, which diffuse in the membrane and can associate with 
various enzymes and ion channels, causing activation or 
inactivation as the case may be. The process is terminated when 
the hydrolysis of GTP to GDP occurs through the GTPase 
activity of the α-subunit. The resulting  α-GDP dissociates from  
 
 
Scheme 1.  Activation of G-protein coupled receptor. 
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the effector and reunites with the βγ-complex, completing the 
cycle. There are several types of G-protein, which interact with 
different receptors and control different effectors, e.g. the 
muscarinic acetylcholine receptor, adrenoceptors and 
neuropeptide receptors. 
It is now well established that there are three well defined 
types of opioid receptors: the µ, δ and κ receptors.25-27 Genes 
encoding for these receptors have been cloned.28-31 The 
comparison of the amino acid sequences of three main opioid 
receptors revealed that they show extensive structural homology 
with each other. Physiological roles for each of the opioid 
receptors have not been clearly defined. Pain relief effects are 
mediated by all three receptor types, but in different degree: i) 
µ-receptor mediates the most potent antinociceptive effects, 
accompanied however by the development of dependence; ii) δ-
receptor has lower efficacy in mediating pain relief, but might 
have a reduced addictive potential; iii) κ-receptor mediates 
analgesic effects in peripheral tissues. 
It would be most useful to have the 3D structures of the 
opioid receptor to help study the mechanism of the new opioid 
receptor agonists, but there are no available 3D structures of 
opioid receptors determined by X-ray or NMR studies. 
Fortunately, the X-ray structure of bovine Rhodopsin, that 
belong to the GPCRs family, was solved (Figure 7)32 and this 
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structure has been widely applied to homology modelling, based 
on the hypothesis of structural mimicry.33  
 
 
Figure 7.  Crystal structure model of bovine rhodopsin. 
 
Indeed, several authors have recently developed alternative 
opioid receptor models using the rhodopsin X-ray structure as a 
template of these receptors.34, 35 
 
1.2 Stucture-activity relationship studies and 
bioactive conformation of EMs 
 
The EMs are highly active and selective MOR agonists, 
which possess several important biological effects and modulate 
a variety of physiological processes through the activation of 
membrane bound MOR. These tetrapeptides play a relevant role 
in the regulation of pain perception and in the analgesia;23,36,37 
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they show complex effects in the cardiovascular system;38-41 
they have gastrointestinal and respiratory functions;37,42 they 
regulate the release of neurotransmitters;43,44 furthermore, they 
display immunomodulatory properties.45-47 
Due to the above-mentioned complex biological effects of 
EMs, it is important to identify the structural features of these 
tetrapeptides, which play a role in the formation of bioactive 
conformation and are responsible for the activity and selectivity 
toward MOR. 
 
1.2.1 Pharmacophoric groups in EMs 
 
From the structural point of view, the EMs can be divided 
into two biologically important parts,48 which are the “message” 
and the “address” sequences. The “message” fragments are the 
N-terminal Tyr1-Pro2-Trp3 and Tyr1-Pro2-Phe3 tripeptide units, 
while the “address” fragment is the remaining C-terminal Phe4-
NH2 unit (Figure 8). These two distinct sequences of EMs play a 
relevant role: the “message” sequence is required for the 
receptor binding and recognition and it is important in the 
formation of bioactive conformation; the “address” sequence is 
supposed to stabilize the bioactive conformation, among various 
conformations accessible to the N-terminal message sequence. 
The data obtained from different studies pointed out that, for 
EM-1 and EM-2, the N-terminal amino (NH2) group, the Tyr 
amino acid in position 1, and a further aromatic amino acids 
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(Trp or Phe) in position 3 or 4 can be considered as 
pharmacophore elements49 (Figure 8). Since the aromatic side 
chain of Tyr1, Trp3/Phe3, and Phe4 amino acids rank among the 
putative pharmacophore elements of EMs, their conformations 
and orientation, as well as their relative spatial arrangements, are 
also important in the formation of bioactive conformation and in 
the binding to the receptor. Between the Tyr1 and the other 
aromatic amino acids, Pro is located in position 2 as a spacer 
residue, which join(s) the pharmacophoric residues of the 
message sequence. Spacer residue plays a significant role in 
orienting the biologically important Tyr and Trp/Phe residues in 
the correct array necessary for opioid activity.  
 
 
Figure 8. Message and address fragments as well as the putative 
pharmacophore elements of EM-1and EM-2.  
 
Recent studies50 established the importance of aromatic-
aromatic or proline-aromatic interactions in the determination 
and stabilization of the structures of endomorphins. These 
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interactions may be also important in the association with the 
receptor and in ligand recognition. 
Aromatic-aromatic interactions between different aromatic 
amino acids (Phe, Tyr and Trp) are important non-covalent 
interactions in proteins and peptides since determine and 
stabilize the three-dimensional structures and ligand bindings. 
Both EMs contain aromatic amino acids (Tyr, Trp and Phe 
for EM-1, and Tyr and Phe for EM-2), which can interact with 
each other. The non-covalent interactions between residues with 
aromatic side-chains can stabilize the different conformers of 
EMs. Another important interaction in stabilizing protein 
structures which is also relevant in protein-protein, protein-
peptide interactions and molecular recognition, is the C-H···π-
interaction that can occur between a C-H-donor and a π-acceptor 
and can be treated as weak H-bond. One type of C-H···π-
interaction, also found in peptides and proteins, is -in EMs- the 
interplay between the Pro and the aromatic amino acid side 
chains. It has been found that the C-H···π-interactions between 
side chains close to Pro and an aromatic amino acid can stabilize 
the cis peptide bond and may also be important in the 
stabilization of the structure of β-turns.50 
 
1.2.2 Bioactive conformation of EMs 
 
Determination of the bioactive conformation of 
endomorphins is an essential step to understand the action of 
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these peptides at their receptors. In small peptides such as 
endomorphins, the amino acid side-chains exhibit considerable 
conformational flexibility: it is difficult to establish the three-
dimensional arrangement of endomorphins and the cis/trans 
rotamers of the amide linkage at Tyr-Pro allow endomorphins to 
exist as cis- and trans-isomers.51 The question arises whether 
endomorphins adopt the cis or trans configuration of Tyr-Pro 
peptide bond, when bound to the receptor.  
Recently, Gentilucci et al.49 carried out different studies to 
establish the preferred conformation of EMs. Some studies 
performed on EM-1 indicated a biologically relevant 
conformation having Tyr1 in proximity to Trp2 and a cis Tyr1-
Pro2 bond. On the other hand, other studies performed on EM-1 
indicated a β-turn shaped geometry with a trans Tyr1-Pro2 bond. 
Concerning EM-2, both the trans and cis conformers adopted 
similar extended conformations, showing their backbones 
twisted at the Pro2-Phe3 moiety, except for the different 
orientation of Tyr respect Pro. 
Then, several studies have been performed on EMs analogues 
and also these studies gave rise to distinct and contrasting 
models. 
Keller et al.52 synthesized analogs of EM-2 containing a 
dimethylated pseudoproline residue in place of Pro2 that were all 
full µ-opioid agonists, showing good potency in functional 
assays and high µ-receptor binding affinities in the binding 
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assay. These results provided a direct evidence that EM-2 have 
the cis-configuration around Tyr-Pro peptide bond in the 
bioactive conformation. Similarly, a preference for the cis-
configuration in the Dmt-Pro analogs was observed by Okada et 
al..53 All these data contradict the earlier findings by Podlogar et 
al.51 and Eguchi et al.54 who, based on NMR analyses, proposed 
an extended conformation of trans EM-1 as a potential bioactive 
form, and more recent report of In et al.,55 who demonstrated, on 
the basis of 2D 1H NMR and molecular docking, that EM-2 
binds to the µ-opioid receptor in a trans Tyr-Pro conformation. 
A different approach to increase the conformational 
flexibility at Tyr-Pro bond was represented by incorporating 1-
aminocyclopentane-1-carboxylic acid (Ac5c) and 1-
aminocyclohexane-1-carboxylic acid (Ac6c),56 achiral analogs of 
α,α-disubstituted glycine. There is no rotational limitation on 
the N-Cα bond of Ac5c and Ac6c and the bulkiness of their 
aliphatic side-chains is similar to that of Pro. Incorporation of 
these amino acids into the sequence of EM-2 produced analogs 
with well conserved µ-affinities and retained selectivities. X-ray 
diffraction analysis revealed that [(Ac6c)2]EM-2 is folded into 
the trans-form for Tyr-Ac6c. Since the selectivity of this analog 
was well conserved, it can be suggested that the folded form is 
important for the µ-selectivity. A different conclusion was 
presented by Shao et al.,57 who studied conformational 
requirements of EM-2 analogs containing Phe-mimics, 
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phenylglycine (Phg) and homophenylalanine (Hfe). It has been 
suggested that the flexible side chains of aromatic amino acids 
in position 3 and/or 4 may cause the backbone of EM-2 analogs 
to adopt a folded structure, which results in weaker binding to 
the µ-opioid receptor.  
 
1.3 Adopted structural modification strategies 
 
Endomorphin-1 (EM-1) and endomorphin-2 (EM-2) are two 
endogenous opioid peptides with high affinity and selectivity for 
µ-opioid receptors.23 Since the µ-opioid receptors mediate the 
most prominent pharmacological effects of morphine, the 
discovery of EM-1 and EM-2 has encouraged the application of 
natural and synthetic peptides as analgesics instead of 
morphine.42,58,59 Indeed, both EM-1 and EM-2 exhibit potent 
antinociceptive effects in acute, inflammatory and neuropathic 
pain models without some of the undesirable side effects of 
morphine.42,60,61 However, EMs as well as opioid peptides in 
general, show a poor bioavailability, mainly due to their 
inability to penetrate the gut-blood or the blood-brain 
barriers,62,63 and rapid degradation in vivo by different 
proteases.64 To circumvent these problems, different strategies 
have been adopted to modify opioid peptide properties.52,65-67 
Research efforts are focused on the design of analogues and 
peptidomimetics in order not only to improve EMs properties as 
potential drugs but also to better understand the key structural 
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and conformational features on which receptor recognition and 
binding are based.68 
In several cases, peptide analogues or peptidomimetics have 
been found to possess much higher biological activity than that 
expected on the basis of simple binding studies or tissue 
bioassays. In this context, we have recently reported the 
synthesis, conformational study and pharmacological 
characterization of a series of EMs analogues characterized by 
the presence of conformationally constrained amino acid in 
position 2 of EM-1 and EM-2 and in position 3 and/or 4 in EM-
2. 
 
1.4  Synthesis and evaluation of new 
endomorphin analogues modified at the Pro2 
residue* 
 
Several chemical modifications performed on EMs have been 
described previously and many of them were focused on the Pro 
at position 2.56,58,65,69-74 The presence of Pro, the sole 
proteinogenic amino acid possessing a cyclic structure and a 
secondary amino group, represents a crucial factor in 
determining the structural and conformational properties of 
proteins and peptides. In the specific context of studies on EMs 
analogues, the Pro2 is considered a stereochemical spacer, 
                                                 
*Torino, D.; Mollica, A.; Pinnen, F.; Lucente, G.; Feliciani, F.; Davis, 
P.; Lai, J.; Ma, S-W.; Porreca, F.; Hruby, V. J. Bioorg. Med. Chem. 
Lett. 2009, 19, 4115. 
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capable of favouring proper spatial orientation of the aromatic 
side chain groups, a key factor for ligand recognition and 
interaction with the receptor.50,66 
Here we reports on the EM analogues given in Figure 9, 
which are obtained by replacing the Pro in position 2 with one 
of the four amino acid residues depicted in Figure 10. These 
amino acids, characterized by different constraints and  
structural features, can deeply alter the tetrapeptide backbone 
conformation and thus modulate in new ways the bioactivity of 
the peptide. 
 
Figure 9.  Molecular structure of the EM analogues 1-6. 
 
 
 
Figure 10.  Molecular structure of the amino acids used to replace the native 
Pro2 residue in endomorphins: (S)-azetidine-2-carboxylic acid (Aze); 3,4-
dehydro-(S) proline (∆3Pro); azetidine-3-carboxylic acid (3Aze); dehydro-
alanine (∆Ala). 
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A first modification, which leads to the EM-2 analogue 1, is 
based on the introduction of the 3,4-dehydro-(S)-proline (∆3Pro) 
residue. This amino acid, as compared with Pro, has an almost 
planar and less flexible cyclic side chain ring, which does not 
allow rapid interconversion between ring-puckered forms 
typical of Pro residues and enhances, at the same time, the 
population of cis conformers around the CO-N tertiary amide 
bond.75,76 In addition to this, the presence of the double bond 
may significantly improve, through π-π interactions, its binding 
to opioid receptors.77,78 A related ∆3Pro2 containing EM-2 
analogue, namely [Dmt1, ∆3Pro2]EM-2, has been previously 
reported by Toth and Szemenyei79 and utilised for the synthesis 
of the corresponding tritium labelled [3H2]Pro2 analogue. Two of 
the other modified ligands here reported analogues contain a 
cyclic lower homologue of Pro. In particular, in analogues 
[Aze2]EM-1 (2) and [Aze2]EM-2 (3) the (S)-azetidine-2-
carboxylic acid (Aze) has been incorporated. Literature data 
show that the four-membered ring system of N-acylated (S)-
azetidine-2-carboxylic acid (Aze) is either planar or only 
slightly puckered80-82 and presents, as compared with proline, 
reduced side chain steric effects, with increased backbone 
flexibility.83 This latter property generates a larger number of 
low energy conformers with a population of the cis rotamers 
around the CO-N amide bond which has been suggested to be 
higher than that observed in Pro-containing peptides.84 
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Furthermore, the different ring size may significantly influence 
the type of folding with β-turns and γ-turns preferentially 
induced by Pro and Aze, respectively.83  
The azetidine ring system also has been incorporated into the 
backbone of the analogues [3Aze2]EM-1 (4) and [3Aze2]EM-2 
(5). Azetidine-3-carboxylic acid (3Aze) is an achiral 
conformationally restricted analogue of β-alanine which, 
although not used in opioid chemistry, has been employed for 
the synthesis of other pharmaceutical compounds.85-87 As 
compared with Aze and Pro residues, 3Aze maintains the cyclic 
structure and the secondary amino group in the ring but is 
devoid of both chirality and restricted rotation around the N-Cα 
bond. Among 5-membered chiral β-residues related to 3Aze, 
both β-proline (pyrrolidine-3-carboxylic acid) and β-
homoproline (2-pyrrolidineacetic acid) have already been used 
to replace Pro2 in EM analogues.58,65 Furthermore, EM-2 
analogues containing cyclic 6-membered higher homologues of 
β-proline and 3Aze [viz nipecotic acid (piperidine-3-carboxylic 
acid) and isonipecotic acid (piperidine-4-carboxylic acid), 
respectively)] have been recently reported.74  
The last analogue under study here is [∆Ala2]EM-2 (6) which 
contains the rigid skeleton of dehydro-alanine (∆Ala). The local 
conformational restriction imposed on the backbone by the 
planar structure of ∆Ala moiety, as well as its electronic 
distribution, significantly influences the properties of this 
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compound. Although a variety of molecular modifications 
performed on native EMs have been reported, analogues 
containing α,β-unsaturated amino acid residues are very 
scarce.88 Thus, the reported data on compound 6 represent, to 
the best of our knowledge, the first information available in the 
literature on receptor binding affinity and selectivity of this type 
of EM analogues. 
 
1.4.1 Chemistry 
 
The solution phase synthesis of peptides 1-5 were performed 
following standard literature methods89 which are given in 
Scheme 2. 
 
2 2
2 2
2 2
3
 
Scheme 2.  Synthesis of EM analogues 1-5. Xaa = ∆3Pro; Yaa = Phe (1); Xaa 
= Aze; Yaa = Trp (2); Xaa = Aze; Yaa = Phe (3); Xaa = 3Aze; Yaa = Trp (4); 
Xaa = 3Aze; Yaa = Phe (5). Intermediates: Yaa = Phe = a; Yaa = Trp = b. 
Xaa = ∆3Pro = c; Xaa = Aze = d; Xaa = 3Aze = e. 
 
The synthesis of the dehydro-alanine-containing analogue 6, 
was accomplished by exploiting the reactivity of the 
methylcysteine sulfoxide90 as illustrated in Scheme 3. 
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Scheme 3. Synthesis of EM-2 analogue 6. Reagents and conditions: a) 
SOCl2, MeOH, 15 min  0 °C, 3 h rt; b) Boc-Tyr-OH, EDC, HOBt, DIPEA, 
CH2Cl2 30 min 0 °C, 12 h rt; c) 1N NaOH, MeOH 5 h rt; d) HCl·H2N-Phe-
OMe, EDC, HOBt, DIPEA, CH2Cl2 30 min 0 °C, 12 h rt; e) NaIO4, H2O, 
dioxane 1 h 0 °C; f) DBU, MeOH, 1.5 h rt; g) 1N NaOH, MeOH 5 h rt; h) 
HCl·H2N-Phe-NH2, EDC, HOBt, DIPEA, CH2Cl2 30 min 0 °C, 12 h rt; i) 
TFA/CH2Cl2 1:1, 1.5 h rt under N2. 
 
1.4.2 Results and conclusions 
 
As shown in Table 1 all analogues, except [3Aze2]EM-1 (4), 
which can be considered a µ/δ mixed agonist, show high 
selectivity for µ-receptors and functional bioactivities in good 
agreement with the binding values. The highest affinity and 
selectivity is shown by the Aze-containing peptides 2 and 3. 
This finding, together with the good activity of the [∆3Pro2]EM-
2 analogue 1, confirms the role of the residue at position 2 as a 
stereochemical spacer. 
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Table 1.  Binding affinity and in vitro activity for compounds 1-6. 
a Displacement of [3H]DAMGO (µ-selective) and [3H]DPDPE (δ-selective) 
from rat brain membrane binding sites. 
b ± S.E.M. 
c n.c.= not binding recorded. 
 
The two analogues containing a β-residue, namely 
[3Aze2]EM-1 (4) and [3Aze2]EM-2 (5) exhibit highly different 
activity profiles (Table 1). The much lower activity shown by 5, 
as compared to the Trp3 containing analogue [3Aze2]EM-1 (4), 
can be interpreted on the basis of the well recognised role of the 
aromatic residues on ligand-receptor interactions. Several 
studies on EM-1 and EM-2 clearly show that aromatic side 
chains with different size, distinct noncovalent interactions and 
H-bonding capability, can highly influence conformations49  and 
binding.50,51,91 Results of ligands 4 and 5 indicate that the 
beneficial effect on the activity, constantly observed in EM 
analogues containing the indole ring system at position 3, gives 
Chapter 1 
 
40 
results that are particularly efficient as compared to the Phe3 
residue in models containing the achiral 3Aze residue. 
The low activity shown by [3Aze2]EM-2 (5) appears, 
however, is quite unexpected when compared to the high 
activity shown by EM analogues containing other cyclic β-
residues in place of the native Pro2. In particular, among the 
recently examined EM-2 analogues containing positional 
isomers of the 6-membered piperidine-carboxylic acid, 
replacement of Pro2 with the chiral nipecotic acid (viz 
piperidine-3-carboxylic acid) led, in accordance with the results 
concerning other related cyclic β-residues,58,65 to a highly active 
analogue.74 On the contrary, Pro2 replacement with the achiral 
piperidine-4-carboxylic acid (viz isonipecotic acid) resulted, as 
in the case of the here reported analogue 5, to a practically 
inactive ligand.74 It can be argued that the high conformational 
restriction and the reduced flexibility of the 4-membered achiral 
3Aze are detrimental features which prevail over the advantages 
which, in larger cyclic systems, derive from the presence of a β-
positioned carboxylic group. 
Peptide 6, containing the rigid skeleton of ∆Ala residue, has 
only modest affinity and bioactivity at the µ-opioid receptor, and 
this suggests that an efficient constraint at position 2 involves an 
amino acid residue with a cyclic structure. 
 
1.4.3 Experimental section 
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Materials and methods. Boc-Aze-OH (purissimum, ≥99%), 
Boc-3Aze-OH (purissimum, ≥99%) and Boc-∆3Pro-OH 
(purissimum, ≥99%) were obtained commercially and used 
without further purification. Spectrograde solvents were 
purchased from Merck; all the other solvents and reagents were 
of the purest grade commercially available. Optical rotations 
were taken at 20 °C with a Schmidt-Haensch Polartronic D 
polarimeter (1 dm cell, c 1.0 in CHCl3, unless otherwise 
specified). IR spectra were recorded in 1% CHCl3 (unless 
otherwise specified) solution employing a Perkin-Elmer FT-IR 
Spectrum 1000 spectrometer. 1H NMR experiments were 
performed at 400 MHz on a Bruker AM 400 spectrometer in 
CDCl3 solution (unless otherwise specified), chemical shifts (δ) 
are quoted in parts per million (ppm) and were indirectly 
referred to TMS. TLC (thin layer chromatography) and PLC 
(preparative layer chromatography) were performed on silica gel 
Merck 60 F254 plates. The drying agent was sodium sulphate. All 
new compounds were also characterized by elemental analysis.  
 
1.4.3.1 Chemistry. General procedures 
 
A. Coupling with the carbodiimide method. To an ice-
cooled mixture containing the required N-Boc-amino 
acid (1.0 mmol), HOBt (1.1 mmol), EDC (1.1 mmol) 
and NMM or DIPEA (2.2 mmol) in anhydrous CH2Cl2, 
the amino-derivative salt (1.1 mmol) was added. The 
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reaction mixture was allowed to warm to 0 °C for 10 min 
and then to room temperature. After 12 h the reaction 
mixture was diluted with EtOAc (20 mL) and washed 
with 5% citric acid (3 x 15 mL), NaHCO3 ss (3 x 15 mL) 
and NaCl ss (2 x 15 mL). The organic layer was dried 
and evaporated under reduced pressure. 
B. Deprotection of Boc-derivatives. The Boc group was 
removed by treatment with TFA in CH2Cl2 (1:1) for 1 h 
at room temperature. Removal of solvent and 
precipitation of the residue with diethyl ether gave the 
TFA salt that was used in the next step without further 
purification. 
C. Preparation of peptide amides. The peptide methyl 
ester is allowed to stand in a pressure bottle at room 
temperature for 48 h in anhydrous MeOH previously 
saturated with ammonia gas at 0 °C. The solution is then 
concentrated to dryness in vacuo at a temperature not 
exceeding 40° C. Compounds were purified by PLC. 
 
1.4.3.2 Synthesis 
 
N-Boc-Phe-Phe-OMe (7a). N-Boc-Phe-OH (0.895 g, 3.71 
mmol) in CH2Cl2 (60 mL) was treated with HCl·H2N-Phe-OMe 
(0.727 g, 3.37 mmol) according to the general procedure A. The 
title compound was obtained as a white solid, pure on TLC 
(1.246 g, 87%); [a]D +34.28° (c 1, CHCl3); IR (CHCl3): ν 3423, 
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1742, 1677 cm-1; 1H NMR (CDCl3): δ 1.42 [9H, s, C(CH3)3], 
3.07 (4H, m, Phe3 and Phe4 β-CH2), 3.70 (3H, s, COOCH3), 
4.35 (1H, m, Phe3 α-CH), 4.81 (1H, m, Phe4 α-CH), 4.93 (1H, 
br s, Phe3 NH), 6.29 (1H, br s, Phe4 NH), 7.00-7.30 (10H, m, 
aromatics). Anal. Calcd for C24H30N2O5: C, 67.59; H, 7.09; N, 
6.57. Found: C, 67.86; H, 7.11; N, 6.59. 
TFA·H2N-Phe-Phe-OMe (8a). Deprotection of the N-Boc 
group was performed by adopting the general procedure B: 7a 
(0.381 g, 0.89 mmol), CH2Cl2/TFA (6 mL) gave 8a (0.392 g, 
quantitative yield).  
N-Boc-Trp-Phe-OMe (7b). N-Boc-Trp-OH (1.0 g, 3.62 
mmol) in CH2Cl2 (58.6 mL) and DMF (10 mL) was treated with 
HCl·H2N-Phe-OMe (0.71 g, 3.29 mmol) according to the 
general procedure A. The title compound was obtained as a 
white foam, pure on TLC (1.428 g, 93%); [a]D +16° (c 1, 
CHCl3); IR (CHCl3): ν 3477, 3418, 1742, 1673 cm-1; 1H NMR 
(CDCl3): δ 1.44 [9H, s, C(CH3)3], 2.85-3.43 (4H, m, Trp and 
Phe4 β-CH2), 3.64 (3H, s, COOCH3), 4.45 (1H, m, Trp α-CH), 
4.75 (1H, m, Phe4 α-CH), 5.14 (1H, br s, Trp NH), 6.22 (1H, br 
s, Phe4 NH), 6.72-7.80 (10H, m, aromatics), 8.08 (1H, s, Trp 
Ind-NH). Anal. Calcd for C26H31N3O5: C, 67.08; H, 6.71; N, 
9.03. Found: C, 67.28; H, 6.73; N, 9.05. 
TFA·H2N-Trp-Phe-OMe (8b). Deprotection of the N-Boc 
group was performed by adopting the general procedure B: 7b 
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(0.26 g, 0.558 mmol), CH2Cl2/TFA (6 mL) gave 8b (0.267 g, 
quantitative yield). 
 N-Boc-Aze-Phe-Phe-OMe (9ad). N-Boc-Aze-OH (0.166 g, 
0.83 mmol) in CH2Cl2 (15 mL) was treated with TFA·H2N-Phe-
Phe-OMe (0.330 g, 0.75 mmol) according to the general 
procedure A. Silica gel chromatography (CHCl2/EtOAc 8:2) 
gave a pure product 9ad as a white foam (0.302 g, 79%); [a]D -
90° (c 1, CHCl3); IR (CHCl3): ν 3408, 1742, 1682 cm-1; 1H 
NMR (CDCl3): δ 1.46 [9H, s, C(CH3)3], 2.10-2.40 (2H, br s, 
Aze C3H2), 2.93-3.19 (4H, m, Phe3 β-CH2 and Phe4β-CH2), 3.68 
(3H, s, COOCH3), 3.64 and 3.85 (2H, two m, Aze C4H2), 4.55 
(1H, m, Aze α-CH), 4.67 (1H, m, Phe3 α-CH), 4.81 (1H, m, 
Phe4 α-CH), 6.55 (1H, br s, Phe4 NH), 7.04-7.28 (10H, m, 
aromatics), 7.52 (1H, br s, Phe3 NH). Anal. Calcd for 
C28H35N3O6: C, 65.99; H, 6.92; N, 8.25. Found: C, 66.05; H, 
6.93; N, 8.26. 
TFA·HN-Aze-Phe-Phe-OMe (10ad). Deprotection of the N-
Boc group was performed by adopting the general procedure B: 
9ad (0.257 g, 0.505 mmol), CH2Cl2/TFA (6 mL) gave 10ad 
(0.264 g, quantitative yield). 
N-Boc-Tyr-Aze-Phe-Phe-OMe (11ad). N-Boc-Tyr-OH 
(0.156 g, 0.555 mmol) in CH2Cl2 (10 mL) was treated with 
TFA·HN-Aze-Phe-Phe-OMe (0.264 g, 0.505 mmol) according 
to the general procedure A. Silica gel chromatography 
(CHCl3/EtOAc 1:1) gave a pure product 11ad as a white foam 
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(0.295 g, 90%); [a]D -14.7° (c 0.68, CHCl3); IR (CHCl3): ν 
3429, 1741, 1670 cm-1; 1H NMR (CDCl3): δ 1.43 [9H, s, 
C(CH3)3], 1.90-2.32 (2H, m, Aze C3H2), 2.65-2.90 (2H, m, Tyr 
β-CH2), 2.91-3.34 (4H, m, Phe3 β-CH2 and Phe4β-CH2) 3.70 
(3H, s, COOCH3), 3.68 and 4.01 (2H, two m, Aze C4H2), 4.25 
(1H, m, Tyr α-CH), 4.60 (1H, m, Phe3 α-CH), 4.69 (1H, m, Aze 
α-CH), 4.80 (1H, m, Phe4 α-CH), 5.22 [1H, apparent t (the 
signals of two conformers are superimposed), Tyr NH], 6.67 
(1H, d, J = 7.6 Hz Phe4 NH), 6.72-7.33 (14H, m, aromatics), 
7.54 (1H, d, J = 7.0 Hz Phe3 NH). Anal. Calcd for C37H44N4O8: 
C, 66.05; H, 6.59; N, 8.33. Found: C, 66.12; H, 6.60; N, 8.35. 
N-Boc-Tyr-Aze-Phe-Phe-NH2 (12ad). A solution of the 
peptide methyl ester 11ad (0.15 g, 0.22 mmol) in MeOH/NH3 
sat. (6.3 mL) is allowed to stand in a pressure bottle at room 
temperature according to the general procedure C. The title 
compound was obtained as a white solid pure on TLC (0.139 g, 
95%); 1H NMR (DMSO-d6): δ 1.45 [9H, s, C(CH3)3], 1.78 and 
2.31 (2H, two m, Aze C3H2), 2.59-3.22 (6H, m, Phe3 β-CH2, 
Phe4 β-CH2 and Tyr β-CH2), 3.77 and 4.10 (2H, two m, Aze 
C4H2), 3.99 (1H, m, Tyr α-CH), 4.45-4.50 (2H, m, Phe3 α-CH 
and Phe4 α-CH), 4.62 (1H, m, Aze α-CH), 6.60-7.34 (16H, m, 
aromatics and CONH2), 8.01-8.28 (2H, m, Phe3 NH, Phe4 NH), 
9.40 (1H, s, Tyr OH). Anal. Calcd for C36H42N4O8: C, 65.64; H, 
6.43; N, 8.51. Found: C, 65.72; H, 6.44; N, 8.53. 
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TFA·H2N-Tyr-Aze-Phe-Phe-NH2 (3). Deprotection of the 
N-Boc group was performed by adopting the general procedure 
B: 12ad (0.034 g, 0.052 mmol), CH2Cl2/TFA (6 mL) gave 3 
(0.035 g, quantitative yield); 1H NMR (DMSO-d6): δ 1.78 and 
2.31 (2H, two m, Aze C3H2), 2.59-3.22 (6H, m, Phe3 β-CH2, 
Phe4 β-CH2 and Tyr β-CH2), 3.77 and 4.10 (2H, two m, Aze 
C4H2), 3.99 (1H, m, Tyr α-CH), 4.45-4.50 (2H, m, Phe3 α-CH 
and Phe4 α-CH), 4.62 (1H, m, Aze α-CH), 6.60-7.34 (16H, m, 
aromatics and CONH2), 8.01-8.28 (5H, m, Phe3 NH, Phe4 NH 
and Tyr NH3+), 9.40 (1H, s, Tyr OH). Anal. Calcd for 
C33H36F3N5O7: C, 59.01; H, 5.40; N, 10.43. Found: C, 59.24; H, 
5.42; N, 10.40. 
N-Boc-Aze-Trp-Phe-OMe (9bd). N-Boc-Aze-OH (0.142 g, 
0.709 mmol) in CH2Cl2 (13 mL) was treated with TFA·H2N-
Trp-Phe-OMe (0.309 g, 0.645 mmol) according to the general 
procedure A. Silica gel chromatography (CHCl3/MeOH 99:1) 
gave a pure product 9bd  as a white foam (0.250 g, 71%); [a]D -
92° (c 1, CHCl3); IR (CHCl3): ν 3428, 1742, 1681 cm-1; 1H 
NMR (CDCl3): δ 1.44 [9H, s, C(CH3)3], 1.79-2.45 (2H, m, 
AzeC3H2), 2.85-3.10 (2H, m, Trp β-CH2), 3.20-3.41 (2H, m, Phe 
β-CH2), 3.52 (1H, m, Aze HC4H), 3.64 (3H, s, COOCH3), 3.92 
(1H, m, Aze HC4H), 4.58 (1H, m, Aze α-CH), 4.75 (2H, m, Phe 
α-CH and Trp α-CH), 6.90 and 7.82 [2H, br s (two conformers), 
Trp NH and Phe NH], 6.92-7.80 (10H, m, aromatics), 8.12 (1H, 
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s, Trp Ind-NH). Anal. Calcd for C30H36N4O6: C, 65.68; H, 6.61; 
N, 10.21. Found: C, 65.72; H, 6.62; N, 10.23. 
TFA·HN-Aze-Trp-Phe-OMe (10bd). Deprotection of the N-
Boc group was performed by adopting the general procedure B: 
9bd (0.218 g, 0.398 mmol), CH2Cl2/TFA (6 mL) gave 10bd 
(0.224 g, quantitative yield). 
N-Boc-Tyr-Aze-Trp-Phe-OMe (11bd). N-Boc-Tyr-OH 
(0.123 g, 0.438 mmol) in CH2Cl2 (10 mL) was treated with 
compound 10bd (0.224 g, 0.398 mmol) according to the general 
procedure A. Silica gel chromatography (CHCl3/EtOAc 1:1) 
gave a pure product 11bd as a white foam (0.145 g, 51%); [a]D -
11° (c 1, CHCl3); IR (CHCl3): ν 3477, 3428, 1741, 1666 cm-1; 
1H NMR (CDCl3): δ 1.41 [9H, s, C(CH3)3], 2.15-2.25 (2H, m, 
AzeC3H2), 2.51-3.80 (2H, m, Tyr β-CH2), 2.85-3.10 (2H, m, Trp 
β-CH2), 3.15-3.36 (2H, m, Phe β-CH2), 3.25 (1H, m, Aze 
HC4H), 3.65 (3H, s, COOCH3), 3.81 (1H, m, Aze HC4H), 4.23 
(1H, m, Tyr α-CH), 4.70 (3H, m, Aze α-CH, Phe α-CH and Trp 
α-CH), 5.21 (1H, d, J = 7.2 Hz Tyr NH), 6.50 (1H, d, J = 7.2 Hz 
Phe NH), 6.75 (1H, d, J = 7.6 Hz Trp NH), 6.60-7.80 (14H, m, 
aromatics), 8.38 (1H, s, Trp Ind-NH). Anal. Calcd for 
C39H45N5O8: C, 65.81; H, 6.37; N, 9.84. Found: C, 65.90; H, 
6.38; N, 9.86. 
N-Boc-Tyr-Aze-Trp-Phe-NH2 (12bd). A solution of the 
peptide methyl ester 11bd (0.073 g, 0.103 mmol) in MeOH/NH3 
sat. (3 mL) is allowed to stand in a pressure bottle at room 
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temperature according to the general procedure C. The title 
compound was obtained as a white solid pure on TLC (0.063 g, 
88%); 1H NMR (DMSO-d6): δ 1.45 [9H, s, C(CH3)3], 1.78 and 
2.29 (2H, two m, Aze C3H2), 2.60-3.20 (6H, m, Phe β-CH2, Trp 
β-CH2 and Tyr β-CH2), 3.67 and 4.04 (2H, two m, Aze C4H2), 
3.94 (1H, m, Tyr α-CH), 4.41 (1H, m, Trp α-CH), 4.48 (1H, m, 
Phe α-CH), 4.60 (1H, m, Aze α-CH), 6.55-7.35 (17H, m, 
aromatics, Tyr NH and CONH2), 8.00-8.25 (2H, m, Phe NH, 
Trp NH), 9.39 (1H, s, Tyr OH), 10.78 (1H, s, Trp Ind-NH). 
Anal. Calcd for C38H44N6O7: C, 65.50; H, 6.36; N, 12.06. 
Found: C, 65.69; H, 6.38; N, 12.09. 
TFA·H2N-Tyr-Aze-Trp-Phe-NH2 (2). Deprotection of the 
N-Boc group was performed by adopting the general procedure 
B: 12bd (0.030 g, 0.043mmol), CH2Cl2/TFA (6 mL) gave 2 
(0.031 g, quantitative yield); 1H NMR (DMSO-d6): δ 1.78 and 
2.29 (2H, two m, Aze C3H2), 2.60-3.20 (6H, m, Phe β-CH2, Trp 
β-CH2 and Tyr β-CH2), 3.67 and 4.04 (2H, two m, Aze C4H2), 
3.94 (1H, m, Tyr α-CH), 4.41 (1H, m, Trp α-CH), 4.48 (1H, m, 
Phe α-CH), 4.60 (1H, m, Aze α-CH), 6.55-7.35 (16H, m, 
aromatics and CONH2), 8.00-8.25 (5H, m, Phe NH, Trp NH and 
Tyr NH3+), 9.39 (1H, s, Tyr OH), 10.78 (1H, s, Trp Ind-NH). 
Anal. Calcd for C35H37F3N6O7: C, 59.15; H, 5.25; N, 11.82. 
Found: C, 59.27; H, 5.26; N, 11.83. 
N-Boc-3Aze-Phe-Phe-OMe (9ae). N-Boc-3Aze-OH (0.214 
g, 1.067 mmol) in CH2Cl2 (16 mL) was treated with compound 
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8a (0.392 g, 0.89 mmol) according to the general procedure A. 
Silica gel chromatography (CHCl3) gave a pure product 9ae as a 
white foam (0.440 g, 97%); [a]D +21° (c 1, CHCl3); IR (CHCl3): 
ν 3406, 1742, 1682 cm-1; 1H NMR (CDCl3): δ 1.46 [9H, s, 
C(CH3)3], 2.94-3.16 (5H, m, 3Aze α-CH, Phe3 and Phe4 β-CH2), 
3.70 (3H, s, COOCH3), 3.90-4.07 (4H, m, 3Aze C2H2 and 3Aze 
C4H2), 4.64 (1H, m, Phe3 α-CH), 4.75 (1H, m, Phe4 α-CH), 6.08 
(1H, d, J = 7.2 Hz Phe4 NH), 6.14 (1H, d, J = 7.2 Hz Phe3 NH) 
7.00-7.30 (10H, m, aromatics). Anal. Calcd for C28H35N3O6: C, 
65.99; H, 6.92; N, 8.25. Found: C, 66.25; H, 6.91; N, 8.28. 
TFA·HN-3Aze-Phe-Phe-OMe (10ae). Deprotection of the 
N-Boc group was performed by adopting the general procedure 
B: 9ae (0.405 g, 0.796 mmol), CH2Cl2/TFA (6 mL) gave 10ae 
(0.416 g, quantitative yield). 
N-Boc-Tyr-3Aze-Phe-Phe-OMe (11ae). N-Boc-Tyr-OH 
(0.246 g, 0.876) in CH2Cl2 (14 mL) was treated with compound 
10ae (0.416 g, 0.796 mmol) according to the general procedure 
A. Silica gel chromatography (CHCl3/EtOAc 9:1) gave a pure 
product 11ae as a white foam (0.350 g, 65%); [a]D +26° (c 1, 
CHCl3); IR (CHCl3): ν 3426, 1741, 1661 cm-1; 1H NMR 
(CDCl3): δ 1.46 [9H, s, C(CH3)3], 2.75-3.21 (11H, m, 3Aze 
C2H2, 3Aze C4H2, Tyr β-CH2, Phe3 β-CH2, Phe4 β-CH2 and Phe3 
α-CH), 3.73 (3H, s, COOCH3), 3.63-4.08 (1H, m, 3Aze α-CH), 
4.15 (1H, m, Tyr α-CH), 4.75 (1H, m, Phe4 α-CH), 5.80 (1H, br 
s, Tyr NH), 5.96 (1H, br s, Phe3 NH), 6.61 (1H, d, J = 7.2 Hz 
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Phe4 NH), 6.72-7.35 (14H, m, aromatics). Anal. Calcd for 
C37H44N4O8: C, 66.05; H, 6.59; N, 8.33. Found: C, 65.85; H, 
6.57; N, 8.30. 
N-Boc-Tyr-3Aze-Phe-Phe-NH2 (12ae). A solution of the 
peptide methyl ester 11ae (0.12 g, 0.176 mmol) in MeOH/NH3 
sat. (5 mL) is allowed to stand in a pressure bottle at room 
temperature according to the general procedure C. The title 
compound was obtained as a white solid pure on TLC (0.11 g, 
96%); 1H NMR (DMSO-d6): δ 1.46 [9H, s, C(CH3)3], 2.55-3.90 
(11H, m, 3Aze C3H2, 3Aze C4H2, Tyr β-CH2, Phe3 β-CH2, Phe4 
β-CH2 and 3Aze α-CH), 3.99 (1H, m, Tyr α-CH), 4.47-4.53 
(2H, m, Phe3 α-CH and Phe4 α-CH), 6.50 (1H, d, J = 7.2 Hz, 
Tyr NH), 6.61-7.36 (16H, m, aromatics and CONH2), 8.00-8.31 
(2H, m, Phe3 NH and Phe4 NH), 9.41 (1H, s, Tyr OH). Anal. 
Calcd for C36H43N5O7: C, 65.74; H, 6.59; N, 10.65. Found: C, 
65.93; H, 6.60; N, 10.68. 
TFA·H2N-Tyr-3Aze-Phe-Phe-NH2 (4). Deprotection of the 
N-Boc group was performed by adopting the general procedure 
B: 12ae (0.049 g, 0.075 mmol), CH2Cl2/TFA (6 mL) gave 4 
(0.050 g, quantitative yield); 1H NMR (DMSO-d6): δ 2.55-3.90 
(11H, m, 3Aze C3H2, 3Aze C4H2, Tyr β-CH2, Phe3 β-CH2, Phe4 
β-CH2 and 3Aze α-CH), 3.99 (1H, m, Tyr α-CH), 4.47-4.53 
(2H, m, Phe3 α-CH and Phe4 α-CH), 6.61-7.36 (16H, m, 
aromatics and CONH2), 8.00-8.31 (5H, m, Phe3 NH, Phe4 NH 
and Tyr NH3+), 9.41 (1H, s, Tyr OH). Anal. Calcd for 
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C33H36F3N5O7: C, 59.01; H, 5.40; N, 10.43. Found: C, 59.22; H, 
5.41; N, 10.45.  
N-Boc-3Aze-Trp-Phe-OMe (9be). N-Boc-3-Aze-OH (0.123 
g, 0.613 mmol) in CH2Cl2 (10 mL) was treated with compound 
8b (0.267 g, 0.558 mmol) according to the general procedure A. 
Silica gel chromatography (CHCl3) gave a pure product 9be as a 
white foam (0.244 g, 80%); [a]D +24° (c 1, CHCl3); IR (CHCl3): 
ν 3477, 1743, 1682 cm-1; 1H NMR (CDCl3): δ 1.46 [9H, s, 
C(CH3)3], 2.88-3.45 (6H, m, 3Aze C3H2, Trp β-CH2 and Phe4 β-
CH2), 3.68 (3H, s, COOCH3), 3.96-4.05 (2H, m, 3Aze C4H2), 
4.01 (1H, m, 3Aze α-CH), 4.72 (2H, m, Phe α-CH and Trp α-
CH), 6.00 (1H, br s, Trp NH), 6.35 (1H, br s, Phe4 NH), 6.82-
7.75 (10H, m, aromatics), 8.12 (1H, s, Trp Ind-NH). Anal. Calcd 
for C30H36N4O6: C, 65.68; H, 6.61; N, 10.21. Found: C, 65.74; 
H, 6.62; N, 10.23. 
TFA·HN-3Aze-Trp-Phe-OMe (10be). Deprotection of the 
N-Boc group was performed by adopting the general procedure 
B: 9be (0.217 g, 0.396 mmol), CH2Cl2/TFA (6 mL) gave 10be 
(0.222 g, quantitative yield). 
N-Boc-Tyr-3Aze-Trp-Phe-OMe (11be). N-Boc-Tyr-OH 
(0.123 g, 0.436 mmol) in CH2Cl2 (10 mL) was treated with 
compound 10be (0.222 g, 0.396 mmol) according to the general 
procedure A. Silica gel chromatography (CHCl3/EtOAc 1:2) 
gave a pure product 11be as a white foam (0.200 g, 71%); [a]D 
+10° (c 1, CHCl3); IR (CHCl3): ν 3475, 3424, 1741, 1656 cm-1; 
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1H NMR (CDCl3): δ 1.45 [9H, s, C(CH3)3], 2.72-3.23 (8H, m, 
3Aze C3H2 Trp β-CH2, Phe4 β-CH2 and Tyr β-CH2), 3.57-3.99 
(3H, m, 3Aze C3H2 and 3Aze α-CH), 3.67 (3H, s, COOCH3), 
4.01 (1H, m, 3Aze α-CH), 4.14 (1H, m, Tyr α-CH), 4.72 (2H, 
m, Phe α-CH and Trp α-CH), 5.45 (1H, m, Tyr NH), 6.23 (1H, 
br s, Trp NH), 6.68 and 7.63 (1H, two conformers, Phe NH), 
6.82-7.63 (14H, m, aromatics), 8.74 (1H, s, Trp Ind-NH). Anal. 
Calcd for C39H45N5O8: C, 65.81; H, 6.37; N, 9.84. Found: C, 
66.01; H, 6.38; N, 9.86. 
N-Boc-Tyr-3Aze-Phe-Trp-NH2 (12be). A solution of the 
peptide methyl ester 11be (0.07 g, 0.098 mmol) in MeOH/NH3 
sat. (3 mL) is allowed to stand in a pressure bottle at room 
temperature according to the general procedure C. The title 
compound was obtained as a white solid pure on TLC (0.058 g, 
85%); 1H NMR (DMSO-d6): δ 1.43 [9H, s, C(CH3)3], 2.55-3.90 
(11H, m, 3Aze C3H2, 3Aze C4H2, Tyr β-CH2, Trp β-CH2, Phe β-
CH2 and 3Aze α-CH), 3.99 (1H, m, Tyr α-CH), 4.42 (1H, m, 
Trp α-CH), 4.52 (1H, m, Phe α-CH), 6.58-7.59 (17H, m, 
aromatics, Tyr NH and CONH2), 8.04-8.33 (2H, m, Trp NH, 
Phe NH), 9.40 (1H, s, Tyr OH), 10.79 (1H, s, Trp Ind-NH). 
Anal. Calcd for C38H44N6O7: C, 65.50; H, 6.36; N, 12.06. 
Found: C, 65.63; H, 6.24; N, 12.09. 
TFA·H2N-Tyr-3Aze-Trp-Phe-NH2 (5). Deprotection of the 
N-Boc group was performed by adopting the general procedure 
B: 12be (0.043 g, 0.062 mmol), CH2Cl2/TFA (6 mL) gave 5 
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(0.044 g, quantitative yield); 1H NMR (DMSO-d6): δ 2.55-3.90 
(11H, m, 3Aze C3H2, 3Aze C4H2, Tyr β-CH2, Trp β-CH2, Phe β-
CH2 and 3Aze α-CH), 3.99 (1H, m, Tyr α-CH), 4.42 (1H, m, 
Trp α-CH), 4.52 (1H, m, Phe α-CH), 6.58-7.59 (16H, m, 
aromatics and CONH2), 8.04-8.33 (5H, m, Trp NH, Phe NH and 
Tyr NH3+), 9.40 (1H, s, Tyr OH), 10.79 (1H, s, Trp Ind-NH). 
Anal. Calcd for C35H37F3N6O7: C, 59.15; H, 5.25; N, 11.82. 
Found: C, 59.29; H, 5.27; N, 11.78. 
Boc-∆3Pro-Phe-Phe-OMe (9ac). N-Boc-∆3Pro-OH (0.118 g, 
0.554 mmol) in CH2Cl2 (10 mL) was treated with compound 8a 
(0.222 g, 0.504 mmol) according to the general procedure A. 
Silica gel chromatography (CHCl3/EtOAc 1:2) gave a pure 
product 9ac as a white foam (0.186 g, 71%); 1H NMR (CDCl3): 
δ 1.45 [9H, s, C(CH3)3], 2.83-3.09 (4H, m, Phe3 β-CH2, Phe4 β-
CH2), 3.67 (3H, s, COOCH3), 3.93-4.61 (4H, m, Phe3 α-CH, 
Phe4 α-CH and ∆3Pro C5H2), 5.18 (1H, s, ∆3Pro α-CH), 5.72 and 
6.01 (2H, 2 br s, ∆3Pro CH=CH), 6.09-7.36 (10H, m, aromatics), 
8.12-8.25 (2H, m, Phe3 NH and Phe4 NH). Anal. Calcd for 
C29H35N3O6: C, 66.78; H, 6.76; N, 8.06. Found: C, 66.98; H, 
6.78; N, 8.08. 
TFA·HN-∆3Pro-Phe-Phe-OMe (10ac). Deprotection of the 
N-Boc group was performed by adopting the general procedure 
B: 9ac (0.150 g, 0.288 mmol), CH2Cl2/TFA (6 mL) gave 10ac 
(0.154 g, quantitative yield). 
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Boc-Tyr-∆3Pro-Phe-Phe-OMe (11ac). N-Boc-Tyr-OH 
(0.089 g, 0.317 mmol) in CH2Cl2 (10 mL) was treated with 
compound 10ac (0.154 g, 0.288 mmol) according to the general 
procedure A. Silica gel chromatography (CHCl3/EtOAc 1:2) 
gave a pure product 11ac as a white foam (0.128 g, 65%); 1H 
NMR (CDCl3): δ 1.43 [9H, s, C(CH3)3], 2.83-3.09 (6H, m, Phe3 
β-CH2, Phe4 β-CH2, Tyr β-CH2), 3.67 (3H, s, COOCH3), 3.93-
4.61 (5H, m, Phe3 α-CH, Phe4 α-CH, Tyr α-CH and ∆3Pro 
C5H2), 5.18 (1H, s, ∆3Pro α-CH), 5.72 and 6.01 (2H, 2 br s, 
∆3Pro CH=CH), 6.09-7.36 (15H, m, aromatics and Tyr NH), 
8.12-8.25 (2H, m, Phe3 NH, Phe4 NH), 9.51 (1H, s, Tyr OH). 
Anal. Calcd for C38H44N4O8: C, 66.65; H, 6.48; N, 8.18. Found: 
C, 66.84; H, 6.49; N, 8.20.  
Boc-Tyr-∆3Pro-Phe-Phe-NH2 (12ac). A solution of the 
peptide methyl ester 11ac (0.090 g, 0.131 mmol) in MeOH/NH3 
sat. (6.3 mL) is allowed to stand in a pressure bottle at room 
temperature according to the general procedure C. The title 
compound was obtained as a white solid pure on TLC (0.061 g, 
70%); 1H NMR (DMSO-d6): δ 1.43 [9H, s, C(CH3)3], 2.83-3.09 
(6H, m, Phe3 β-CH2, Phe4 β-CH2, Tyr β-CH2), 3.93-4.61 (5H, m, 
Phe3 α-CH, Phe4 α-CH, Tyr α-CH and ∆3Pro C5H2), 5.18 (1H, s, 
∆3Pro α-CH), 5.72 and 6.01 (2H, 2 br s, ∆3Pro CH=CH), 6.09-
7.36 (17H, m, aromatics, Tyr NH and CONH2), 8.12-8.25 (2H, 
m, Phe3 NH and Phe4 NH), 9.51 (1H, s, Tyr OH). Anal. Calcd 
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for C37H43N5O7: C, 66.35; H, 6.47; N, 10.46. Found: C, 66.54; 
H, 6.48; N, 10.49.  
TFA·H2N-Tyr-∆3Pro-Phe-Phe-NH2 (1). Deprotection of the 
N-Boc group was performed by adopting the general procedure 
B: 12ac (0.040 g, 0.06 mmol), CH2Cl2/TFA (6 mL) gave 1 
(0.041 g, quantitative yield); 1H NMR (DMSO-d6): δ 2.83-3.09 
(6H, m, Phe3 β-CH2, Phe4 β-CH2, and Tyr β-CH2), 3.93-4.61 
(5H, m, Phe3 α-CH, Phe4 α-CH, Tyr α-CH and ∆3Pro C5H2), 
5.18 (1H, s, ∆3Pro α-CH), 5.72 and 6.01 (2H, 2 br s, ∆3Pro 
CH=CH), 6.09-7.36 (16H, m, aromatics and CONH2), 8.12-8.25 
(5H, m, Phe3 NH, Phe4 NH and Tyr NH3+), 9.51 (1H, s, Tyr 
OH). Anal. Calcd for C34H36F3N5O7: C, 59.73; H, 5.31; N, 
10.24. Found: C, 59.55; H, 5.36; N, 10.30.  
Boc-Tyr-Cys(Me)-OMe. N-Boc-Tyr-OH (0.834 g, 2.97 
mmol) in CH2Cl2 (10 mL) was treated with HCl·H2N-Cys(Me)-
OMe (0.500 g, 2.70 mmol) according to the general procedure 
A. Silica gel chromatography (CHCl3/EtOAc 1:1) gave a pure 
product as a white foam (0.845 g, 76%); 1H NMR (CDCl3): δ 
1.45 [9H, s, C(CH3)3], 2.15 (3H, s, Cys CH3), 2.72-3.01 (4H, m, 
Cys β-CH2 and Tyr β-CH2), 3.73 (3H, s, COOCH3), 3.93 (1H, 
m, Tyr α-CH), 4.49 (1H, m, Cys α-CH), 6.62 (1H, d, J = 7.6 Hz, 
Tyr NH), 6.99 (1H, d, J = 8.0 Hz, Cys NH), 6.68 and 7.08 (4H, 
m, aromatics), 9.51 (1H, s, Tyr OH). Anal. Calcd for 
C19H28N2O6S: C, 55.32; H, 6.84; N, 6.79. Found: C, 55.48; H, 
6.86; N, 6.81. 
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Boc-Tyr-Cys(Me)-Phe-OMe. N-Boc-Tyr-Cys(Me)-OH 
(0.772 g, 1.94 mmol), obtained by treatment with 1N NaOH (3 
equiv.) in MeOH (10 mL), in CH2Cl2 (10 mL) was treated with 
HCl·H2N-Phe-OMe (0.378 g, 1.76 mmol) according to the 
general procedure A. Silica gel chromatography (CHCl3/EtOAc 
1:1) gave a pure product as a white foam (0.688 g, 70%); 1H 
NMR (CDCl3): δ 1.45 [9H, s, C(CH3)3], 2.15 (3H, s, Cys CH3), 
2.72-3.09 (6H, m, Cys β-CH2, Phe β-CH2 and Tyr β-CH2), 3.73 
(3H, s, COOCH3), 3.93 (1H, m, Tyr α-CH), 4.49 (1H, m, Cys α-
CH), 4.52 (1H, m, Phe α-CH), 6.62 (1H, d, J = 7.6 Hz, Tyr NH), 
6.99 (1H, d, J = 8.0 Hz, Cys NH), 6.65-7.03 (10H, m, aromatics 
and Phe NH), 9.51 (1H, s, Tyr OH). Anal. Calcd for 
C28H37N3O7S: C, 60.09; H, 6.66; N, 7.51. Found: C, 60.27; H, 
6.67; N, 7.53. 
Boc-Tyr-Cys[(O)Me)]-Phe-OMe (3a). Sodium 
metaperiodate (0.251 g, 1.18 mmol) was dissolved in water (5 
mL) and cooled to 0 °C. Boc-Tyr-Cys(Me)-Phe-OMe (0.600 g, 
1.07 mmol) was dissolved in dioxane (10 mL) and added 
dropwise to the oxidant. Stirring was continued for 1 h. The 
reaction mixture was concentrated to remove organic solvent 
and the product extracted with CH2Cl2 (2 x 25 mL). The 
combined organic phases were washed with water (2 x 30 mL), 
brine (30 mL) and dried. Concentration of the organic phases in 
vacuo yielded both diastereoisomers of the title compound 
(0.609 g, 99%); 1H NMR (CDCl3): δ 1.45 [9H, s, C(CH3)3], 2.65 
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(3H, s, Cys-(O)CH3), 2.72-3.09 (6H, m, Cys β-CH2, Phe β-CH2 
and Tyr β-CH2), 3.71 (3H, s, COOCH3), 3.93 (1H, m, Tyr α-
CH), 4.49 (1H, m, Cys α-CH), 4.52 (1H, m, Phe α-CH), 6.62 
(1H, d, J = 7.6 Hz, Tyr NH), 6.99 (1H, d, J = 8.0 Hz, Cys NH), 
6.65-7.03 (10H, m, aromatics and Phe NH), 9.51 (1H, s, Tyr 
OH). Anal. Calcd for C28H37N3O8S: C, 58.42; H, 6.48; N, 7.30. 
Found: C, 58.59; H, 6.49; N, 7.32. 
Boc-Tyr-∆Ala-Phe-OMe. Compound 3a (0.59 g, 1.03 
mmol) was dissolved in MeOH (5 mL), DBU (0.313 g, 0.31 
mL) added and the reaction mixture stirred at room temperature 
for 1.5 h. The reaction mixture was evaporated to dryness. The 
resulting compound was purified by column chromatography on 
silica gel (EtOAc/hexane 1:1) yielding the title compound as a 
colourless glass (0.505 g, 96% yield); 1H NMR (DMSO-d6): δ 
1.45 [9H, s, C(CH3)3], 2.83-3.09 (4H, m, Phe β-CH2 and Tyr β-
CH2), 3.71 (3H, s, COOCH3), 3.93 (1H, m, Tyr α-CH), 4.52 
(1H, m, Phe α-CH), 4.80 and 5.47 (2H, s, ∆Ala CH2), 6.62 (1H, 
d, J = 7.6 Hz, Tyr NH), 6.65-7.21 (9H, m, aromatics), 7.46 (1H, 
s, ∆Ala NH), 8.11 (1H, d, J = 7.2 Hz, Phe NH), 9.51 (1H, s, Tyr 
OH). Anal. Calcd for C27H33N3O7: C, 63.39; H, 6.50; N, 8.21. 
Found: C, 63.58; H, 6.52; N, 8.23. 
Boc-Tyr-∆Ala-Phe-OH (4a). Boc-Tyr-∆Ala-Phe-OMe 
(0.480 g, 0.94 mmol) was dissolved in MeOH (8 mL) and 
cooled on an ice bath whilst 1N NaOH (4.7 mL) was added 
dropwise. The reaction was allowed to warm to room 
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temperature over 1.5 h. The reaction mixture was concentrated, 
acidified to pH 4 with 2M KHSO4 and the product extracted into 
CH2Cl2 (2 x 30 mL). The combined organics were washed with 
water, brine, dried and concentrated in vacuo yielding the 
desired compound 4a as a white foam (0.467 g, quantitative 
yield). 
Boc-Tyr-∆Ala-Phe-Phe-NH2 (5a). Compound 4a (0.450g, 
0.905 mmol) in CH2Cl2 (10 mL) was treated with HCl·H2N-Phe-
NH2 (0.164 g, 0.822 mmol) according to the general procedure 
A. Silica gel chromatography (CHCl3/EtOAc 1:2) gave a pure 
product 5a as a white foam (0.264 g, 50%); 1H NMR (DMSO-
d6): δ 1.45 [9H, s, C(CH3)3], 2.83-3.09 (6H, m, Phe3 β-CH2, 
Phe4 β-CH2 and Tyr β-CH2), 3.93 (1H, m, Tyr α-CH), 4.47-4.53 
(2H, m, Phe3 α-CH and Phe4 α-CH), 4.80 and 5.47 (2H, s, ∆Ala 
CH2), 6.62 (1H, d, J = 7.6 Hz, Tyr NH), 6.65-7.21 (16H, m, 
aromatics and CONH2), 7.46 (1H, s, ∆Ala NH), 8.11 (1H, d, J = 
7.2 Hz, Phe3 NH), 8.37 (1H, d, J = 7.2 Hz, Phe4 NH), 9.51 (1H, 
s, Tyr OH). Anal. Calcd for C35H41N5O7: C, 65.30; H, 6.42; N, 
10.88. Found: C, 65.49; H, 6.44; N, 10.91. 
TFA·H2N-Tyr-∆Ala-Phe-Phe-NH2 (6). Deprotection of the 
N-Boc group was performed by adopting the general procedure 
B: 5a (0.1 g, 0.155 mmol), CH2Cl2/TFA (6 mL) gave 6 (0.101 g, 
quantitative yield); 1H NMR (DMSO-d6): δ 2.74-3.07 (6H, m, 
Tyr β-CH2, Phe3 β-CH2, Phe4 β-CH2), 4.24 (1H, m, Tyr α-CH), 
4.50-4.58 (2H, m, Phe3 α-CH and Phe4 α-CH), 5.54 and 6.17 
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(2H, two s, ∆Ala CH2), 6.69-7.29 (16H, m, aromatics and 
CONH2), 7.46 (1H, s, ∆Ala NH), 8.09 (3H, br, Tyr NH3+), 8.18 
and 8.56 (2H, two d, Phe3 NH and Phe4 NH), 9.69 (1H, s, Tyr 
OH). Anal. Calcd for C32H34F3N5O7: C, 58.44; H, 5.21; N, 
10.65. Found: C, 58.37; H, 5.26; N, 10.61. 
 
1.4.3.3 Biological assays 
 
Receptor binding affinities to the δ- and µ-opioid receptors 
were performed using cell membrane preparations from 
transfected cells that stably express the respective receptors. The 
radiolabeled ligands used were [3H]DPDPE and [3H]DAMGO 
for δ- and µ-receptors, respectively (for more details about the 
procedure see Ref. 92). The in vitro tissue bioassays (MVD and 
GPI/LMMP) were performed as described previously.93 IC50 
values represent means of no less than four experiments. IC50 
values, relative potency estimates, and their associated standard 
errors were determined by fitting the data to the Hill equation by 
a computerised non-linear least-squares method. 
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1.5 Synthesis and evaluation of new endomorphin-2 
analogues containing (Z)-α,β-dehydrophenilalanine 
(∆ZPhe) residues*  
 
The alteration of the backbone sequence of native bioactive 
peptides through incorporation of unnatural amino acids or 
exogenous fragments of a different structure, is a common 
strategy adopted in medicinal chemistry in order to study their 
structure activity relationships and to obtain compounds with 
improved potency, selectivity, and potential therapeutic value. 
Recent and significant examples of this approach can be 
found in the field of endomorphins, two endogenous 
neuropeptides [endomorphin-1: Tyr-Pro-Trp-Phe-NH2 (EM-1) 
and endomorphin-2: Tyr-Pro-Phe-Phe-NH2 (EM-2)], whose 
main proposed biological function is the pain control through 
activation, with high affinity and selectivity, of µ-opioid 
receptors.23,24 A systematic evaluation of a variety of synthetic 
endomorphin analogues have provided insights into various 
structural and conformational features which are critical for the 
bioactivity of this family of neuropeptides.94,95 The role exerted 
by the proline residue at position 2 of the tetrapeptide backbone 
as well as the spatial orientation adopted by the two Phe 
aromatic side chains at positions 3 and 4 appear to be 
                                                 
*Torino, D.; Mollica, A; Pinnen, F.; Feliciani, F.; Lucente, G.;  
Fabrizi, G.; Portalone, G.; Davis, P.; Lai, J.; Ma, S-W.; Porreca F.; 
Hruby, V. J. J. Med. Chem. (submitted) 
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particularly relevant.50,68,91 Several papers, dealing with the 
incorporation at position 2 of EM with higher and lower 
homologues of proline,74,96,97 and cyclic β-residues58,65,69 
document the attention dedicated to this first point. Also clearly 
documented is the influence that the mutual spatial orientation 
of the aromatic rings exerts on the interaction between EMs and 
their receptors.57,98,99 The interest focused on this specific effect 
is based on the well recognized influence of the non bonded 
aromatic/aromatic and backbone/aromatic interactions on the 
conformational stability of the peptide.  
In accordance with the above reported observations, a 
literature examination reveals that several papers, have 
described structural modifications performed on the EM native 
sequences, which specifically focused on replacement of the 
Phe3 and Phe4 residues. In Figure 11 most of the so far 
incorporated Phe mimic residues are illustrated. 
Of particular interest appears the enhancement of activity 
and selectivity of EM analogues obtained through incorporation 
of β-methylated Phe residues (Figure 11) performed by 
Tomboly and coworkers.102 The interesting rationale followed 
by these authors is based on the reduction of the conformational 
mobility of the Phe aromatic side chains by biasing, according to 
the original proposals of Hruby,103,104 the population of the χ1 
(torsion angle) rotamers. By following a related and still 
unexplored  approach  we  decided  to synthesize and investigate 
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Figure 11.  Structures a-g illustrate examples of aromatic amino acids so far 
used to replace native residues at positions 3 and/or 4 of endomorphins. The 
structure in the box refers to ∆ZPhe, the achiral α,β-didehydro-amino acid 
adopted in the present study. (a): 3-(1-naphtyl)-alanine (1Nal);70 (b): 3-(2-
naphthyl)-alanine (2Nal);70 (c): phenylglycine (Phg);57,100 (d): 
homophenylalanine (Hfe);100 (e): p-Cl phenylalanine;101 (f): histidine;98 (g): β-
methyl-phenylalanine (β-MePhe).102 
 
the properties of a series of EM analogues incorporating α,β-
unsaturated phenylalanine residues at the position 3 and 4. In 
analogues with this structure the aromatic ring, and each of its 
two adjacent backbone amide groups, are bound to a sp2 
hybridized Cβ or Cα atom, respectively. As a consequence, the 
achiral ∆Phe residue exerts conformational constraint on the 
backbone and restricts, at the same time, the β-aromatic 
substituent to the either (Z) or (E) orientation. These steric and 
stereochemical features, together with the chemical properties 
connected with the electronic distribution within the involved 
peptide bonds, render α,β-dehydroamino acids an appealing tool 
for the development of variants of naturally occurring bioactive 
peptides. The consequences of this structural alteration appear 
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quite relevant in the case of the tetrapeptidic EMs molecule. 
Here in fact three closely located aromatic side chains are 
present and their location involves both the “message” Tyr-Pro-
Phe- N-terminal moiety and the Phe-NH2 “address” C-terminal 
fragment.105 
 
1.5.1 Chemistry 
 
The syntheses of three EM-2 analogues Tyr-Pro-∆ZPhe-Phe-
NH2 {[∆ZPhe3]EM-2} (1), Tyr-Pro-Phe-∆ZPhe-NH2 
{[∆ZPhe4]EM-2} (2) and Tyr-Pro-∆ZPhe-∆ZPhe-NH2 
{[∆ZPhe3,4]EM-2} (3) are here reported. Incorporation of the 
∆ZPhe residue has been accomplished by performing an acetic 
anhydride mediated azlactonization-dehydration reaction on 
dipeptide or tripeptide units containing C-terminal β-hydroxy-
D,L-phenylalanine.106 Scheme 4 outlines the synthesis of the 
[∆ZPhe3] and [∆ZPhe3,4] EM-2 analogs. The common 
intermediate Boc-Pro-∆ZPhe-azlactone 5 is used to obtain both 
the final tetrapeptides 1 and 3. Ring opening of the C-terminal 
unsaturated azlactone 5 with the sodium salt of β-hydroxy-D,L-
phenylalanine, followed by azlactonization and subsequent 
treatment with MeOH/DMAP is the key step for the 
incorporation of the two consecutive ∆ZPhe residues in the 
tetrapeptide 3. An analogous synthetic pathway is illustrated in 
Scheme 5 where the synthesis of [∆ZPhe4]EM-2 (2) is outlined. 
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Scheme 4. Synthesis of compound 1-3. Reagents and conditions: a) 
(CH3CO)2O/CH3COONa, 24 h rt; b) HCl·H2N-Phe-OMe, DIEA, DMAP, 
CH2Cl2, 12 h rt; c) TFA/CH2Cl2 1:1, 1 h rt; d) Boc-Tyr-OH, EDC, HOBt, 
NMM, CH2Cl2, 30 min 0 °C, 12 h rt; e) NH3/MeOH, 48 h rt; f) DL-3-β-
(OH)Phe-OH, 1N NaOH, acetone, 12 h rt; g) DMAP, MeOH, 12 h rt. 
 
3
3 2
 
Scheme 5. Synthesis of compound 2. Reagents and conditions: a) 
(CH3CO)2O/CH3COONa, 24 h rt; b) DMAP, MeOH, 12 h rt; c) TFA/CH2Cl2 
1:1, 1 h rt; d) Boc-Pro-OH, EDC, HOBt, NMM, CH2Cl2, 30 min 0 °C, 12 h 
rt; e) Boc-Tyr-OH, EDC, HOBt, NMM, CH2Cl2, 30 min 0 °C, 12 h rt; f) 
NH3/MeOH, 48 h  rt. 
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1.5.2 Results and discussion 
 
Table 2 summarizes binding affinity and functional 
bioactivity for µ and δ opioid receptors of the here studied EM-2 
analogues. Data reported indicate that [∆ZPhe3]EM-2 (1) and 
[∆ZPhe3,4]EM-2 (3) bind weakly to µ receptors (Kiµ = 202 nM 
and 128 nM, respectively) and are, although with a certain µ 
selectivity, weakly active in the GPI assay. Conversely, the 
analogue [∆ZPhe4]EM-2 (2) shows potent µ binding affinity and 
high µ versus δ selectivity (Kiδ /Kiµ = 1200 ca.) with high 
potency in the GPI assay, comparable to the parent EM-2. Thus, 
binding and bioassays data indicate that, the incorporation of the 
∆ZPhe at position 3 or at positions 3 and 4 simultaneously, are 
both detrimental structural modifications. The corresponding 
alteration, performed at position 4 only, leads to the ligand 2 
which maintains high affinity and activity together with the µ 
selectivity typical of the native ligand. 
 
Table 2.  Binding affinity and in vitro activity for compounds 1-3 and EM-2.  
 
a Displacement of [3H]DAMGO (µ-selective) and [3H]DPDPE (δ-selective) 
from rat brain membrane binding sites. 
b ± S.E.M. 
c n.c. = not binding recorded. 
Chapter 1 
 
66 
In order to gain further information on the preferred 
conformation of the new ligands we examined the 2D 1H NMR 
structures of the new ligands 1-3, the conformation adopted in 
solution, and in the crystal structure of 8, the Nα-Boc derivative 
of 1, namely Boc-Tyr-Pro-∆ZPhe-Phe-NH2 (see Scheme 4). 
Single crystals of 8 were successfully obtained by slow 
evaporation from a solution in  MeOH. The molecule (Figure 12 
and Table 3) presents a trans Tyr-Pro amide bond and adopts a 
H-bond stabilized β-turn structure with the Pro and ∆ZPhe 
residues at the i+1 and i+2 corner positions, respectively, of the 
turn. As for the endomorphin µ-receptor agonists, only two other 
crystal structures  have been reported,  i.e. [D-Tic2]EM-2107  and 
[Chx2]EM-256 in addition to the C-terminal free acid Tyr-Pro-
Phe-Phe-OH,55 this latter completely devoid of µ-opioid 
receptor agonist activity. The X-ray crystal structure of 8 gives 
then the first available information on the solid state 
conformation adopted by an N-protected EM analogue. As 
shown in Table 4 and Figure 13 [∆ZPhe3]EM-2 (1) and its Nα-
Boc protected derivative 8 show strong sequential NOEs Pro 
CαH···∆ZPhe3 NH. This effect is observed, for both 1 and 8,  by 
two interresidue NOEs which are not found in the case of 
[∆ZPhe4]EM-2 (2) and [∆ZPhe3,4]EM-2 (3): the first between the 
NH groups of ∆ZPhe3 and Phe4 and the second between Pro CαH 
and Phe4 NH (i.e. between the “i+2 and i+3” and “i+1 and i+3” 
residues, respectively, of a β-turn).  
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Figure 12.  X-ray crystal structure of Boc-Tyr-Pro-∆ZPhe-Phe-NH2 (8), with 
numbering of the atoms. The intramolecular H-bond is shown as a dashed 
double line.  
 
Table 3.  Main backbone and side chains torsion 
angles (°) of the X-ray crystal structure of 8a. 
 
a Numbers in parenthesis are e.s.d. values. 
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Table 4.  Observed NOE cross peaks and intensities 
of analogs 1-3 and 8a in DMSO-d6. 
 
a NOE intensities are classified as weak (1.6 - 5.0 Å), 
medium (1.6 - 3.6 Å) and strong (1.6 - 2.9 Å). b The 
Pro CαH is partially overlapped with Phe CαH. 
 
These data strongly suggest that the Nα-Boc derivative 8 
maintains in DMSO-d6 solution the folded conformation found 
in the crystal and that the same conformational preference is 
also shown by its N-terminal free analog 1. It is worth noting 
that findings on 1 and 8 are those expected on the basis of 
literature on peptides containing α,β-didehydro amino acid 
where the strong tendency of the ∆ZPhe residue to occupy the 
i+2 position of β-turns is well documented.108,109 No NOEs 
indicative of folded structures could be found in the spectra of 
the two peptides [∆ZPhe4]EM-2 (2) and [∆ZPhe3,4]EM-2 (3). 
Furthermore, the presence of the sequential NOEs Pro CαH···Phe 
NH and Phe NH···∆ZPhe NH in the spectrum of 2 are consistent 
with an extended structure. 
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Figure 13. Relevant interproton correlations as deduced by ROESY 
experiments of compounds 1, 2 and 8. 
 
1.5.3 Conclusions 
 
As revealed by literature data the tetrapeptidic molecule of 
EMs is characterized by considerable conformational  flexibility 
involving both the backbone and the aromatic side chains. 
Although the optimal three-dimensional arrangement of the EM 
pharmacophoric elements favouring selectivity and potency as µ 
agonist is not yet resolved, the relevant role of a proper spatial 
orientation of the aromatic rings, and in particular of the 
benzylic side chains at position 3 and 4, is well established. Here 
we have examined the properties of new EM analogues in which 
Phe mimics, with the aromatic ring blocked in the (Z) spatial 
orientation, have been incorporated. A remarkable difference is 
observed in the receptor affinity and functional bioactivity 
between [∆ZPhe4]EM-2 (2), possessing the aromatic at position 
3 free to adopt a proper spatial orientation, and the analogue 
[∆ZPhe3]EM-2 (1) in which the Phe at position 3 is forced to the 
rigid (Z) orientation imposed by the olefinic geometry of the 
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residue. These results underline the importance of the correct 
orientation of the aromatic rings, and suggest, at the same time, 
that the performed modification of Phe3, in the Tyr-Pro-Phe- 
“message” moiety, leads to the ligand 1 in which both the folded 
conformation of the backbone and the third aromatic ring spatial 
orientation are unfavourable features for proper interaction with 
the receptor. The [∆ZPhe4]EM-2 (2) analogue, which maintains 
unchanged the native EM “message” sequence and an extended 
backbone conformation exhibits a high activity, comparable to 
that of EM-2. In this analogue the aromatic side chain at 
position 3 is not forced to a ∆Z orientation and can adopt a 
proper orientation in the receptor pocket. This interpretation 
appears to be in agreement with the previously described EM 
analogues containing β-MePhe stereoisomers.102 Here, the 
highest activity is shown by the ligand Tyr-Pro-Phe-(2S,3S)-β-
MePhe-NH2 which maintains the native Phe3 residue and 
possesses at position 4 an aromatic side chain properly oriented 
by the stereochemistry of the β-MePhe residue. 
 
1.5.4 Experimental section 
 
Materials and methods. Spectrograde solvents were 
purchased from Merck; all the other solvents and reagents were 
of the purest grade commercially available. TLC (thin layer 
chromatography) and PLC (preparative layer chromatography) 
were performed on silica gel Merck 60 F254 plates. The drying 
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agent was sodium sulphate. All 1D and 2D 1H NMR 
experiments were performed at 400 MHz on a Bruker Avance 
400 NMR spectrometer with a constant temperature at 298 K. 
The ROESY spectra were obtained using standard pulse 
programs, with a mixing times of 300 ms. The 2D NMR 
matrixes were created and analyzed using the TOPSPIN 3.0a 
computer program (Bruker Biospin - 2009). Each two-
dimensional spectrum was acquired in a 1024 x 1024 data 
matrix complex points in F1 and F2. Zero filling in F1 and sine 
windows in both dimensions were applied before Fourier 
transformation. Chemical shifts (δ) are quoted in parts per 
million (ppm) downfield from tetramethylsilane, and values of 
coupling constants are given in Hz. The purity of all tested 
compounds was determined by combustion analysis and they are 
≥ 95% pure. HRMS data of final products are also reported. 
 
1.5.4.1 Chemistry. General procedures 
 
A. Coupling with the carbodiimide method. To an ice-
cooled mixture containing the required N-Boc-amino 
acid (1.0 mmol), HOBt (1.1 mmol), EDC (1.1 mmol) 
and NMM (2.2 mmol) in anhydrous CH2Cl2, the amino-
derivative salt (1.1 mmol) was added. The reaction 
mixture was allowed to warm to 0 °C for 10 min and 
then to room temperature. After 12 h the reaction 
mixture was diluted with EtOAc (20 mL) and washed 
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with 5% citric acid (3 x 15 mL), NaHCO3 ss (3 x 15 
mL) and NaCl ss (2 x 15 mL). The organic layer was 
dried over Na2SO4 and evaporated under reduced 
pressure. 
B. Deprotection of Boc-derivatives. The Boc group was 
removed by treatment with TFA in CH2Cl2 (1:1) for 1 h 
at room temperature. Removal of solvent and 
precipitation of the residue with diethyl ether gave the 
TFA salt that was used in the next step without further 
purification. 
C. Preparation of peptide amides. The peptide methyl 
ester is allowed to stand in a pressure bottle at room 
temperature for 48 h in anhydrous methanol previously 
saturated with ammonia gas at 0 °C. The solution is then 
concentrated to dryness in vacuo at a temperature not 
exceeding 40 °C.  
 
1.5.4.2 Synthesis 
 
N-Boc-Pro-β-(OH)Phe-OH (4). To a precooled solution (-10 
°C) of Boc-Pro-OH (2 g, 9.3 mmol) in THF, NMM (9.3 mmol) 
and iBuOCOCl (9.3 mmol) were added. After 10 min of stirring, 
a solution of DL-(β-OH)Phe (2.22 g, 11.16 mmol) in 1N NaOH 
(11.1 mL) was added and the mixture stirred at 0 °C for 2 h and 
at room temperature overnight. The organic solvent was 
removed under reduced pressure and the acqueous phase was 
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acidified with solid citric acid to pH 3 and extracted with EtOAc 
(3 x 15 mL). EtOAc layer was washed with water, dried and 
evaporated under reduced pressure to give TLC pure title 
product 4 as colourless oil (2.89 g, 82%). 
N-Boc-Pro-Phe-azlactone (5). To a solution of 4 (2.89 g, 
7.65 mmol) in acetic anhydride (11.7 mL) was added freshly 
fused sodium acetate (0.627 g, 7.65 mmol) and the mixture was 
left overnight at room temperature. The reaction mixture was 
poured over crushed ice and stirred. Then was extracted with 
EtOAc and organic layer was washed with 10% NaHCO3, water 
and dried under reduced pressure. The azlactone 5 (2.48 g, 95%) 
was used for preparation of 6 without further purification. 
N-Boc-Pro-∆ZPhe-PheOMe (6). To a stirred solution of 
azlactone 5 (2.48 g, 7.24 mmol) and HCl·H2N-Phe-OMe in 
CH2Cl2 (20 mL), DIEA (1.24 mL, 7.24 mmol) and DMAP 
(0.035 g, 0.04 mmol, 4 mol %) were added at 0 °C and the 
reaction mixture was stirred overnight at room temperature. 
Then the reaction mixture was diluted with CH2Cl2 and the 
organic layer was washed by saturated acqueous NaHCO3, water 
and brine. The organic layer was dried and evaporated under 
reduced pressure to give TLC pure title product 6 as white foam 
(3.23 g, 86%); 1H NMR (DMSO-d6): δ 1.41 [9H, s, C(CH3)3], 
1.70-2.19 (4H, m, Pro C3H2 and Pro C4H2), 3.05-3.10 (2H, m, 
Phe β-CH2), 3.56 (3H, s, COOCH3), 3.40-3.60 (2H, m, Pro 
C5H2), 4.27 (1H, m, Pro α-CH), 4.54 (1H, m, Phe α-CH), 7.18-
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7.61 (11H, m, aromatics and ∆ZPhe β-CH), 8.02 (1H, d, J = 7.2 
Hz, Phe NH), 9.69 (1H, s, ∆ZPhe NH). 
N-Boc-Tyr-Pro-∆zPhe-Phe-OMe (7). The Boc group of 6 
was removed in according to general procedure B to give a 
quantitative yield of TFA·HN-Pro-∆ZPhe-Phe-OMe. N-Boc-Tyr-
OH (0.924 g, 3.28 mmol) in CH2Cl2 (20 mL) was treated with 
TFA·HN-Pro-∆ZPhe-Phe-OMe (1.597 g, 2.98 mmol) according 
to the general procedure A. Silica gel chromatography 
(CH2Cl2/MeOH 98:2) gave a pure product 7 as a white foam 
(0.816 g, 40%); 1H NMR (CDCl3): δ 1.3 [9H, s, C(CH3)3], 1.61-
2.15 (4H, m, Pro C3H2 and Pro C4H2), 2.80-3.20 (4H, m, Phe β-
CH2 and Tyr β-CH2), 3.30 and 3.75 (2H, m, Pro C5H2), 3.71 
(3H, m, COOCH3), 4.57 (1H, m, Pro α-CH), 4.70 (1H, m, Tyr 
α-CH), 4.89 (1H, m, Phe α-CH), 5.22 (1H, d, J = 8.8 Hz, Tyr 
NH), 6.60-7.55 (16H, m, aromatics, ∆ZPhe β-CH and ∆ZPhe 
NH), 7.09 (1H, d, J = 4.4 Hz, Phe NH). 
N-Boc-Pro-∆zPhe-Phe-azlactone (9). Prepared as above 
described for compound 5. The azlactone 9 (1.13 g, 99%) was 
used for preparation of 10 without further purification. 
N-Boc-Pro-∆zPhe-∆zPhe-OMe (10). To a stirred solution of 
azlactone 9 (0.28 g, 0.70 mmol) in MeOH (10 mL), DMAP 
(0.085 g, 0.70 mmol) was added at room temperature and the 
reaction mixture was stirred at room temperature overnight. 
Then the reaction mixture was acidified with saturated aqueous 
citric acid to pH 4, the organic solvent was evaporated and the 
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acqueous phase was extracted with Et2O (3 x 15 mL). Et2O layer 
was washed with citric acid 5% and brine, dried and evaporated 
under reduced pressure. Silica gel chromatography 
(CH2Cl2/EtOAc 8:2) gave a pure product 10 as a white foam 
(0.720 g, 60%); 1H NMR (CDCl3): δ 1.31 [9H, s, C(CH3)3], 
1.70-2.35 (4H, m, Pro C3H2 and Pro C4H2), 3.44 (2H, m, Pro 
C5H2), 3.88 (3H, s, COOCH3), 4.30 (1H, m, Pro α-CH), 7.20-
7.68 (12H, m, aromatics, ∆ZPhe3 β-CH and ∆ZPhe4 β-CH), 7.84 
(1H, s, ∆ZPhe4 NH), 8.54 (1H, s, ∆ZPhe3 NH). 
N-Boc-Tyr-Pro-∆ZPhe-∆ZPhe-OMe. The Boc group of 10 
was removed in according to general procedure B to give a 
quantitative yield of TFA·HN-Pro-∆ZPhe-∆ZPhe-OMe. N-Boc-
Tyr-OH (0.202 g, 0.72 mmol) in CH2Cl2 (10 mL) was treated 
with TFA·HN-Pro-∆ZPhe-∆ZPhe-OMe (0.344 g, 0.65 mmol) 
according to the general procedure A. Silica gel chromatography 
(CH2Cl2/EtOAc 7:3) gave a pure product as a white foam (0.198 
g, 44%); 1H NMR (CDCl3): δ 1.40 [9H, s, C(CH3)3], 1.60-1.93 
(4H, m, Pro C3H2 and Pro C4H2), 2.62-2.69 (2H, m, Tyr β-CH2), 
3.12 and 3.68 (2H, m, Pro C5H2), 3.85 (3H, s, COOCH3), 4.44 
(1H, m, Pro α-CH), 4.65 (1H, m, Tyr α-CH), 5.13 (1H, d, J = 
8.0 Hz, Tyr NH), 6.50-7.63 (16H, m, aromatics, ∆ZPhe3 β-CH 
and ∆ZPhe4 β-CH), 7.68 (1H, s, ∆ZPhe4 NH), 8.37 (1H, s, 
∆ZPhe3 NH). 
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N-Boc-Phe-β-(OH)Phe-OH (12). Prepared as above 
described for compound 4. Pure on TLC (quantitative yield). 
N-Boc-Phe-Phe-azlactone (13). Prepared as above described 
for compound 5. The azlactone 13 (0.276 g, 75%) was used for 
preparation of 14 without further purification. 
N-Boc-Phe-∆ZPhe-OMe (14). Prepared as above described 
for compound 10. Pure on TLC (0.284 g, 95%); 1H NMR 
(CDCl3): δ 1.37 [9H, s, C(CH3)3], 3.02 and 3.15 (2H, m, Phe 
CβH2), 3.77 (3H, s, COOCH3), 4.46 (1H, m, Phe α-CH), 4.93 
(1H, d, J = 8.4 Hz, Phe NH), 7.00-7.40 (11H, m, aromatics and 
∆ZPhe4 β-CH), 7.61 (1H, s, ∆ZPhe4 NH). 
N-Boc-Pro-Phe-∆zPhe-OMe (15). The Boc group of 14 was 
removed in according to general procedure B to give a 
quantitative yield of TFA·Η2Ν-Phe-∆ZPhe-OMe. N-Boc-Pro-OH 
(0.159 g, 0.74 mmol) in THF (10 mL) was treated with 
TFA·H2N-Phe-∆ZPhe-OMe (0.293 g, 0.67 mmol) according to 
the general procedure A. Silica gel chromatography 
(CH2Cl2/EtOAc 9:1) gave a pure product 15 as a white foam 
(0.155 g, 44%); 1H NMR (CDCl3): δ 1.37 [9H, s, C(CH3)3], 
1.60-2.10 (4H, m, Pro C3H2 and Pro C4H2), 3.20 (4H, m, Phe β-
CH2 and Pro C5H2), 3.83 (3H, s, COOCH3), 4.14 (1H, m, Pro α-
CH), 4.86 (1H, m, Phe α-CH), 6.67 (1H, d, J = 8.0 Hz, Phe 
NH), 7.19-7.51 (11H, m, aromatics and ∆ZPhe4 β-CH), 8.25 
(1H, s, ∆ZPhe4 NH). 
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N-Boc-Tyr-Pro-Phe-∆zPhe-OMe. The Boc group of 15 was 
removed in according to general procedure B to give a 
quantitative yield of TFA·ΗΝ-Pro-Phe-∆ZPhe-OMe. N-Boc-Tyr-
OH (0.078 g, 0.28 mmol) in CH2Cl2 (10 mL) was treated with 
TFA·ΗΝ-Pro-Phe-∆ZPhe-OMe (0.135 g, 0.25 mmol) according 
to the general procedure A. Silica gel chromatography 
(CH2Cl2/EtOAc 3:2) gave a pure product as a white foam (0.068 
g, 40%); 1H NMR (CDCl3): δ 1.37 [9H, s, C(CH3)3], 1.60-1.90 
(4H, m, Pro C3H2 and Pro C4H2), 2.71-3.62 (6H, m, Phe β-CH2, 
Tyr β-CH2 and Pro C5H2), 3.83 (3H, s, COOCH3), 4.48 (1H, m, 
Pro α-CH), 4.50 (1H, m, Tyr α-CH), 4.71 (1H, m, Phe α-CH), 
5.10 (1H, d, J = 8.8 Hz, Tyr NH), 6.08 (1H, d, J = 7.6 Hz, Phe 
NH), 6.50-7.51 (15H, m, aromatics and ∆ZPhe4 β-CH), 8.12 
(1H, s, Tyr OH), 8.51 (1H, s, ∆ZPhe4 NH). 
N-Boc-Tyr-Pro-∆ZPhe-Phe-NH2 (8). A solution of the 
peptide methyl ester 15 (0.020 g, 0.029 mmol) in MeOH/NH3 
sat. (3 mL) is allowed to stand in a pressure bottle at room 
temperature according to the general procedure C. The title 
compound 8 was purified by crystallization from MeOH (0.018 
g, 95%); mp = 228-232 °C; 1H NMR (DMSO-d6): δ 1.30 [9H, s, 
C(CH3)3], 1.85-2.31 (4H, m, Pro C3H2 and Pro C4H2), 2.58-3.20 
(4H, m, Phe3 β-CH2 and Tyr β-CH2),  3.58-3.70 (2H, m, Pro 
C5H2), 4.17 (1H, m, Tyr α-CH), 4.39 (1H, m, Pro CαH), 4.50 
(1H, m, Phe3 α-CH), 6.60-7.55 (18H, m, aromatics, Tyr NH, 
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∆ZPhe4 β-CH and CONH2), 7.90 (1H, d, J = 8.4 Hz, Phe3 NH), 
9.18 (1H, s, Tyr OH), 9.70 (1H, s, ∆ZPhe4 NH); HRMS for 
[M+H]+: m/z calcd 670.3241; found 670.3248.  
N-Boc-Tyr-Pro-Phe-∆ZPhe-NH2 (16). A solution of the 
peptide methyl ester (0.106 g, 0.155 mmol) in MeOH/NH3 sat. 
(7 mL) is allowed to stand in a pressure bottle at room 
temperature according to the general procedure C. The title 
compound 16 was purified by PLC (CHCl3/MeOH 95:5); (0.058 
g, 55%); 1H NMR (DMSO-d6): δ 1.30 [(9H, s, C(CH3)3], 1.70-
2.00 (4H, m, Pro C3H2 and Pro C4H2), 2.50-3.10 (4H, m, Phe4 β-
CH2 and Tyr β-CH2), 3.48 and 3.58 (2H, m, Pro C5H2), 4.21 
(1H, m, Tyr α-CH), 4.32 (1H, m, Pro α-CH), 4.53 (1H, m, Phe4 
α-CH), 6.60-7.51 (18H, m, aromatics, Tyr NH, ∆ZPhe3 β-CH 
and CONH2), 8.31 (1H, d, J = 7.2 Hz, Phe4 NH), 9.66 (1H, 
s, ∆ZPhe3 NH), 9.45 (1H, s, Tyr OH); HRMS for [M+H]+: m/z 
calcd 670.3241; found 670.3238.  
N-Boc-Tyr-Pro-∆ZPhe-∆ZPhe-NH2 (11). A solution of the 
peptide methyl ester (0.112 g, 0.16 mmol) in MeOH/NH3 sat. (7 
mL) is allowed to stand in a pressure bottle at room temperature 
according to the general procedure C. The title compound 11 
was purified by PLC (CHCl3/MeOH 95:5); (0.061 g, 55%); 1H 
NMR (DMSO-d6): δ 1.30 [(9H, s, C(CH3)3], 1.71-2.26 (4H, m, 
Pro C3H2 and Pro C4H2), 2.62-2.75 (2H, m, Tyr β-CH2),  3.48-
3.72 (2H, m, Pro C5H2), 4.25 (1H, m, Tyr α-CH), 4.46 (1H, m, 
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Pro α-CH), 6.60-7.80 (19H, m, aromatics, Tyr NH, ∆ZPhe3 β-
CH, ∆ZPhe4 β-CH and CONH2), 9.22 (1H, s, Tyr OH), 9.52 (1H, 
s, ∆ZPhe4 NH), 10.12 (1H, s, ∆ZPhe3 NH); HRMS for [M+H]+ : 
m/z calcd 668.3084; found 668.3091.  
TFA·H2N-Tyr-Pro-∆zPhe-Phe-NH2 (1). Deprotection of the 
N-Boc group was performed by adopting the general procedure 
B: 8 (0.030 g, 0.046 mmol), CH2Cl2/TFA (5 mL) gave 1 (0.031 
g, quantitative yield); 1H NMR (DMSO-d6): δ 1.85-2.13 (4H, m, 
Pro C3H2 and Pro C4H2), 2.70-3.20 (4H, m, Phe4 β-CH2 and Tyr 
β-CH2),  3.41 and 3.61 (2H, m, Pro C5H2), 4.21 (1H, m, Tyr α-
CH), 4.50 (2H, m, Phe4 α-CH and Pro α-CH), 6.60-7.60 (17H, 
m, aromatics, ∆ZPhe3 β-CH and CONH2), 7.77 (1H, d, J = 8.0 
Hz, Phe4 NH), 8.09 (3H, br, Tyr NH3+), 9.36 (1H, s, Tyr OH), 
9.82 (1H, s, ∆ZPhe3 NH); HRMS for [M+H]+: m/z calcd 
684.2645; found 684.2652. Anal. Calcd for C34H36F3N5O7: C, 
59.73; H, 5.31; N, 10.24. Found: C, 59.96; H, 5.33; N, 10.28.  
TFA·H2N-Tyr-Pro-Phe-∆zPhe-NH2 (2). Deprotection of the 
N-Boc group was performed by adopting the general procedure 
B: 16 (0.020 g, 0.036 mmol), CH2Cl2/TFA (5 mL) gave 2 
(0.0205 g, quantitative yield); 1H NMR (DMSO-d6): δ 1.69-2.08 
(4H, m, Pro C3H2 and Pro C4H2), 2.70-3.20 (4H, m, Phe3 β-CH2 
and Tyr β-CH2),  3.40-3.68 (2H, m, Pro C5H2), 4.17 (1H, m, Tyr 
α-CH), 4.41 (1H, m, Pro α-CH), 4.63 (1H, m, Phe3 α-CH), 
6.60-7.55 (17H, m, aromatics, ∆ZPhe4 β-CH and CONH2), 8.09 
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(3H, br, Tyr NH3+), 8.30 (1H, d, J = 7.8 Hz, Phe3 NH), 9.38 (1H, 
s, Tyr OH), 9.70 (1H, s, ∆zPhe4 NH); HRMS for [M+H]+: m/z 
calcd 684.2645; found 684.2639. Anal. Calcd for C34H36F3N5O7: 
C, 59.73; H, 5.31; N, 10.24. Found: C, 59.49; H, 5.28; N, 10.19. 
TFA·H2N-Tyr-Pro-∆zPhe-∆zPhe-NH2 (3). Deprotection of 
the N-Boc group was performed by adopting the general 
procedure B: 11 (0.028 g, 0.042 mmol), CH2Cl2/TFA (5 mL) 
gave 3 (0.0286 g, quantitative yield); 1H NMR (DMSO-d6): δ 
1.71-2.20 (4H, m, Pro C3H2 and Pro C4H2), 2.68-3.07 (2H, m, 
Tyr β-CH2),  3.40-3.68 (2H, m, Pro C5H2), 4.17 (1H, m, Tyr α-
CH), 4.53 (1H, m, Pro α-CH), 6.60-7.80 (18H, m, aromatics, 
∆ZPhe3 β-CH, ∆ZPhe4 β-CH and CONH2), 8.09 (3H, br, Tyr 
NH3+), 9.35 (1H, s, Tyr OH), 9.42 (1H, s, ∆ZPhe4 NH), 10.13 
(1H, s, ∆ZPhe3 NH); HRMS for [M+H]+: m/z calcd 682.2489; 
found 682.2496. Anal. Calcd for C34H34F3N5O7: C, 59.91; H, 
5.03; N, 10.27. Found: C, 59.67; H, 5.01; N, 10.22. 
1.5.4.3 X-ray crystallographic data for 8 
 
Crystal Data 
C37H43N5O7, FW = 669.76. Monoclinic, space group P21, a = 
13.401(4), b = 8.9611(15), c = 15.027(4) Å, β = 103.31(3)°, 
V = 1756.0(8) Å3, Z = 2,  ρcalc = 1.267 Mg m–3, λ = Mo Kα, µ 
= 0.09 mm–1. 
 
Data Collection and Refinement 
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A clear colourless 0.15 x 0.10 x 0.10 mm crystal was 
mounted on an Oxford Diffraction Xcalibur diffractometer 
equipped with a CCD detector. Lattice parameters were 
obtained using CrysAlis CCD from 1162 reflections in the 
range 3 < θ <  29°. 2785 reflections (1959 independent) were 
collected at room temperature and corrected for Lorentz, 
polarization and absorption effects. The structure was solved 
with SIR97 and refined with the aid of SHELXL-97. In the 
final full-matrix least-squares calculations 455 parameters 
were refined. H atoms were included using a riding model 
[C-H bond distances in the range 0.93 - 0.97 Å, Uiso(H) equal 
to 1.2 or 1.5 Ueq(C)]. Final residuals were R1 = 0.036 for the 
1372 reflections having Fo > 4σ(Fo) and 0.060 for all data. 
Final difference Fourier excursions were 0.10 and -0.12 eÅ3. 
 
1.5.4.4 Biological Assays 
 
Receptor binding affinities to δ- and µ-opioid receptors were 
performed using cell membranes preparations from transfected 
cells that stably express the respective receptors. The 
radiolabeled ligands used were [3H]DPDPE and [3H]DAMGO 
for δ- and µ- receptors, respectively.92 The in vitro tissue 
bioassays (MVD and GPI/LMMP) were performed as described 
previously.93 IC50 values represent means of no less than four 
experiments. IC50 values, relative potency estimates, and their 
associated standard errors were determined by fitting the data to 
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the Hill equation by a computerized non-linear least-squares 
method.  
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 CHAPTER 2 
 
Chemotactic N-formyl peptides 
 
2.1 Chemotaxis 
 
Chemotaxis, the reaction by which the direction of migration 
of cells is determined by substances, called chemotactic agents, 
in their environment, is one of the fundamental responses of 
prokaryotic and eukaryotic cells to external stimuli.1 Prokaryotic 
microorganisms such as bacteria use it to search for food and 
avoid toxins. In vertebrates, chemotaxis is generally accepted as 
a major process bringing leukocytes from the blood to the tissue 
sites of inflammation.  
Various families of chemoattractant agents have been 
described over the years. These include the large family of 
chemokines, complement fragments (C5a, C3a), cathelicidins 
and defensins, chemerin, lipid mediators (platelet activating 
factor, leukotriene B4, etc), and a host of pathogen-derived 
molecules. 
Human neutrophils represent the major subset (50 to 60%) of 
circulating leukocytes, and are phagocytic cells specialized in 
the “first line of defence” against infectious agents or “non-self” 
substances which penetrate the body's physical barriers.2 They 
are also the major cell type associated with acute inflammatory 
reactions. Their targets include bacteria, fungi, protozoa, 
viruses, virally infected cells and tumor cells. 
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Neutrophils circulate in the bloodstream, and can be recruited 
in high numbers in infected or inflamed tissues along the 
concentration gradients of chemoattractants either released by 
the microorganisms themselves, or arising from inflammatory 
reaction in the infected tissue.  
Various inflammatory mediators, including the N-formyl-
methionyl peptides derived from bacterial metabolism or from 
disrupted mitochondria, are capable of activating neutrophils via 
specific receptors.3,4 The N-formyl tripeptide for-Met-Leu-Phe-
OH (fMLF) (Figure 1) is the main chemotactic factor produced 
by Escherichia coli5 and, with its synthetic methyl ester 
derivative, for-Met-Leu-Phe-OMe (fMLF-OMe) (Figure 1), is 
the highly potent chemoattractant for phagocytes.  
 
 
Figure 1.  N-formyl tripeptide and its methyl ester. 
 
2.1.1 The role of neutrophils in acute inflammation 
 
Leukocytes, such as neutrophils, continuously patrol the 
vasculature, monitoring for signals of bacterial infection or 
inflammation. Substances released from pathogens, such as 
lipopolysaccharide (LPS) or classical chemoattractants e.g. 
fMLF, and tissue damage, such as tumor necrosis factor-α 
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(TNF-α), upregulate the expression of adhesion molecules on 
vascular endothelium, and this, in turn, initiates the 
extravasation of leukocytes to the inflamed area. 
Leukocyte extravasation from blood into tissues involves 
several steps called random contact, rolling, sticking, diapedesis 
and chemotaxis6 (Figure 2). When the leukocytes approach the 
post-capillary venules in areas of subendothelial inflammation, 
the initial random contact changes into rolling, which can be 
described as low affinity adhesive interaction between 
leukocytes and the endothelium, and defined as leukocyte 
movement through vessels. 
 
 
Figure 2.  Activation of neutrophil functions in the inflammatory process: (1) 
margination: the adhesion of neutrophils to endothelium causes them to 
aggregate along the vessel walls, owing to the upregulation of the expression 
of adhesion molecules in both neutrophils and endothelial cells; (2) 
diapedesis: transmigration of neutrophils across the endothelial barrier; (3) 
chemotaxis: after leaving nearby blood vessels, neutrophils are attracted to 
the inflammatory sites up a gradient of chemicals factors. They lose their 
round configuration and assume a polarized morphology with an anterior 
lamellipodium extended in the direction of movement; (4) phagocytosis: once 
the neutrophil has arrived at the site of inflammation, it ceases to move and at 
the high concentrations of chemoattractants found here, the cell begins to 
phagocyte foreign particles. 
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After firm attachment (sticking, the more stable adhesion), 
leukocytes start migrating across the endothelium (diapedesis) 
via intercellular junctions into the subendothelial space. Finally, 
leukocytes are attracted to the inflammatory sites (chemotaxis) 
through the production of exogenous and endogenous 
chemoattractant mediators. Exogenous chemotaxins include 
bacterial oligopeptides of the fMLF type, lectins, denatured 
proteins, some lipids and lipopolysaccharides. Endogenous 
chemotaxins are produced by the host organism and are of 
humoral (complement fragment C5a, C5a-des-Arg and C3a, 
fibrinopeptides, kallikrein and plasminogen activator) or cellular 
type (from different cells: leukotriene B4, platelet activated 
factor, chemotactic cytokines etc.).7,8 Once the neutrophil has 
arrived at the site of inflammation, it ceases to move, probably 
due to the lack of defined chemoattractant gradient. At the high 
concentrations of chemoattractants found here, the cell begins 
phagocytosis and killing (oxygen independent and dependent) of 
foreign particles.9 Phagocytosis is accompanied by lysosomal 
enzyme secretion and production of two types of free radicals by 
neutrophils: a) reactive oxygen intermediates which are formed 
in neutrophils by the activity of NADPH oxidase, the membrane 
associated enzyme of the respiratory burst;10 b) reactive nitrogen 
intermediates, the first of which, nitric oxide, is produced by 
nitric oxide synthase.11 These, together with the contents of 
neutrophil granules, have an extensive killing capacity.12 
        Chapter 2 
 
95 
2.1.2 Formyl peptide receptors (FPRs) 
 
FMLF, together with its synthetic methyl ester derivative, 
fMLF-OMe, is used as a model chemoattractant due to its highly 
effective ability to activate all physiological functions of 
neutrophils through cell surface receptors coupled to 
intracellular effectors through guanine nucleotide regulatory 
proteins (G proteins). The interaction of fMLF with its receptor 
expressed on neutrophils activates signal transduction pathways. 
This activation is known to provoke various biochemical 
responses which contribute to physiological defence against 
bacterial infection and cell disruption. In fact, it has long been 
known that the signal transduction pathway underlying the 
chemotactic response differs from those responsible for 
cytotoxic functions, and several previous experiments carried 
out utilizing pharmacological manipulation of the signal 
transduction pathway have highlighted the fact that distinct 
mechanisms are involved in each of these neutrophil responses. 
This can be rationalized on the basis of the existence of at least 
two different functional receptor subtypes or isoforms; low 
doses of a full agonist (or “pure” chemoattractant) are required 
to interact with a high-affinity receptor subtype, FPR, which 
activates the signal transduction pathway responsible for the 
chemotactic response, while the increase in full agonist 
concentration (typical of infection sites) allows binding with its 
low-affinity subtype, FPRL1, which is able to activate the signal 
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transduction pathways responsible for superoxide anion 
production and lysozyme release.  
The classic fMLF chemoattractant exerts its effects by 
binding to FPRs, which are classical G-protein coupled 
receptors characterized by seven hydrophobic transmembrane 
segments connected by hydrophilic domains; potential N-linked 
glycosylation or phosphorylation sites are present on the 
extracellular or intracellular receptor surface, respectively.13 
Human FPR was first defined biochemically in 1976 as a 
high-affinity binding site for the prototype fMLF on the surface 
of neutrophils. It was then cloned in 1990, by Boulay et al., 
from a differentiated HL-60 myeloid leukaemia-cell cDNA 
library.14 Two additional human genes, designated FPRL1 (FPR 
like-1) and FPRL2 (FPR like-2), were subsequently isolated by 
low-stringency hybridization using FPR cDNA as a probe.15-17  
Physiologically, the FPR is predominantly if not exclusively 
coupled to pertussis toxin (PTX)-sensitive G-proteins of the Gi-
family,18-21 although in recombinant systems, the FPR also 
possesses the potential to couple to the PTX-insensitive G-
proteins Gα15 and Gα16.22 Gi proteins are the most abundant 
and important G proteins in phagocytes as they mediate most, if 
not all, of the stimulatory effects of chemoattractants. 
It is generally accepted that FPRL1 shares signal transduction 
features with FPR, since both receptors are sensitive to pertussis 
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toxin (PTX) and possess a high degree of amino acid identity in 
the cytoplasmic signaling domains. 
Following ligand binding (Figure 3), FPRs undergo a 
conformational change that enables them to interact with the 
PTX-sensitive Gi proteins. After binding of its agonists, the 
receptor activates the heterotrimeric G protein, which 
dissociates into α and βγ subunits. Upon activation, the receptor 
triggers exchange of GDP to GTP binding in the α subunit. Giα-
GTP is capable of inhibiting certain adenylyl cyclase isoforms,23 
but adenylyl cyclase inhibition is of little, if any, importance in 
phagocytes.21  
 
 
 
Figure 3. Schematic signaling pathways of an activated formyl peptide 
receptor (FPR). 
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Rather, the βγ-complex activates phospholipase C (PLC) 
isoenzymes β2 and β324,25 and phosphoinositide 3-kinase-
γ (PI3Kγ).26 Gene knock-out studies in the mouse revealed that 
phospholipases C-β2 and β3 as well as phosphoinositide 3-
kinase-γ play crucial roles in the activation of down-stream 
phagocyte functions, e.g. chemotaxis and oxygen radical 
formation.27-29 
PI3K converts the membrane phosphatidylinositol 4,5 
bisphosphate (PIP2) into phosphatidylinositol-3,4,5 
trisphosphate (PIP3). PIP3 is catabolized by PLC to the 
secondary messengers inositol trisphosphate (IP3) and 
diacylglycerol (DAG). While IP3 regulates the mobilization of 
Ca2+ from intracellular stores, DAG activates protein kinase C 
(PKC). Calcium enhancement appears to occur in two stages: an 
initial transient release from intracellular storage sites followed 
by a more delayed influx across the plasma membrane. Increase 
in Ca2+ cytosolic levels has been postulated to be a necessary 
condition for neutrophil response to formyl  peptides, as it is one 
of the earliest detectable events induced by cell exposure to 
fMLF. The release of Ca2+ from internal stores induces the 
opening of the store-operated Ca2+ channel in the plasma 
membrane and a sustained influx of Ca2+ takes place.30 Other 
intracellular effectors coupled to FPR signaling cascade include 
phospholipases A2, D, mitogen-activated protein kinase 
(MAPK),31,32 and the tyrosine kinase lyn.33 Following activation 
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by ligand, FPR undergoes rapid serine and threonine 
phosphorylation, and is desensitized and internalized.34,35 
However, FPR internalization can occur in the absence of 
desensitization, indicating that desensitization and 
internalization are controlled by distinct mechanisms.36,37 
Further studies38 suggest that FPR internalization is mediated 
by mechanisms independent of the actions of arrestin, dynamin 
and clathrin, which, on the other hand, are involved in the 
internalization of some other G protein-coupled receptors such 
as the β-adrenergic receptor. 
Unlike FPR, the signal transduction pathways mediated by 
FPRL1 have not been extensively studied. Nevertheless, it is 
suggested that FPRL1 may share many signaling characteristics 
observed with FPR based on their high level of homology, 
sensitivity to PTX, and mediation of potent phagocyte activation 
by agonists. In addition to its role in bacterial host defense, the 
FPR may play a more general role in inflammatory reactions. 
This notion is supported by the fact that the FPR is also 
expressed in cell types other than classic phagocytes such as 
astrocytes, hepatocytes, epithelial cells, T lymphocytes, 
neuroblastoma cells and microvascular endothelial cells.39,40  
Moreover, formyl peptides released from damaged mitochondria 
activate the FPR.41  
Furthermore, various non-formylated peptides, specifically 
human immunodeficiency virus-1 envelope protein-derived 
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peptides, annexin I and annexin I-derived peptides are FPR 
agonists.40,42 Annexin I peptides have been recently reported as 
novel, endogenous fMLF receptor ligands able to induce anti-
inflammatory effects.43 
 
2.2 Structure-activity relationship of fMLF 
 
In spite of the numerous studies into the biological responses 
of human neutrophils arising from their interaction with the 
chemotactic fMLF,44-52 nobody has yet clarified which chemical 
mechanisms are involved in the binding of this ligand to its 
receptor. The receptor has been studied in order to understand its 
position in the membrane and the steric characteristics which 
allow the best biological responses,16,53-56 but not to establish 
how the ligand hooks into its receptor pocket.  
The tripeptide fMLF together with fMLF-OMe, is a potent 
chemoattractant for phagocytes and is also generally adopted as 
the reference model for evaluating the activity of newly 
synthesized analogues. In addition to its high lipophilic 
character, due to the presence of the three hydrophobic side 
chains, this compound is characterized by a pronounced 
conformational flexibility of the backbone, which appears to be 
an important feature for establishing efficient interactions with 
the FPR.57 
Several fMLF-OMe analogues have been synthesized and 
utilized in different laboratories with the aim of characterizing 
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formyl peptide interaction in phagocytes, as well as in cellular 
activation.30,58-63  
In the working model of the portion of the receptor 
accommodating the tripeptide, five critical areas in the receptor 
that interact with the peptide were identified. Further studies 
have also revealed that the ligand binding pocket is large enough 
to accommodate a fourth amino acid residue,64,65 up to 5 amino 
acids in length.66  
 
N-Formyl group (H-CO) 
As regards prototype fMLF, it is ascertained that N-
formylation is necessary for optimal activity, simulating the 
situation at the amino end of proteins produced by bacteria such 
as E. coli. 
Furthermore, the formyl group (H-CO) on the N-terminal 
methionine is small enough to reach the bottom of the binding 
cavity; it participates as hydrogen donor in linking to the 
receptor and it seems that its role in this interaction cannot be 
ruled out. Relevant is the observation that modifications centred 
at this function can modulate the neutrophil biological 
responses. Indeed, the presence of a free amino group and 
acetylation at the N-terminus of MLF both result in drastic 
losses in agonist activity as compared to fMLF.45 Both urea and 
carbamate derivatized fMLF analogues, among which Boc-Met-
Leu-Phe-OMe, containing the bulky tBuOCO (Boc) group in 
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place of the native H-CO (For), have been studied and found 
active as antagonists.67,68  
The development of FPR antagonist is therefore of 
considerable interest, in particular for their potential use as 
therapeutic agent in the treatment of inflamation-related 
disorders. Indeed, in several pathological conditions the 
inappropriate activation of neutrophils can cause tissue damage. 
 
Methionine residue (Met)  
An important area of interaction is the hydrophobic cavity in 
the receptor occupied by the Met side chain. This cavity is of 
limited depth: side chains larger than four carbon atoms show no 
further increase in activity. In addition, a discrete area of 
positive charge in this cavity was postulated as complementary 
to the relatively electron-rich sulphur atom of the Met residue.69 
 
Leucine residue (Leu) 
The central hydrophobic Leu, although critical for backbone 
conformation, results to be the most tolerant towards 
replacement and modification.70  
It was proposed a hydrophobic pocket in the receptor where 
leucine fits. Indications and conformational analyses have 
revealed that it is a rather large hydrofobic pocket, which fits 
from four up to seven carbon atoms. Full activity is reached only 
when the pocket is filled, so several analogues have been 
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prepared, where Leu has been replaced by, for example, α,α-
disubstituted amino acids.71,72  
Other several fMLF analogues modified at position-2 with 
high activity and selectivity have been described.73,74 
 
Phenylalanine residue (Phe) 
Studies have also determined that the C-terminal amino acid 
should be aromatic, Phe being the preferred choice.45,75,76 Leu 
and Phe side-chain, are accommodated in a hydrophobic pocket. 
 
Carboxylic group (Phe C=O) 
Several studies demonstrated the necessity of a carboxylic 
group, both free and esterified, to trigger a biological response 
in human neutrophils. Esterification (e.g. methylation) of the C-
terminal carboxylic group does not result in a reduction of 
activity.77 A critical interaction of the Phe C=O group with the 
receptor, possibly via hydrogen bonding, has also been 
hypothesized.46,78 
Several years ago my research group and then I, during my 
PhD, initiated a research program based on the synthesis of new 
fMLF-OMe analogues in order to: (i) obtain more effective and 
selective ligands; (ii) gain information on the structural features 
and conformational preferences of chemotactic formyl 
tripeptides.   
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2.3 Hybrid α/β-peptides: For-Met-Leu-Phe-OMe 
analogues containing geminally disubstituted β2,2- 
and β3,3-amino acids at the central position* 
 
Neutrophils are involved in the first line of defence 
mechanism against pathogen microorganisms. They migrate 
from blood to sites of infection by following the concentration 
gradients of chemoattractants such as the cleavage products of 
bacterial and mitochondrial proteins. The hydrophobic N-formyl 
tripeptide For-Met-Leu-Phe-OH (fMLF) and its synthetic 
methyl ester (fMLF-OMe) are among the early recognized and 
highly potent chemotactic agents. Their binding to specific 
receptors located on the neutrophil plasma membrane gives rise, 
in addition to the directed migration (chemotaxis), to a cascade 
of biochemical responses including activation of radical oxygen 
production and release of proteolytic enzymes.42,75  
A number of primary structure–activity studies, based on 
structurally modified fMLF analogues, have been performed and 
several fundamental points concerning the key role of the N-
terminal protecting group in modulating the activity as well as 
the nature of the constituent amino acids have been 
established.45,46,68 A more complex picture emerges from the 
analysis of the literature data analyzing conformation–activity 
                                                 
*Mollica, A.; Paglialunga Paradisi, M.; Torino, D.; Spisani, S.; 
Lucente G. Amino Acids 2006, 30, 453. 
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relationships. Here different tridimensional structures have been 
proposed as representatives of optimal interaction with the 
neutrophil formyl peptide receptors.79 However, both structure–
activity and conformation–activity studies62,80,81 on fMLF 
analogues highlight the role exerted on the activity by the nature 
of the central residue. Suitable replacements of the native Leu 
can in fact give rise to stabilized folded or extended 
conformations82,83 and allow at the same time key interactions 
with the central hydrophobic site which is known to be an 
important modulator of the biological functions50,59 of N-formyl 
chemotactic tripeptides. 
In accordance with the above reported observations several 
papers have examined synthesis and activity of fMLF analogues 
characterized by replacements at the central position. Particular 
attention has been paid to For-Met-Xaa-Phe-OMe models 
incorporating Cα,α-dialkylated glycines with linear [e.g., α-
aminoisobutyric acid (Aib); di-n-propylglycine (Dpg)] and 
cyclic [e.g., 1-aminocycloalkane-1-carboxylic acids (Acnc)] 
alkyl side chains at position 2 (Figure 4).50,62,81  
 
 
Figure 4. Geminally disubstituted α- and β-amino acids containing a 
cyclohexyl side chain. 
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These α,α-disubstituted aminoacidic residues significantly 
restrict the available range of backbone conformations and the 
derived conformationally constrained peptides represent useful 
probes to get informations on the biological active 
conformations. In particular, the chemoattractant tripeptides 
For-Met-Acnc-Phe-OMe (with n = 6 and 7), containing 1-
aminocycloalkane-1-carboxylic acids in place of native Leu, 
were found to be very interesting ligands which exhibit both 
high activity and H-bond stabilized folded conformation.50  
By taking into account the above considerations and as part 
of our previous research aimed at exploring the consequences of 
incorporating β-residues and higher homologues into short α-
peptide sequences,84-86 we report here studies on the two new 
fMLF analogues For-Met-β3hAc6c-Phe-OMe 6 and For-Met-
β2hAc6c-Phe-OMe 12 (Figure 5) in which the central Leu has 
been replaced by two positional isomers of a geminally 
disubstituted β-residue87 which shares with the Ac6c the 
presence of a cyclohexyl side chain (Figure 4). 
It should be noted here that although hybrid α/β-peptides are 
less studied as compared with the well known class of β-amino 
acid oligomers (β-peptides),88,89 they represent an emerging 
approach for generating analogues of α-peptide endowed with 
selected resistance to proteolysis and specific conformational 
properties.90,91 In particular we have focused our interest on 
these two unnatural amino acids by taking into account the 
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possibility to combine different points of interest: the 
improvement of the bioactivity due to the lipophilic side chain; 
the influence of the different spatial positioning of the side chain 
on the peptide backbone; the stabilization of folded 
conformations. 
 
6
t t
3
6
2
6
 
Figure 5.  Structures of the relevant compounds investigated in this study. 
 
2.3.1 Chemistry 
 
The synthesis of Boc-Met-β3hAc6c-Phe-OMe (5) and Boc-
Met-β2hAc6c-Phe-OMe (11) has been performed by following 
two different strategies shown in Schemes 1 and 2. A direct 
transformation of the N-Boc derivatives 5 and 11 into the 
corresponding N-formyl analogues 6 and 12 was performed by 
following the procedure of Lajoie and Kraus.92 Tripeptide 5 
containing the β3hAc6c residue was synthesized starting from 
methylenecyclohexane by using chlorosulphonyl isocyanate to 
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give the spirolactame 1 (Scheme 1).93 A different strategy87 was 
used to obtain the β2hAc6c-containing tripeptide 11 by using 
methyl cyanoacetate as key reagent (Scheme 2). 
 
 
Scheme 1.  Synthesis of the β3hAc6c-containing peptide derivatives 5 and 6. 
Reagents and conditions: a) Chlorosulphonyl isocyanate, Et2O, 10 min 0 °C 
then Na2SO3, 1h rt; b) Boc2O, DMAP, CH3CN, 15 min 0 °C, overnight rt; c) 
H2N.Phe-OMe, KCN, DMF dry, 16h 50 °C under N2; d) SOCl2, MeOH, 40 
min -15 °C, 3h 45°C; e) Boc-Met-OH, iBuOCOCl, NMM, CH2Cl2/DMF, 30 
min -15 °C, overnight rt; f) HCOOH, overnight rt then EEDQ, CHCl3, 24h rt.   
 
2.3.2 Conformational studies 
 
In order to ascertain the involvement of the NH groups of N-
formyl analogues 6 and 12 in intramolecular H-bonds, a 1H 
NMR solvent perturbation experiment was undertaken. In 
Figure 6, the chemical shift dependence of the three NH groups 
of each compound is reported as a function of increasing 
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DMSO-d6 concentration in CDCl3 solution (10 mM). The results 
clearly show the different behaviors of the two models 6 and 12. 
The NH groups of the two external residues of 6 (Figure 6A) 
interact freely with the DMSO while the NH of the central 
β3hAc6c is slightly shielded and then probably involved in a 
weak intramolecular H-bond (the ∆δ ppm values shown by the 
three NH groups are 0.75, 0.31, and 0.50 for Met, β3hAc6c, and 
Phe, respectively). However, when the IR spectrum in CHCl3 of 
6 was examined, the absorptions in the 3400-3300  cm-1 
stretching region, where the intramolecular H-bonds commonly 
appear, were found to be very weak. 
 
 
Scheme 2. Synthesis of the β2hAc6c containing peptide derivatives 11 and 
12. Reagents and conditions: a) K2CO3, 1,5-dibromo-pentane, DMF, 5h rt; b) 
H2-Pd/C 10%, 10N HCl, MeOH, 6h rt; c) Boc-Met-OH, iBuOCOCl, NMM, 
CH2Cl2/DMF, overnight rt; d) 1N LiOH, THF/H2O 5:1, overnight rt; e) 
HCl·H2N-Phe-OMe, EDC, HOBt, NMM, CH2Cl2, 30 min 0 °C, overnight rt; 
f) HCOOH, overnight rt then EEDQ, CHCl3, 24h rt. 
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The tripeptide 12 (Figure 6B) exhibits a strong H-bonding 
involvement of the NH of the central β2hAc6c together with that 
of the C-terminal Phe, while the NH of the N-terminal Met 
appears completely free (the ∆δ ppm values are 1.21, -0.16, and 
0.21 for Met, β2hAc6c, and Phe, respectively). In contrast to the 
IR spectrum of 6, that of 12 in CHCl3 shows strong absorption 
bands in the 3400-3300 cm-1 stretching region. 
 
 
 
 
Figure 6. Delineation of hydrogen-bonded NH groups in tripeptides 6 and 
12. Chemical shift dependence of the NH resonances as a function of the 
DMSO-d6 concentration (% v/v) in CDCl3 solution. Peptide concentration 10 
mM. (A) HCO-Met-β3hAc6c-Phe-OMe 6; (B) HCO-Met-β2hAc6c-Phe-OMe 
12. 
 
For the β3hAc6c-containing model 6, the above reported data 
suggest, in addition to a large amount of unfolded 
conformations, the occurrence of a limited population of folded 
structures centered at the β-residue (C6 conformation) and 
Met NH Ac6c NH Phe NH
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associated with a weak intraresidue electrostatic interaction 
which is not clearly detected by IR spectroscopy.94 In the case of 
the β2hAc6c- containing model 12, the strong involvement in H-
bonding of the β-residue NH is accompanied by an analogous, 
albeit less pronounced behavior of the Phe C-terminal NH. A 
reasonable interpretation of these data indicates a system of t\wo 
consecutive local foldings centered at the β2hAc6c (C8 
conformation; pseudo γ-turn)95 and at the Met residue (C7 
conformation; γ-turn) as depicted in Figure 7. In this case, both 
the intramolecular H-bonds are not highly distorted and clearly 
revealed by IR spectroscopy. 
 
 
Figure 7.  Representation of the molecular structure of the products 6 and 12. 
 
2.3.3 Biological results 
 
The agonistic activity of the new ligands has been determined 
on human neutrophils and compared with that of the standard 
tripeptide fMLF-OMe; directed migration (chemotaxis), 
superoxide anion production, and lysozyme release have been 
measured. 
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Except for a modest activity shown as chemoattractants 
(Figure 8A) and lysozyme releasers (Figure 8C), the two N-Boc 
derivatives 5 and 11 are completely inactive in the superoxide 
anion production (Figure 8B). On the contrary, both the N-For-
tripeptides 6 and 12 have been found highly active in inducing 
neutrophil chemotaxis exhibiting an analogous peak which at a 
concentration of 10-10 M reaches the activity of the reference 
molecule (chemotactic index, 1.0) (Figure 8A).  
 
 
Figure 8.  Biological activity of the tripeptides 5-12 compared with the 
reference ligand fMLF-OMe. (A) Chemotactic index; (B) Superoxide anion 
production; (C) Release of neutrophil granule enzymes evaluated by 
determining lysozyme activity. 
 
Analogues 6 and 12 exhibit a comparably weak activity in the 
superoxide anion production (Figure 8B). However, for the 
lysozyme release activity (Figure 8C) the tripeptide 12 
containing the β2hAc6c residue is notably more potent and 
efficient than the positional isomer 6 containing the β3hAc6c 
residue. 
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2.3.4 Discussion and conclusions 
 
As previously mentioned, studies on chemotactic tripeptides 
indicate that the substitution at the central position of fMLF-
OMe is critical for the activity. Concerning replacements related 
with the here examined analogues, it can be recalled that the 
incorporation of a central β-Ala or β3hLeu leads to inactive or 
scarcely active ligands. The present results show, however, that 
the geminal substitution at the β-residue with the cyclohexyl 
side chain, regardless of the β2,2 or the β3,3 location, restores the 
activity in accordance with the effects produced by the same 
cyclic side chain on Ac6c-containing α-peptides. Only in the 
case of the activity connected with the lysozyme release, the two 
positional isomers 6 and 12 exhibit clearly different behaviors. 
In fact, as previously mentioned, the β2,2 isomer 12 is sensibly 
both more efficient and more potent than the β3,3 and at a 
concentration of 10-6 M shows a peak reaching that of the 
reference molecule (Figure 8C). Finally, the conformational 
behavior exhibited in CDCl3 solution by 6 and 12 shows the 
effects exerted by the different location of the side chain on the 
β-residue. However, despite the distinct preferred 
conformations, the two molecules show substantially 
comparable biological responses, except for the secretagogue 
activity. This suggests an induced fit mechanism operative 
during the interaction of this type of ligands with the human 
neutrophil receptors. 
Chapter 2 
 
114 
2.3.5 Experimental section 
 
Materials and methods. Boc-Met-OH (purum, ≥98%) and 
HCl·H2N-Phe-OMe (purissimum, ≥99%) were purchased from 
Fluka. Spectrograde solvents were purchased from Merck; all 
the other solvents and reagents were of the purest grade 
commercially available. Melting points were determined with a 
Büchi B 540 apparatus and are uncorrected. Optical rotations 
were taken at 20 °C with a Schmidt-Haensch Polartronic D 
polarimeter (1 dm cell, c 1.0 in CHCl3, unless otherwise 
specified). IR spectra were recorded in 1% CHCl3 (unless 
otherwise specified) solution employing a Perkin-Elmer FT-IR 
Spectrum 1000 spectrometer. 1H NMR experiments were 
performed at 400 MHz on a Bruker AM 400 spectrometer in 
CDCl3 solution (unless otherwise specified) and chemical shifts 
(δ) are quoted in parts per million (ppm) and were indirectly 
referred to TMS. TLC (thin layer chromatography) and PLC 
(preparative layer chromatography) were performed on silica gel 
Merck 60 F254 plates. The drying agent was sodium sulphate. 
Light petroleum refers to the 40-60 °C bp fraction. Elemental 
analyses were performed in the laboratories of the Servizio 
Microanalisi del CNR, Area della Ricerca di Roma, 
Montelibretti, Italy, and were within ±0.4% theoretical values. 
The abbreviations used are as follows: β3hAc6c, (1-
aminocyclohexyl)-acetic acid; β2hAc6c, 1-(aminomethyl)-
cyclohexanecarboxylic acid; Boc, tert-butyloxycarbonyl; 
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Boc2O, di-tert-butyl dicarbonate; DMF, dimethylformamide; 
EEDQ, ethyl 2-ethoxy-1,2-dihydro-1-quinolinecarboxylate; 
EDC, N-(3-dimethylaminopropyl)-N’-ethylcarbodiimide 
hydrochloride; Et2O, diethyl ether; HOBt, 1-
hydroxybenzotriazole; iBuOCOCl, iso-butyl chloroformate 
97%; KRPG, Krebs–Ringer phosphate containing 0.1% (w/v) d-
glucose; NMM, N-methylmorpholine; PLC, preparative-layer 
chromatography; TEA, triethylamine; TLC, thin-layer 
chromatography. 
 
2.3.5.1 Synthesis 
 
N-Boc-β3hAc6c-Phe-OMe (3). KCN (1 mmol) and freshly 
prepared H2N-Phe-OMe (1.2 mmol) were added to a solution of 
287 in dry DMF (6 mL). The mixture was stirred at 50 °C under 
N2 atmosphere for 16 h, then the solvent was evaporated in 
vacuo and the residue diluted with CHCl3, washed with 5% 
citric acid, NaHCO3 ss, and NaCl ss. The organic layer was 
dried, filtered and evaporated in vacuo to give crude 3. The 
product was purified by silica gel chromatography using a 
gradient of CHCl3/EtOAc as eluant to afford 0.32 g of pure 3 
(76%) as an oil; [a]D +18° (c 1.0, CHCl3); IR (CHCl3): ν 3439, 
2935, 1742, 1704, 1666, 1498 cm-1; 1H NMR (CDCl3): δ 1.37-
1.97 [19H, m, C(CH3)3 and Ac6c side chain], 2.63 (2H, m, CH2-
CO), 3.02-3.16 (2H, A and B of an ABX, J = 5.9, 7.2, and 14.0 
Hz, Phe β-CH2), 3.72 (3H, s, COOCH3), 4.49 (1H, s, Ac6c NH), 
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4.87 (1H, m, Phe α-CH), 6.17 (1H, d, J = 7.8 Hz, Phe NH), 
7.15-7.33 (5H, m, aromatics). 
N-Boc-Met-β3hAc6c-Phe-OMe (5). The mixture of Boc-
Met-OH (0.67 mmol) in 5 mL of CH2Cl2 was cooled at -15 °C 
for 10 min, then iBuOCOCl (0.75 mmol) and NMM (0.75 
mmol) were added and the mixture was stirred for 10 min at the 
same temperature. To the solution of 4 (0.67 mmol) in CH2Cl2, 
10% DMF and NMM (0.75 mmol) were added. After 15 min at 
-15 °C, the mixture was kept at room temperature overnight. 
The mixture was diluted with CHCl3, washed with 5% citric 
acid, NaHCO3 ss and NaCl ss. The combined organic layers 
were dried and filtered and the solvent was removed in vacuo to 
afford 0.35 g of crude 5. This was purified by silica gel column 
chromatography using a gradient of CHCl3/EtOAc as eluant to 
give 0.240 g of pure 5 as colorless oil (65%); [a]D +12° (c 0.5 
CHCl3); IR (c 0.5% CHCl3): ν 3420, 3360, 2936, 1737, 1671 
cm-1; 1H NMR (CDCl3): δ 1.27-1.90 [19H, m, C(CH3)3 and Ac6c 
side chain], 1.87-2.58 (6H, m, β3hAc6c CH2CO, Met β-CH2 and 
Met γ-CH2), 2.13 (3H, s, SCH3), 3.00-3.25 (2H, m, Phe β-CH2), 
3.74 (3H, s, COOCH3), 4.20 (1H, m, Met α-CH), 4.86 (1H, m, 
Phe α-CH), 5.34 (1H, d, J = 7.7 Hz, Met NH), 6.27 (1H, s, 
β3hAc6c NH), 6.40 (1H, d, J = 7.3 Hz, Phe NH), 7.15-7.34 (5H, 
m, aromatics). 
N-Boc-Met-β2hAc6c-OMe (9). The mixture of Boc-Met-OH 
(0.814 mmol) in 5 mL of CH2Cl2 was cooled at -15 °C for 15 
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min, then iBuOCOCl (0.82 mmol) and NMM (0.9 mmol) were 
added and the mixture was stirred for 15 min at the same 
temperature. Then a solution of 8 (0.814 mmol) in CH2Cl2 (4 
mL) and DMF (0.4 mL) was added. After 10 min at -15 °C, the 
mixture was kept at room temperature overnight. The mixture 
was diluted with CH2Cl2 and washed with of 10% citric acid, 
NaHCO3 ss, and NaCl ss. The combined organic layers were 
dried, and filtered and the solvent removed in vacuo to obtain 
crude 9. The product was purified by PLC, with EtOAc/CHCl3 
(1:1) as eluant to give pure 9 (90%); [a]D -15° (c 1.0, CHCl3); IR 
(c 0.5% CHCl3): ν 3433, 3029, 1712, 1678, 1496 cm-1; 1H NMR 
(CDCl3): δ  1.26-1.58 (19H, m, C(CH3)3 [s at 1.46] and β2hAc6c 
side chain), 1.95-2.58 (7H, m, S-CH3, [s at 2.13] Met β-CH2 and 
Met γ-CH2), 3.39 (2H, m, β2hAc6c NHCH2), 3.71 (3H, s, 
COOCH3), 4.22 (1H, m, Met α-CH), 5.21 (1H, d, J = 7.3 Hz, 
Met NH), 6.52 (1H, m, β2hAc6c NH). 
N-Boc-Met-β2hAc6c-OH (10). 1N LiOH (1.43 mL) was 
added to the solution of 9 (0.7 mmol) in THF/H2O (5:1) (3 mL), 
stirred at 0 °C for 15 min and then left at room temperature 
overnight. The mixture was concentrated in vacuo and extracted 
with Et2O. The aqueous phase was acidified with 1N HCl and 
extracted with EtOAc. The organic layer was washed with NaCl 
ss, dried and evaporated in vacuo to give 0.13 g (50%) of crude 
product. The obtained 10 was used into the next step without 
further purification. 
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N-Boc-Met-β2hAc6c-Phe-OMe (11). Product 10 (0.4 mmol) 
was added at rt to a mixture of EDC (0.4 mmol) and HOBt (0.4 
mmol) and NMM (0.8 mmol) in 20 mL of dry CH2Cl2. After 10 
min, HCl·H2N-Phe-OMe (0.36 mmol) was added. The reaction 
flask was kept at room temperature under N2 atmosphere 
overnight. The mixture was concentrated in vacuo, diluted with 
EtOAc, and washed with 5% citric acid, NaHCO3 ss, and NaCl 
ss. The combined organic layers were dried, filtered and the 
solvent was removed in vacuo to obtain the crude 11. The 
product was purified by PLC using CH2Cl2/MeOH (95:5) as 
eluant to give 0.16 g of a pure 11 as colorless oil (72%); 1H 
NMR (CDCl3): δ 1.25-1.90 (21H, m, C(CH3)3, [s at 1.46] Met β-
CH2 and β2hAc6c side chain), 2.10 (3H, s, SCH3), 2.53 (2H, m, 
Met γ-CH2), 3.10-3.30 (2H, A and B of an ABX, J = 4.4, 11.0 
and 14.0 Hz, Phe β-CH2), 2.70 and 3.70 (2H, two m, β2hAc6c 
NHCH2), 3.81 (3H, s, COOCH3), 4.08 (1H, m, Met α-CH), 4.88 
(1H, m, Phe α-CH), 5.16 (1H, d, J = 8.4 Hz, Met NH), 7.01 (1H, 
d, J = 8.4 Hz, Phe NH), 7.10-7.30 (5H, m, aromatics), 7.70 (1H, 
br s, β2hAc6c NH). 
For-Met-β3hAc6c-Phe-OMe (6). [a]D +16° (c 0.5 CHCl3); 
IR(CHCl3): ν 3423, 3032, 2400, 1739, 1675, 1510 cm-1; 1H 
NMR (CDCl3): δ 1.27-2.32 [17H, m, β3hAc6c side chain and 
CH2CO, Met β-CH2, SCH3 (s at 2.15)], 2.57 (2H, m, Met γ-
CH2), 3.07 and 3.11 (2H, A and B of ABX, J = 5.5, 7.5, 14.0 
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Hz, Phe β-CH2), 3.75 (3H, s, COOCH3), 4.59 (1H, m, Met α-
CH), 4.83 (1H, m, Phe α-CH), 6.02 (1H, s, β3hAc6c NH), 6.35 
(1H, d, J = 8.2 Hz, Phe NH), 6.55 (1H, d, J = 7.5 Hz, Met NH), 
7.15-7.35 (5H, m, aromatics), 8.20 (1H, s, HCO). 
For-Met-β2hAc6c-Phe-OMe (12). [a]D -29.5° (c 0.17 
CHCl3); IR (c 0.5%, CHCl3) 3429, 3369, 3337, 2934, 1728, 
1673, 1498 cm-1; 1H NMR (CDCl3): δ 1.15-2.05 (12H, m, Met 
β-CH2 and β2hAc6c side chain), 2.15 (3H, s, SCH3), 2.60 (2H, 
m, Met γ-CH2), 3.15-3.27 (2H, A and B of an ABX, J = 4.6, 
10.0, 14.0 Hz, Phe β-CH2), 2.86 and 3.75 (2H, m, β2hAc6c 
NHCH2), 3.84 (3H, s, COOCH3), 4.48 (1H, m, Met α-CH), 4.83 
(1H, m, Phe α-CH), 6.50 (1H, d, J = 7.6 Hz Met NH), 6.77 (1H, 
d, J = 8.0 Hz, Phe NH), 7.20-7.35 (5H, m, aromatics), 7.56 (1H, 
br s, NH), 8.18 (1H, s, HCO). 
 
2.3.5.2 Biological assays 
 
Cell preparation 
Cells were obtained from the blood of healthy subjects, and 
human peripheral blood neutrophils were purified by using the 
standard techniques of dextran (Pharmacia, Uppsala, Sweden) 
sedimentation, centrifugation on Ficoll-Paque (Pharmacia), and 
hypotonic lysis of contaminating red cells. Cells were washed 
twice and resuspended in Krebs-Ringer phosphate (KRPG), pH 
7.4, at final concentration of 50 x 106 cells/mL and kept at room 
temperature until used. Neutrophils were 98-100% viable, as 
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determined using the Trypan Blue exclusion test. The study was 
approved by the local Ethics Committee and informed consent 
was obtained from all participants. 
 
Random locomotion 
Random locomotion was performed with 48-well 
microchemotaxis chamber (Bio Probe, Milan, Italy) and 
migration into the filter was evaluated by the leading-front 
method.96 The actual control random movement is 35 ± 3 µm 
(mean with standard error) of 10 separate experiments 
performed in duplicate. 
 
Chemotaxis 
Each peptide was added to the lower compartment of the 
chemotaxis chamber. Peptides were diluted from a stock 
solution with KRPG containing 1 mg/mL of bovine serum 
albumin (BSA) (Orha Behringwerke, Germany) and used at 
concentrations ranging from 10-12 to 10-5 M. Data were 
expressed in terms of chemotactic index (CI), which is the ratio 
of the difference of migration toward test attractant minus 
migration toward the buffer to the migration toward the buffer; 
the values are the means of six separate experiments performed 
in duplicate. Standard errors are in the 0.02-0.09 CI range. 
 
Superoxide anion production 
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Superoxide anion was measured by the superoxide 
dismutase-inhibitable reduction of ferricytochrome c (Sigma) 
modified for microplate-based assays. Tests were carried out in 
a final volume of 200 mL containing 4 x 105 neutrophils, 100 
nmoles cytochrome c, and KRPG. At zero time, different 
amounts (1 x 10-10 to 8 x 10-5 M) of each peptide were added and 
the plates were incubated into a microplate reader (Ceres 900, 
Bio-TeK Instruments, Inc.) with the compartment temperature 
set at 37 °C. Absorbance was recorded at 550 and 468 nm. The 
difference in absorbance at the two wavelengths was used to 
calculate nanomoles of O2- produced using an absorptivity for 
cytochrome c of 18.5 mM-1 cm-1. Neutrophils were incubated 
with 5 µg/mL cytochalasin B (Sigma) for 5 min prior to 
activation by peptides. Results were expressed as net nanomoles 
of O2- per 1 x 106 cells per 5 min and are the means of six 
separate experiments performed in duplicate. Standard errors are 
in 0.1-4 nanomoles O2- range. 
 
Enzyme assay 
The release of neutrophil granule enzymes was evaluated by 
determination of lysozyme activity, modified for microplate 
based assays. Cells, 3 x 106/well, were first incubated in 
triplicate wells of microplates with 5 µg/mL cytochalasin B at 
37 °C for 15 min and then in the presence of each peptide at a 
final concentration of 1 x 10-10 to 8 x 10-5 M for a further 15 
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min. The plates were then centrifuged at 400 x g for 5 min and 
the lysozyme was quantified nephelometrically by the rate of 
lysis of cell wall suspension of Micrococcus lysodeikticus. The 
reaction rate was measured using a microplate reader at 465 nm. 
Enzyme release was expressed as the net percentage of total 
enzyme content released by 0.1% Triton X-100. Total enzyme 
activity was 85 x 1mg per 1 x 107 cells/min. The values are the 
means of five separate experiments done in duplicate. Standard 
errors are in the range of 1-6%. 
 
2.4 Chemotactic tripeptides incorporating at 
position 2 α-amino acid residues with unsaturated 
side chains* 
 
Directed migration of neutrophils along an increasing 
chemical gradient (chemotaxis) from blood to inflammatory 
sites is the first line of defence against bacterial infections. 
Chemotaxis depends upon the interaction of a variety of 
extracellular messengers with specific receptors located on 
neutrophil plasma membrane. Several chemically unrelated 
substances, such as arachidonic acid metabolites, complement 
fragment C5a, bacterial or mitochondrial protein-derived N-
formyl peptides and a number of chemokines have the ability to 
initiate the migratory response.97 Binding of these ligands with 
                                                 
*Lucente, G.; Paradisi Paglialunga, M.; Giordano, C.; Sansone, A.; 
Torino, D.; Spisani, S. Amino Acids 2008, 35, 329. 
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neutrophil receptors gives rise, in addition to chemotaxis, to a 
series of connected biochemical events consisting primarily in 
particle phagocytosis, superoxide anion production and release 
of proteolytic enzymes. Among chemotactic agents, highly 
specific for human neutrophils, N-For-Met-Leu-Phe-OH (fMLF) 
and its methyl ester (fMLF-OMe) are recognized as the 
reference molecules for studies aimed at elucidating the 
structure-activity relationships. These tripeptide ligands bind to 
at least two G protein coupled receptors, the high-affinity FPR 
and its low-affinity variant FPRL1.98 It has been shown that 
complex intracellular signal transduction systems exist in human 
neutrophils.99,100 However, although several studies deal with 
this topic, the relationships between intracellular signalling and 
the different biological activities are still not well established. 
Thus, design and synthesis of fMLF analogues capable to 
exhibit selective behaviour,101 represent very useful tools for 
studying signal transduction systems.  
The effects of native amino acid substitutions on fMLF 
sequence, as well as the biological consequences of the 
backbone conformation modifications, have been extensively 
studied.102 While the sulphur containing N-terminal For-Met-
moiety and the aromatic side chain at the C-terminal position are 
crucial for both binding and receptor activation, the hydrophobic 
Leu residue at the position 2, although critical for backbone 
conformation, results to be the most tolerant towards 
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replacements and modifications.70 In accordance with this 
observation, several studies on position 2 fMLF analogues have 
been performed with particular attention focused on: i) the 
control of the backbone conformations and ii) the production of 
ligands capable to exhibit selective behaviour towards the other 
cellular functions associated with the chemotaxis. Well known 
examples of the conformational control are the position 2 
analogues containing Cα,α disubstituted residues with linear or 
cyclic side chains, characterized by extended structure62,83 and 
β-turn folding,50 respectively. Representative of a selectively 
acting analogue is the tripeptide [∆ZLeu]2fMLF-OMe containing 
an α,β-didehydro residue replacing the native Leu; this 
compound is practically inactive as chemoattractant and highly 
active in the superoxide anion generation and lysozyme 
release.103  
Based on the above observations indicating that peptide-
receptor interactions in the specific area involving the position 2 
of the N-formyl tripeptides are important modulators of the 
biological effects and as prosecution of our previous research in 
this field,71 we report here on a series of new fMLF-OMe 
analogues characterized by the presence at position 2 of three 
different types of synthetic α-aminoacids (Figure 9), all 
containing γ-δ-didehydro side chains. (Alg = (S)-allylglycine; 
Dag = diallylglycine; Cpg = 1-aminocyclopent-3-ene-1-
carboxylic acid).  
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Figure 9.  Synthetic γ-δ-didehydro-α-amino acid residues replacing native 
(S)-Leucine in the here reported fMLF-OMe analogues. 
 
It can be noted that whereas Cα-allylglycine has been 
frequently used in peptide chemistry as starting residue for ring-
closing metathesis (RCM) reactions, no data seem at the present 
available on biological activity of peptides incorporating the 
Dag or the Cpg residue. Model peptides containing a Boc 
protected Ν-terminal Cpg residue have been recently 
described.104  
 
2.4.1 Chemistry 
 
The synthesis of the Boc-peptides and the corresponding N-
formyl analogues was performed according to Schemes 3-5. 
Fmoc-Alg-Phe-OMe (1) was obtained by coupling Fmoc-Alg-
OH with HCl·H2N-Phe-OMe using EDC/HOBt. After N-
deprotection of 1 by pyperidine treatment, the dipeptide 2 was 
acylated (EDC/HOBt) by Boc-Met-OH to give Boc-Met-Alg-
Phe-OMe (3). 
Coupling of Boc-Met-OH with Dag-OEt (BOP/HOBT) or 
Cpg-OEt (EDC/HOBt) afforded Boc-Met-Dag-OEt (5) and Boc-
Met-Cpg-OEt (8), respectively. C-deprotection by hydrolysis of 
5 and 8 gave the free acids which were coupled (EDC/HOBt) 
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with HCl·H2N-Phe-OMe to give Boc-Met-Dag-Phe-OMe (6) 
and Boc-Met-Cpg-Phe-OMe (9), respectively. 
 
2
 
Scheme 3.  Synthesis of (S)-Allylglycine (Alg) containing tripeptides 3 and 
4. Reagents and conditions: a) HOBt, EDC, TEA, EtOAc, 30 min 0 °C, 12h 
rt; b) piperidine, CH2Cl2, 1/2h rt; c) Boc-Met-OH, HOBt, EDC, TEA, EtOAc 
30 min 0 °C, 12h rt; d) HCOOH, overnight, rt then EEDQ, CHCl3 24h rt.   
 
 
Scheme 4.  Synthesis of Diallylglycine (Dag) containing tripeptides 6-7. 
Reagents and conditions: a) Dag-OEt, BOP, HOBt, NMM, EtOAc, 30 min 0 
°C, 12h rt; b) 2N LiOH, MeOH, overnight rt; c) HCl·H2N-PheOMe, BOP, 
HOBt, NMM, EtOAc, 30 min 0 °C, 12h rt; d) HCOOH, overnight rt then 
EEDQ, CHCl3, 24h rt.   
 
RCM reaction by using second generation Grubbs catalyst 
performed on the tripeptide 6 containing central Dag afforded in 
good yields the Cpg analogue 9. Direct transformation of the N-
Boc derivatives 3, 6, and 9 into the corresponding N-formyl 
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analogs 4, 7 and 10 was performed by treatment of the N-Boc 
derivatives with formic acid followed by EEDQ.92  
 
 
Scheme 5.  Synthesis of 1-Aminocyclopent-3-ene-1-carboxylic acid (Cpg) 
containing tripeptides 9 and 10. Reagents and conditions: a) Cpg-OEt, EDC, 
HOBt, TEA, EtOAc, 30 min 0 °C, 12h rt; b) 1N NaOH, MeOH, overnight rt; 
c) HCl·H2N-Phe-OMe, EDC, HOBt, TEA, EtOAc, 30 min 0 °C, 12h rt; d) 
HCOOH, overnight rt then EEDQ, CHCl3, 24h rt; e) Grubbs catalyst, 
CH2Cl2, 5h rt. 
 
2.4.2 Conformational studies 
 
1H NMR 
Information on the conformational preferences of the 
tripeptides 7, 9 and 10 containing the stereochemically 
constrained residues of Dag and Cpg has been obtained by 
examining the involvement of the NH groups in intramolecular 
H-bonds by using 1H NMR titration experiments. 
In Figure 10 the chemical shift dependence of the shift values 
as a function of increasing DMSO-d6 concentrations in CDCl3 
solution (10 mM) is reported. In Table 1 the solvent exposure of 
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the NH groups is expressed as the difference (∆δ, ppm) between 
the chemical shift observed in neat CDCl3 and in a CDCl3 
solution containing 10% DMSO-d6. High values of 
∆δ correspond to efficient H bonding interaction of the NH 
groups with the DMSO-d6 while low values indicate scarce 
sensibility to solvent composition variation and presumable 
involvement in intramolecular H-bonds. 
The values of here studied peptides reported in Table 1 are 
compared with the data previously observed for the related 
models Boc-Met-Ac5c-Phe-OMe50 and HCO-Met-Dpg-Phe-
OMe62 containing 1-amino-1-cyclopropane carboxylic acid 
(Ac5c) residue and di-n-propylglycine (Dpg), respectively.  
 
 
Figure 10.  Delineation of NH chemical shifts as a function of increasing 
percentage of DMSO-d6 to the CDCl3 solution (vol/vol) for (A): Boc-Met-
Cpg-Phe-OMe (9); (B): For-Met-Cpg-Phe-OMe (10); (C): For-Met-Dag-Phe-
OMe (7). 
 
The solvent perturbation experiments performed on Cpg 
containing models 9 and 10 indicate that the Phe and the Cpg 
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NH (Table 1) are scarcely affected by the change of the solvent 
composition (∆δ = 0.20 and 0.30 ppm for 9 and 0.33 and 0.55 
for 10, respectively). 
 
Table 1. Solvent-composition effects on NH chemical shifts of 
peptides. Values reported are the differences (∆δ, ppm) between NH 
proton chemical shifts observed in CDCl3 solution containing 10% 
DMSO-d6 and neat CDCl3. 
 
a See reference: Toniolo et al. (1989) 
b See reference: Dentino et al. (1991) 
 
The N-terminal Met NH shows, on the other hand, a value of 
1.12 ppm for the HCO-NH of 10 and 0.57 for the Boc-NH of 9. 
To properly evaluate the solvent shielding exhibited by the Met 
NH of 9 it should be recalled that the bulky t-butyloxycarbonyl 
group significantly hinders the interaction of the NH with the 
solvent.105 Thus, the ∆δ value found for 9, lower than that 
expected for a free NH group, is only in part attributable to the 
participation to intramolecular H-bonding since the effect of the 
N-Boc must be considered. By taking into account this latter 
consideration it can be assumed that both 9 and 10 are 
characterized by a similar conformer population characterized 
by the central Cpg and the N-terminal Phe NH groups not freely 
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interacting with the solvent and then presumably involved in 
intramolecular H-bonds.  
It is interesting to note that the above reported 9 and 10 
titration data differ significantly from those exhibited by the 
tripeptide Boc-Met-Ac5c-Phe-OMe.50 In this case (Table 2) both 
the C-terminal Met and the central Ac5c NH groups interact 
efficiently with the solvent (∆δ  = 1.0 and 0.94 ppm, 
respectively) while the Phe NH appears sensibly unaffected by 
the solvent composition (∆δ  = 0.15 ppm).  
 
Table 2.  Observed nuclear Overhauser effects (NOEs) in the Noesy 
spectrum of HCO-Met-Cpg-Phe-OMe 10. 
 
s strong; m medium; w weak. 
 
Thus, the preferred solution conformation of the Ac5c 
containing tripeptide has been described as a type-II β-turn (C10 
ring) stabilized by a single intramolecular H-bond involving the 
Boc CO and the C-terminal Phe NH. In the case of the 
analogues 9 and 10, containing the central Cpg residue, the 
picture is less clearly defined since both the Cpg NH and the C-
terminal Phe NH, appear not completely free to interact with the 
solvent. Thus, a conformation which takes into account this 
situation should be considered. 
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In order to get further information on the preferred 
conformation induced by the central Cpg residue, a two 
dimensional NMR experiment was carried out on the tripeptide 
10. Detection of nuclear Overhauser effects (NOEs) in the 
NOESY spectra are related to the through-space proximity of 
the protons of the molecule. The estimates of the cross-peak 
relative intensities found for 10 are summarized in Table 2 on an 
arbitrary scale. The interresidue NOE HCO···Met NH is in 
accordance with the cis configuration of the two H atoms of the 
H-CO-NH group, as always found in the crystal structures of N-
formyl peptides. Noteworthy is the absence of the NOE between 
the NH groups of the (i + 2) and (i + 3) residue (i.e. Cpg 
NH···Phe NH) which is diagnostic of a β-turn structure. 
Furthermore, the observation of NOEs between the Phe NH and 
the Cpg β- and ε-CH2 groups, does not support the hypothesis of 
the C10 conformation and suggests that the Phe NH interacts 
with the Met-CO thus stabilizing a γ-turn centred at the Cpg 
residue. Concerning the Cpg NH···Met CαH spatial connectivity 
it can be observed that this finding, taken together with the 
partial solvent inaccessibility shown by the Cpg NH (∆δ = 0.30 
ppm), suggests the presence, although in limited extent, of a 
second γ-turn structure106,107 centred at the Met residue and 
involving the formylic carbonyl and the Cpg NH (Figure 11). 
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Figure 11.  Preferred conformation adopted by N-formyl tripeptides 7 and 10 
in CDCl3 solution. The intraresidue H-bond in the C5 conformation of 7 and 
in the two consecutive γ-turns (C7 structures) of 10 are indicated by dotted 
lines. 
 
The titration experiments were then extended to the analogue 
HCO-Met-Dag-Phe-OMe (7) containing the di-allylglycine 
residue in place to the native (S)-leucine (Figure 2C). In this 
case the NH of the central residue presents a pronounced solvent 
inaccessibility (∆δ = 0.20, Table 1) while the Met and, in less 
extent, the Phe NH groups interact efficiently with the solvent. 
In accordance with literature these data suggest the presence in 
CDCl3 solution of a significant population of the peptide 
molecules in an extended conformation with the Dag NH 
involved in a C5 intraresidue H bond (Figure 3). An analogue 
behaviour has been previously observed62 for the corresponding 
saturated formyl tripeptide HCO-Met-Dpg-Phe-OMe in which 
the NH of the central Cα,α tetrasubstituted residue is strongly 
solvent shielded while the Met and Phe NH groups are 
completely free (see Table 1). 
 
IR 
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The presence in the tripeptides under study of 
intramolecularly H bonded NH groups has also been studied by 
the examining the IR absorptions in the NH stretching region 
(CHCl3, 5 mM). In the spectrum of N-Boc derivative 9 two 
bands are observed at 3428 and 3375 cm-1 corresponding to free 
and H bonded groups, respectively. An analogue outcome is 
shown by the corresponding formyl derivative 10 which exhibits 
a shoulder at 3378 cm-1 partially superimposed to the band at 
3411 cm-1 due to the free NH stretching. In the spectrum of 7 
two bands are observed at 3416 and 3368 cm-1; the band at 
lower frequency can be assigned to the intraresidue H bonded 
Dag NH group. Finally a strong absorption band at 3416 cm-1, 
attributable to free NH stretching, is exhibited by the N-formyl 
tripeptide 4 which presents a weak large band centered at 3320 
cm-1. This suggests that, at variance with derivatives 7, 9 and 10, 
only weak intramolecular H-bonds occur in the CHCl3 solution 
of 4. 
 
2.4.3 Biological results 
 
The biological activity of the N-formyl analogues 4, 7, and 
10, together with that of the corresponding N-Boc derivatives 3, 
6 and 9 has been determined on human neutrophils and 
compared with that of the reference ligand fMLF-OMe. Directed 
migration (chemotaxis), superoxide anion production and 
lysozyme release have been measured. The results of the 
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agonistic chemotactic activity of the three N-formyl tripeptides, 
expressed as chemotactic index (C.I.), are summarized in Figure 
12A. It can be seen that the three formyl tripeptides 4, 7, and 10 
are able to significantly stimulate neutrophil chemotaxis 
although with lower potency than the parent ligand fMLF-OMe. 
Notably, the Cpg containing analogue 10 reaches the same 
potency of the parent at a concentration value of 10-7 M. Both 
the Alg and Dag containing models 4 and 7 show an activity 
peak (C.I. = 0.78 and 0.82, respectively) centred at a lower 
concentration (10-10 M) than that of the parent (10-9 M). 
Furthermore, at very low concentration (10-13 M) the Alg 
containing model 4 shows higher activity than the parent 
molecule (C.I. = 0.44 against 0.33), thus exhibiting higher 
efficacy. As also shown in Figure 12A all the N-Boc derivatives 
3, 6, and 9 exhibit a very similar common behaviour with an 
activity peak centred at 10-9 M and a very modest activity. 
As shown in Figure 12B the three formyl peptides 4, 7, and 
10 are  highly  active  in  stimulating  superoxide  anion  
production with the Alg containing analogue 4 showing the 
activity peak at the same concentration of the parent although 
with lower activity. Both the other two analogues 7 and 10 
induce the same maximal anion production at concentration 10-5 
M with a value corresponding to that of the fMLF-OMe. Figure 
12C reports the results concerning the lysozyme release. Here 
all the three N-formyl derivatives exhibit a similar profile of 
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activity with a maximum centred at concentration 10-5 M and a 
rank of potency: 10 = 4 >7. 
 
 
Figure 12.  Biological activity of centrally modified N-For and N-Boc MLF-
OMe analogues 3, 4, 6, 7, 9 and 10. (A) Chemotactic index; (B) Superoxide 
anion production and (C) Release of neutrophil granule enzyme evaluated by 
determining lysozyme activity. 
 
As generally found and as shown in Figures 12B and C the 
three  N-Boc derivatives 3, 6 and 9, at variance with the 
corresponding N-formyl analogues, are completely unable to 
elicit superoxide anion and lysozyme release. 
 
2.4.4 Conclusions 
 
In summary we have described synthesis, conformational 
preferences and activity of a new group of fMLF-OMe 
analogues structurally related by the common presence at 
position 2 of residues bearing unsaturated side chains. As 
reported in Figure 12 all the three N-For analogues 4, 7 and 10 
are capable to elicit high to moderate values of chemotaxis as 
3 4 6 7 9 10 fMLF-OMe 
0
0,5
1
1,5
-16 -14 -12 -10 -8 -6 -4
0
10
20
30
40
50
60
70
-11 -10 -9 -8 -7 -6 -5 -4 -3
0
10
20
30
40
50
60
70
-11 -10 -9 -8 -7 -6 -5 -4 -3
C
he
m
ot
ac
tic
 in
de
x 
nm
ol
es
  O
2-
 
%
 L
ys
oz
ym
e 
re
le
as
e 
Log [M] Log [M] Log [M] 
A B C 
Chapter 2 
 
136 
well as of superoxide anion production and lysozyme release. 
These findings confirm the versatility of the fMLF-OMe to 
accept structural modifications at the central position. 
The preferred conformations of the models incorporating the 
Cα,α-disubstituted residues Dag and Cpg (Figure 11) indicate 
that an analogous effect is induced by the Dag and the 
corresponding saturated residue. It is found in fact that the 
tripeptide 7, containing two linear allylic side chains at position 
2, adopts the expected C5 extended conformation also found in 
the case of the di-n-propylglycine (Dpg) containing tripeptide.62 
On the other hand, the conformation of the tripeptide 10, 
incorporating the Cpg residue differs from the β-turn structure 
found in the case of the related model containing the 
cyclopentane ring.50  
The last reported finding underlines the interest to further 
explore the ability of Cpg to induce specific conformations into 
peptide backbones in which this residue is incorporated. In 
addition to this, the chemical reactivity of the unsaturated 5-
membered ring must be considered. This property appears 
particularly interesting in the light of recent transformation 
reactions performed on N-protected Cpg esters such as 
hydroboration-oxidation reactions108 and 1,3-dipolar 
additions.109 These data and the concomitant lack of information 
on the biochemical consequences of the incorporation of the 
Cpg residue into native peptides, stimulate further studies on 
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this unsaturated cyclic Cα,α-disubstituted amino acid and on 
peptides containing residues with cyclopentenyl side chains. 
 
2.4.5 Experimental section 
 
Materials and methods. Cpg-OEt has been synthesized 
starting from cis-1,4-dichloro-2-butene and the Schiff base 
obtained by reacting ethyl glycinate with 4-
bromobenzaldehyde.110 Dag-OEt was synthesized starting from 
ethyl isocyanoacetate and allyl bromide under phase transfer 
catalysis conditions.111 All other starting materials and reagents 
were obtained commercially and used without further 
purification. Melting points were determined with a Büchi B 
540 apparatus and are uncorrected. Optical rotations were taken 
at 20 °C with a Schmidt-Haensch Polartronic D polarimeter (1 
dm cell, c 1.0 in CHCl3, unless otherwise specified). IR spectra 
were recorded in 1% CHCl3 solution (unless otherwise 
specified) employing a Perkin-Elmer FT-IR Spectrum 1000 
spectrometer. 1H NMR experiments were performed at 400 
MHz on a Bruker AM 400 spectrometer in CDCl3 solution and 
chemical shifts (δ) are quoted in parts per million (ppm) and 
were indirectly referred to TMS. NOESY spectra were recorded 
in CDCl3 on Avance 400 Bruker console with a 800 msec 
mixing time and displayed in the phase-sensitive mode. Usually 
256 x 1024 data points were collected and for each block 64 
transients were collected for two-dimensional experiments. The 
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data sets were linearly predicted to 512 x 1024 data points. A 
Gaussian window was applied in both dimensions. Zero filling 
was used for a final spectrum of 1024 x 1024 data points. TLC 
thin layer chromatography) were performed on silica gel Merck 
60 F254 plates. The drying agent was sodium sulphate. Elemental 
analyses were performed in the laboratories of the Servizio 
Microanalisi del CNR, Area della Ricerca di Roma, 
Montelibretti, Italy, and were within ±0.4% of the theoretical 
values. 
 
2.4.5.1 Chemistry. General procedure 
 
A. Coupling with the carbodiimide method. To an ice-
cooled mixture containing the required N-Boc- or N-
Fmoc-amino acid (1.0 mmol), the amino-derivative.HCl 
(1.0 mmol), HOBt (1.2 mmol), and TEA (2.2 mmol) in 
anhydrous EtOAc (6 mL), EDC (1.2 mmol) was added 
and the reaction mixture was allowed to warm to room 
temperature. After 12 h the reaction mixture was diluted 
with EtOAc (20 mL) and washed with 1M KHSO4 (2 x 
15 mL), saturated aqueous NaHCO3 (2 x 15 mL) and 
brine (15 mL). The organic phase was dried and 
evaporated under reduced pressure. 
B. Preparation of the N-formyl derivatives. The N-Boc 
derivative (1.0 mmol) was dissolved in formic acid (3 
mL) and the mixture was allowed to stand at room 
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temperature overnight. After removal of the excess 
formic acid under vacuum, the residue was dissolved in 
dry CH2Cl2 (10 mL) or dry DMF (2 mL). EEDQ 97% 
(1.2 mmol) was added and the solution was stirred at 
room temperature for 24 h. Evaporation under reduced 
pressure afforded the crude N-formyl derivative.92  
 
2.4.5.2 Synthesis 
 
Fmoc-Alg-Phe-OMe (1). Fmoc-Alg-OH (0.5 g, 1.48 mmol) 
was treated with HCl·H2N-Phe-OMe (0.320 g, 1.48 mmol) 
according to the carbodiimide coupling general procedure. 
Crystallization from EtOAc/Hexane gave the title product as a 
white solid (0.670 g, 90%); mp 150-153 °C; [a]D +14° (c 1 
CHCl3); IR (CHCl3): ν 3421, 1739, 1680 cm-1; 1H NMR 
(CDCl3): δ 2.30 (2H, br s, CH2-CH=CH2), 2.74-3.00 (2H, m, 
Phe β-CH2), 3.50 (3H, s, COOCH3), 3.88-4.30 (4H, m, CH-CH2 
and Alg α-CH), 4.50 (1H, m, Phe α-CH), 4.70-4.90 (2H, m, 
CH2-CH=CH2), 5.30-5.50 (1H, m, CH2-CH=CH2), 6.63 (1H, br 
s, Phe NH), 6.80 (1H, br s, Alg NH), 7.00-7.50 (13H, m, 
aromatics). Anal. Calcd for C30H34N2O5: C, 71.69; H, 6.82; N, 
5.57. Found: C, 71.58; H, 6.77; N, 5.58. 
H2N-Alg-Phe-OMe (2). Fmoc-Alg-Phe-OMe (0.670 g, 1.34 
mmol) in CH2Cl2 (4 mL) was N-deprotected by treatment with 
piperidine (4 mL) for 1/2 h. The reaction solution was diluted 
with CH2Cl2 (2 x 15 mL) and washed with 1N HCl (2 x 15 mL). 
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The aqueous phase was basified with NaHCO3 and the product 
extracted with CH2Cl2. Resulting H2N-Alg-Phe-OMe 2 was 
used without further purification. 
N-Boc-Met-Alg-Phe-OMe (3). The above prepared H2N-
Alg-Phe-OMe 2 was acylated with Boc-Met-OH (0.284 g, 1.14 
mmol) according to the carbodiimide coupling general 
procedure. Silica gel flash chromatography (CH2Cl2/MeOH 
98:2) gave a pure product as a white solid (0.430 g, 64%); [a]D 
+2° (c 0.5, CHCl3); IR (CHCl3): ν 3414, 1741, 1670 cm-1; 1H 
NMR (CDCl3): δ 1.45 [9H, s, C(CH3)3], 1.85-2.11 [5H, m, Met 
β-CH2 and S-CH3 (s at 2.10)], 2.45-2.57 (4H, m, Met γ-CH2 and 
CH2-CH=CH2), 3.05 and 3.17 (2H, A and B of an ABX, J = 5.6, 
10.4 and 6.0 Hz, Phe β-CH2), 3.72 (3H, s, COOCH3), 4.23 (1H, 
m, Met α-CH), 4.40 (1H, m, Alg α-CH), 4.83 (1H, m, Phe α-
CH), 5.07-5.18 (3H, m, CH2-CH=CH2 and Met NH), 5.61-5.68 
(1H, m, CH2-CH=CH2), 6.46 (1H, br s, Phe NH), 6.70 (1H, d, J 
= 7.2 Hz, Alg NH) 7.01-7.5 (5H, m, aromatics). Anal. Calcd for 
C25H37N3O6S: C, 59.15; H, 7.35; N, 8.28. Found: C, 59.13; H, 
7.31; N, 8.09. 
N-Boc-Met-Dag-OEt (5). To a solution of Boc-Met-OH 
(0.476 g, 0.19 mmol) in anhydrous EtOAc (20 mL), BOP (0.955 
g, 0.216 mmol), HOBt (0.357 g, 0.264 mmol) and few drops of 
DMF were added. The solution was then ice cooled for few 
minutes and a suspension of HCl·H2N-Dag-OEt (0.500 g, 2.16 
mmol) and NMM (0.7 mL, 6.48 mmol) in EtOAc (2 mL) was 
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added. After 12 h at room temperature the reaction mixture was 
diluted with EtOAc (20 mL) and washed with 1M KHSO4 (2 x 
15 mL), saturated aqueous NaHCO3 (2 x 15 mL) and brine (15 
mL). The organic phase was dried and evaporated under reduced 
pressure. Silica gel chromatography (CHCl3) gave the pure 
product as pale yellow oil (0.7 g, 86%); [a]D -15° (c 1, CHCl3); 
IR (CHCl3): ν 3423, 1799, 1677 cm-1; 1H NMR (CDCl3): δ 1.25 
(3H, m, COOCH2CH3), 1.43 [9H, s, C(CH3)3], 1.72-2.11 [5H, 
m, Met β-CH2 and SCH3 (s, at 2.09)], 2.48-2.65 (4H, m, Met γ-
CH2 and CH2-CH=CH2), 2.99-3.25 (2H, m, CH2-CH=CH2), 
4.10-4.22 (2H, m, COOCH2CH3 and Met α-CH), 4.99-5.30 (5H, 
m, Met NH and two CH2-CH=CH2), 5.49-5.73 (2H, m, two 
CH2-CH=CH2), 6.95 (1H, s, Dag NH). Anal. Calcd for 
C20H34N2O5S: C, 57.94; H, 8.27; N, 6.76. Found: C, 57.03; H, 
8.28; N, 6.57. 
N-Boc-Met-Dag-OH. Boc-Met-Dag-OEt (0.7 g, 1.64 mmol) 
was treated with 2N LiOH (2 mL) and MeOH (7 mL) and left 
overnight at room temperature. MeOH was removed at reduced 
pressure, water (10 mL) was added and the solution extracted 
with Et2O (2 x 25 mL). The aqueous phase was then acidified 
with 1N KHSO4 and extracted with EtOAc (3 x 20 mL). The 
organic phases were washed with brine, dried and evaporated. A 
white foam (0.406 g, 60%), pure on TLC was obtained and used 
without further purification. 
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N-Boc-Met-Dag-Phe-OMe (6). To a solution of Boc-Met-
Dag-OH (0.406 g, 0.98 mmol) in anhydrous EtOAc (20 mL), 
BOP (0.490 g, 1.1 mmol), HOBt (0.185 g, 1.36 mmol) and few 
drops of DMF were added. The solution was cooled for few 
minutes and a suspension of HCl·H2N-Phe-OMe (0.240 g, 1.11 
mmol) and NMM (0.32 mL, 2.94 mmol) in EtOAc (1 mL) was 
added. The reaction mixture was allowed to stand overnight at 
room temperature. EtOAc (20 mL) was then added and the 
solution washed with 1M KHSO4 (2 x 15 mL), saturated 
acqueous NaHCO3 (2 x 15 mL) and brine (15 mL). The organic 
phase was dried and evaporated under reduced pressure. Silica 
gel chromatography (EtOAc/Hexane 3:7) and crystallization 
from EtOAc/Hexane gave the pure title product 6 as white solid 
(0.3 g, 53%); IR (CHCl3): ν 3432, 1741, 1667 cm-1; 1H NMR 
(CDCl3): δ 1.44 [9H, s, C(CH3)3], 1.89-2.10 [5H, m, Met β-CH2 
and S-CH3 (s, at 2.09)], 2.50-2.63 (4H, m, Met γ-CH2 and CH2-
CH=CH2), 2.76 (2H, m, CH2-CH=CH2), 3.05-3.14 (2H, m, Phe 
β-CH2), 3.70 (3H, s, COOCH3), 4.15 (1H, m, Met α-CH), 4.83 
(1H, m, Phe α-CH), 5.00-5.08 (5H, m, two CH2-CH=CH2 and 
Met NH), 5.45-5.57 (2H, m, two CH2-CH=CH2 ), 6.81 (1H, br s, 
Phe NH), 6.88 (1H, s, Dag NH), 7.00-7.50 (5H, m, aromatics). 
Anal. Calcd for C28H41N3O6S: C, 61.40; H, 7.55; N, 67.00. 
Found: C, 61.26; H, 7.77; N, 67.25. 
N-Boc-Met-Cpg-OEt (8). Boc-Met-OH (0.268 g, 1.07 
mmol) was coupled with Cpg-OEt (0.152 g, 0.980 mmol) 
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according to the carbodiimide coupling general procedure. The 
title compound was obtained as a foam, pure on TLC (0.221 g, 
58%); [a]D +1.1° (c 1, CHCl3); IR (CHCl3): ν 3422, 1739, 1660 
cm-1; 1H NMR (CDCl3): δ 1.27 (3H, t, J = 7.6 Hz, 
COOCH2CH3), 1.46 [9H, s, C(CH3)3], 1.90-2.15 [5H, m, Met β-
CH2 and S-CH3 (s at 2.13)], 2.58-2.69 (4H, m, Met γ-CH2 and 
CH2-CH=CH), 3.10 (2H, apparent t, CH2-CH=CH), 4.21 (2H, q, 
COOCH2CH3), 4.27 (1H, m, Met α-CH), 5.18 (1H, br s, Met 
NH), 5.68 (2H, sharp m, CH=CH), 6.89 (1H, s, Cpg NH). Anal. 
Calcd for C18H30N2O5S: C, 55.94; H, 7.82; N, 7.25. Found: C, 
56.22; H, 7.77; N, 7.22. 
N-Boc-Met-Cpg-OH Boc-Met-Cpg-OEt (0.210 g, 0.54 
mmol) was treated with 1N NaOH (2.17 mL) and MeOH (10 
mL) and left at room temperature overnight. MeOH was 
evaporated under vacuum, water (10 mL) was added and the 
solution extracted with diethyl ether (2 x 25 mL). The aqueous 
phase was then acidified with 1N KHSO4 and the product 
extracted with EtOAc (3 x 20 mL). The organic phases were 
washed with brine, dried and evaporated to give TLC pure title 
product as white foam (0.190 g, quantitative yield). Anal. Calcd 
for C16H26N2O5S: C, 53.61; H, 7.31; N, 7.84. Found: C, 53.77; 
H, 7.49; N, 8.38. 
N-Boc-Met-Cpg-Phe-OMe (9). Boc-Met-Cpg-OH (0.195 g, 
0.54 mmol) was treated with HCl·H2N-Phe-OMe (0.117 g, 0.54 
mmol) according to the carbodiimide coupling general 
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procedure. Crystallization from EtOAc gave the title pure 
product as a colourless crystals (0.181 g, 64%). Boc-Met-Cpg-
Phe-OMe (9) was also prepared by using the ring-closing 
methatesis (RCM) reaction: (20 mg, 0.045 mmol) of Boc-Met-
Dag-Phe-OMe 6 in CH2Cl2 (2 mL) was treated with 2nd 
generation Grubbs catalyst (benzylidene[1,3-bis(2,4,6-
trimethylphenyl)-2-imidazolidinylidene]-dichloro(phenylmethy- 
lene)-(tricyclohexylphosphine) ruthenium) (10% mol) and the 
reaction mixture was left at room temperature for 5 h. The 
solvent was evaporated and the crude product was purified by 
PLC (EtOAc/CHCl3 1:1) to give 11 mg (47%) of product which 
resulted to be identical to Boc-Met-Cpg-Phe-OMe obtained by 
coupling the above reported Boc-Met-Cpg-OH with H2N-Phe-
OMe; mp 148.1-148.9 °C; IR (CHCl3): ν 3428, 1742, 1667 cm-1; 
1H NMR (CDCl3): δ 1.46 [9H, s, C(CH3)3], 1.87-2.14 [5H, m, 
Met β-CH2 and S-CH3 (s at 2.11)], 2.47-2.62 (2H, m, Met γ-
CH2), 2.72-2.92 (4H, m, two CH2-CH=CH), 3.08 and 3.18 (2H, 
A and B of an ABX, J = 5.6, 6.8 and 14.0 Hz, Phe β-CH2) 3.74 
(3H, s, COOCH3), 4.22 (1H, m, Met α-CH), 4.84 (1H, m, Phe 
α-CH), 5.16 (1H, br s, Met NH), 5.71 (2H, m, CH=CH), 6.67 
(1H, br s, Phe NH), 7.16 (1H, s, Cpg NH), 7.09-7.33 (5H, m, 
aromatics). Anal. Calcd for C26H37N3O6S: C, 60.09; H, 7.18; N, 
8.09. Found: C, 59.98; H, 7.11; N, 7.78. 
For-Met-Alg-Phe-OMe (4). From Boc-Met-Alg-Phe-OMe 
(0.100 g, 0.19 mmol) in dry DMF according to the general 
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procedure for preparation of the N-formyl derivatives. Silica gel 
flash chromatography (CH2Cl2/MeOH 98:2) gave the pure 
product as a white solid (0.07 g, 86%); [a]D +3° (c 1, CHCl3); IR 
(CHCl3): ν 3414, 1741, 1670 cm-1; 1H NMR (CDCl3): δ 1.91-
2.11 [5H, m, Met β-CH2 and S-CH3 (s, at 2.09)], 2.40-2.61 (4H, 
m, Met γ-CH2 and CH2-CH=CH2), 3.09 and 3.14 (2H, A and B 
of an ABX, J = 5.6, 6.0 and 13.6 Hz, Phe β-CH2), 3.70 (3H, s, 
COOCH3), 4.54 (1H, m, Alg α-CH), 4.73 (1H, m, Met α-CH), 
4.81 (1H, m, Phe α-CH), 5.10 (2H, m, CH2-CH=CH2), 5.60 (1H, 
m, CH2-CH=CH2), 6.72 (2H, apparent d, Phe NH and Met NH), 
6.93 (1H, d, J = 7.2 Hz, Alg NH), 7.02-7.5 (5H, m, aromatics), 
8.17 (1H, s, HCO). Anal. Calcd for C21H29N3O5S: C, 57.91; H, 
6.71; N, 9.65. Found: C, 57.37; H, 6.76; N, 9.71. 
For-Met-Dag-Phe-OMe (7). From Boc-Met-Dag-Phe-OMe 
(0.100 g, 0.17 mmol) in dry DMF according to the general 
procedure for preparation of the N-formyl derivatives. Silica gel 
flash chromatography (CH2Cl2/MeOH 98:2) gave the pure 
product as a colourless oil (0.06 g, 70%); IR (CHCl3): ν 3414, 
1741, 1670 cm-1; 1H NMR (CDCl3): δ 1.87-2.11 [5H, m, Met β-
CH2 and S-CH3 (s, at 2.09)], 2.48-2.65 (4H, m, Met γ-CH2 and 
CH2-CH=CH2), 2.81-2.90 (2H, m, CH2-CH=CH2), 3.09 and 
3.14 (2H, A and B of an ABX, J = 5.6, 7.2 and 14.0 Hz, Phe β-
CH2), 3.70 (3H, s, COOCH3), 4.57 (1H, m, Met α-CH), 4.83 
(1H, m, Phe α-CH), 4.97-5.10 (4H, m, two CH2-CH=CH2), 
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5.45-5.57 (2H, m, two CH2-CH=CH2), 6.37 (2H, d, J = 7.0 Hz, 
Met NH), 6.63 (1H, d, J = 7.2 Hz, Phe NH), 6.93 (1H, s, Dag 
NH), 7.10-7.30 (5H, m, aromatics), 8.13 (1H, s, HCO). Anal. 
Calcd for C24H33N3O5S: C, 60.61; H, 6.99; N, 8.84. Found: C, 
60.64; H, 6.95; N, 8.65. 
For-Met-Cpg-Phe-OMe (10). From Boc-Met-Cpg-Phe-OMe 
(0.06 g, 0.11 mmol) in CH2Cl2 according to the general 
procedure for preparation of the N-formyl derivatives. Silica gel 
flash chromatography (EtOAc/CHCl3 7:3) gave the pure product 
as a colourless oil (0.05 g, 98%); IR (CHCl3): ν 3411, 1742, 
1670 cm-1; 1H NMR (CDCl3): δ 1.90-2.11 [5H, m, Met β-CH2 
and S-CH3 (s at 2.11)], 2.45-2.63 (2H, m, Met γ-CH2), 2.71-2.98 
(4H, m, two CH2-CH=CH), 3.08 and 3.17 (2H, A and B of an 
ABX, J = 5.6, 6.8 and 14.0 Hz, Phe β-CH2), 3.74 (3H, s, 
COOCH3), 4.64 (1H, m, Met α-CH), 4.83 (1H, m, Phe α-CH) 
5.71 (2H, m, CH=CH), 6.57 (1H, d, J = 7.6 Hz, Met NH), 6.61 
(1H, d, J = 7.6 Hz, Phe NH), 7.08-7.34 (6H, m, aromatics and 
Cpg NH), 8.13 (1H, s, HCO). Anal. Calcd for C25H29N3O5S: C, 
59.34; H, 6.53; N, 9.39. Found: C, 59.01; H, 6.55; N, 9.42. 
 
2.4.5.3 Biological assays 
 
Cell preparation 
Cells were obtained from the blood of healthy subjects, and 
human peripheral blood neutrophils were purified by using the 
standard techniques of dextran (Pharmacia, Uppsala, Sweden) 
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sedimentation, centrifugation on Ficoll-Paque (Pharmacia), and 
hypotonic lysis of contaminating red cells. Cells were washed 
twice and resuspended in Krebs-Ringer phosphate (KRPG), pH 
7.4, at final concentration of 50 x 106 cells/mL and kept at room 
temperature until used. Neutrophils were 98-100% viable, as 
determined using the Trypan Blue exclusion test. The study was 
approved by the local Ethics Committee and informed consent 
was obtained from all participants. 
 
Random locomotion 
Random locomotion was performed with 48-well 
microchemotaxis chamber (Bio Probe, Milan, Italy) and 
migration into the filter was evaluated by the leading-front 
method.96 The actual control random movement is 35 ± 3 µm SE 
of 10 separate experiments performed in duplicate. 
 
Chemotaxis 
Each peptide was added to the lower compartment of the 
chemotaxis chamber. Peptides were diluted from a stock 
solution with KRPG containing 1 mg/mL of bovine serum 
albumin (BSA; Orha Behringwerke, Germany) and used at 
concentrations ranging from 10-12 to 10-5 M. Data were 
expressed in terms of chemotactic index (CI), which is the ratio 
(migration toward test attractant minus migration toward the 
buffer/migration toward the buffer); the values are the mean of 
Chapter 2 
 
148 
six separate experiments performed in duplicate. Standard errors 
are in the 0.02-0.09 CI range. 
 
Superoxide anion (O2-) production 
This anion was measured by the superoxide dismutase-
inhibitable reduction of ferricytochrome c (Sigma, USA) 
modified for microplate-based assays. Tests were carried out in 
a final volume of 200 mL containing 4 x 105 neutrophils, 100 
nmoles cytochrome c and KRPG. At zero time different 
amounts (10-10 -8 x 10-5 M) of each peptide were added and the 
plates were incubated into a microplate reader (Ceres 900, Bio-
TeK Instruments, Inc.) with the compartment temperature set at 
37 °C. Absorbance was recorded at 550 and 468 nm. The 
difference in absorbance at the two wavelengths was used to 
calculate nmoles of O2- produced using an absorptivity for 
cytochrome c of 18.5 mM-1 cm-1. Neutrophils were incubated 
with 5 µg/mL cytochalasin B (Sigma) for 5 min prior to 
activation by peptides. Results were expressed as net nmoles of 
O2- per 1 x 106 cells per 5 min and are the mean of six separate 
experiments performed in duplicate. Standard errors are in 0.1-4 
nmoles O2- range. 
 
Enzyme assay 
The release of neutrophil granule enzymes was evaluated by 
determination of lysozyme activity, modified for microplate-
based assays. Cells, 3 x 106/well, were first incubated in 
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triplicate wells of microplates with 5 µg/mL cytochalasin B at 
37 °C for 15 min and then in the presence of each peptide at a 
final concentration of 10-10 -8 x 10-5 M for a further 15 min. The 
plates were then centrifuged at 400 x g for 5 min and the 
lysozyme was quantified nephelometrically by the rate of lysis 
of cell wall suspension of Micrococcus lysodeikticus. The 
reaction rate was measured using a microplate reader at 465 nm. 
Enzyme release was expressed as a net percentage of total 
enzyme content released by 0.1% Triton X-100. Total enzyme 
activity was 85 ± 1 mg per 1 x 107 cells/min. The values are the 
mean of five separate experiments done in duplicate. Standard 
errors are in the range of 1-6%. 
 
2.5 X-ray crystal structure and conformation of N-
(tert-butyloxycarbonyl)-L-methionyl-(1-aminocyclo- 
pent-3-ene-1-carbonyl)-L-phenylalanine methylester 
(Boc0-Met1-Cpg2-Phe3-OMe)* 
 
Owing to the capacity to induce conformational restrictions 
and stability towards enzymatic degradation to peptides, the 
replacement of natural α-amino acids with synthetic Cα-
tetrasubstitued (quaternary) residues is the object of 
considerable attention in the design of synthetic peptides 
suitable for the use as therapeutical agents.112-114 Since the 
conformational restrictions imposed by Cα-tetrasubstitued 
                                                 
*Mura, P.; Camalli, M.;  Campi, G.; Lucente, G.; Giordano, C.; 
Mollica, A.; Sansone, A.; Torino, D. Z. Kristallogr. 2009, 224, 225. 
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residues on peptide backbones vary and generally increase when 
the quaternary α-carbon atom makes part of a ring structure (as 
compared with models containing two free-rotating side chains 
at the Cα-atom), synthetic α-aminoacidic residues, such as 1-
aminocycloalkane-1-carboxylic acids (Acnc)115-117 and related 
heterocyclic counterparts,113, 118 are the object of special interest. 
Here we report the structure and conformation adopted in the 
crystal by a position-2 modified analogue of the antagonistic 
chemotactic agent N-Boc-Met-Leu-Phe-OMe.100 In the model 
under study (Figure 13) the native central Leu has been replaced 
by the achiral 1-aminocyclopent-3-ene- 1-carboxylic acid (Cpg), 
the unsaturated analogue of the extensively studied Ac5c 
residue. It is worth noting here that, whereas the conformational 
consequences of the incorporation in the peptide skeleton of 
Acnc residues and related heterocyclic ring strucures have been 
extensively studied,50,105,115-118 data on organic compounds, 
including peptides, containing the synthetic 5-membered-ring 
cycloalkenic Cpg residue are very scarce.72,104 The here reported 
structure gives the first information on the conformation adopted  
 
 
 
Figure 13.  Chemical structure of the title tripeptide derivative Boc-Met- 
Cpg-Phe-OMe. 
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in the crystal by a Cpg containing tripeptide model. Synthesis, 
preferred conformation in CDCl3 solution and biological activity 
of the title compound Boc-Met-Cpg-Phe-OMe have been 
previously reported.72  
 
2.5.1 Crystal state conformational analysis 
 
The molecular structure of the peptide Boc-Met-Cpg-Phe- 
OMe together with the atom-labelling is reported in Figure 14. 
 
                            
Figure 14. Geometry126 of Boc-Met-Cpg-Phe-OMe, hydrogen atoms are 
omitted for clarity, thermal ellipsoids are drawn at 30% probability level. 
 
Selected bond lengths (Å) and angles (°) are reported in 
Table 3. The backbone of the N-protected tripeptide adopts a 
folded β-turn conformation (Figure 15). The φ, ω dihedral 
angles (Table 4) relative to the Met (φi+1 = -49.3° and ωi+1 = 
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142.6°) and Cpg (φi+2 = 61.0° and ωi+2 = 32.8°) residues are in 
line with the values assigned to the two aminoacids occupying 
the central positions (i + 1 and i + 2) of a sequence of four 
residues which adopts an ideal type-II (see Figure 15) β-turn 
(φi+1 =  -60°,  ωi+1 = 120°;  φi+2 = 80°,  ωi+2 = 0).119  The  folding,  
 
Table 3. Selected bond lengths (Å) and bond angles (°) in Boc-Met- 
Cpg-Phe-OMe (esd’s are given in parentheses). 
 
 
 
Figure 15.  Schematic illustration of a peptide backbone folded in a β-turn 
(C10) structure. Torsion angles φ and ψ at the two corner residues i + 1 and i 
+ 2 are shown. The dashed line indicates the (i + 3) → (i) NH···CO hydrogen-
bond which frequently stabilizes the folding. 
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Table 4. Main torsion angles (°) of the tripeptide 
methyl ester Boc0-Met1-Cpg2- Phe3-OMe. 
i
i
i
i
2
i
i
 
 
which gives rise to a changement of the backbone direction of 
approximately 180° as compared with an extended 
conformation, is characterized by a weak electrostatic 
interaction between N1 (the Phe NH) and the urethane 
carbonylic oxygen O5 (Figure 15). This generates a ten-
membered pseudo-ring system with the N1···O5 distance 
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(3.356(8) Å) which is slightly beyond the highest values 
observed in the statistical distribution (2.5-3.2 Å) of the 
intramolecular bond distances.120 The degree of the backbone 
folding can be also evaluated by considering the distance 
separating the Cα carbon atoms of the first (i) and the fourth (i + 
3) residue which, in standard β-turns, does not exceed 7 Å.121 In 
the molecule under study the distance observed between O6 
(here replacing the Cαi) and the Phe Cα carbon atom (Cαi+3) is 
5.49(1) Å in perfect accordance with a β-turn folding not 
accompanied by the i + 3 → i intramolecular H-bond.  
As shown in Figure 15 and Table 4 the Met-Cpg (ω1) and 
Cpg-Phe (ω2) amide bonds are in the expected trans 
conformation. Whereas the Cpg-Phe junction is practically 
planar (ω2 = 176.9°), the central Met-Cpg shows a sensible 
deviation from planarity (ω1 = 170.6°). At the N-terminal moiety 
the torsion angles around the O6-C22 and C22-N3 bonds (-173.6° 
and 168.5°, respectively) indicate that the urethane tert-Bu-O-
CO-NH- chain adopts a slightly distorted type b trans-trans 
planar conformation122 with the O6-C23-C25 valence angle 
(102.4°) (Table 3) smaller by about 7° than the tetrahedral value; 
both these findings are in accordance with the geometrical and 
conformational peculiarities derived from crystallographic 
investigations on peptides containing the tert-
butyloxycarbonylamino group.122 At the esterified C-terminus 
the carbonylic oxygen O2 points toward the preceding Cpg 
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carbonyl O3 with the planar CO-OMe methyl ester fragment 
adopting a gauche arrangement (the O2-C2-C3-N1 torsion angle 
being -51.2°). 
The cyclopentene ring points toward the methionine side 
chain and adopts an envelope conformation (Cs) with the Cα 
carbon C12 displaced 0.309(8) Å from the plane of the other four 
ring atoms. Thus, a pseudo-mirror plane, bisecting the olefinic 
bond and passing through the carbon at the flap, can be 
individuated. Due to the constraint imposed by the unsaturated 
5-membered ring all the endocyclic bond angles are 
significantly lower than the theoretical values. The highest 
deviation from the tetrahedral geometry is shown by the angle at 
C16 (101.8° versus 109.5°) while the two olefinic bond angles at 
C14 and C15 deviate of 5.6 and 7.2° respectively from the regular 
value of 120°. 
Mention should be made of the value adopted by the 
exocyclic valence angle (τ angle) at the (Cα carbon atom C12) of 
the Cpg residue. The analysis of the basic geometry of the 
amino acid residues of protein structures has demonstrated the 
almost invariability of all bond lengths and bond angles except 
for τ, the backbone angles at the Cα carbon atoms (N-Cα-C’).123 
This latter angle can be widened or contracted significantly from 
the tetrahedral geometry to accomodate various strains in the 
structure and, owing to its dependence by the local backbone 
conformation, its deviation represents an useful parameter in 
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peptide and protein studies.124 In the case of Cα-tetrasubstituted 
residues it is highly sensible to the type of the adopted local 
conformation and it is smaller than the tetrahedral value in the 
fully extended conformations (typical values: 102-107°). The 
opposite trend is observed in the folded conformations and the 
value here found (τ = 110.8(4)°; Table 3) for the Cpg residue, 
1.3° larger than the tetrahedral value, corresponds to that 
typically adopted by the Acnc containing folded peptides. 
 
2.5.2 Conclusions 
 
The conformational analysis described here shows that the 
unusual synthetic amino acid Cpg maintains, when introduced 
into a peptide backbone, the strong tendency, characteristic of 
the Cα-tetrasubstituted residues, to induce folded conformations. 
This result appears of interest since, at variance with the 
saturated counterparts (i.e. residues of the Acnc type), the 
chemical reactivity offered by the olefinic bond present in the 
Cpg molecule, represents a suitable point of attack for a variety 
of chemical trasformations. 
 
2.5.3 Experimental section 
 
2.5.3.1 X-ray crystallography 
A crystal of the N-(tert-butyloxycarbonyl)-L-methionyl-(1-
aminocyclopent-3-ene-1-carbonyl)-L-phenylalanine methylester 
was sealed in a glass capillary. Diffraction data sets of the 
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crystal were collected at room temperature on the XRD1 
beamline at the ELETTRA Synchrotron Light Laboratory 
(Trieste, Italy) by using a horizontal single axis goniostat 
diffractometer and a 165 mm MarResearch CCD X-ray detector 
positioned at 40 mm distance from the crystal; φ scans with 3° 
steps were performed to obtain the data. Diffraction data were 
processed and scaled by using the CCP4 program package.125 
Unit cell parameters were determined and refined from 15 
frames and the data collection consisted of 120 frames. The 
structure was solved by direct methods and refined using 
Sir2008 (part of Il Milione suite).126 Of the 34.513 reflections 
which were collected, 4851 were independent. All non-hydrogen 
atoms were refined by a full-matrix least squares method with 
anisotropic thermal parameters. The hydrogen atoms were 
idealized (C-H = 0.96 Å); each of them was assigned 1.3 of the 
equiv. isotropic temperature factor of the parent atom and 
allowed to ride on it. The final cycle of full-matrix least-squares 
refinement on F was based on 3433 observed reflections [F > 
3σ(F)]; a final R factor of 0.102, wR = 0.111 and a goodness of 
fit of 0.84 have been obtained for 320 parameters. The final 
difference Fourier map, with a root-mean-square deviation of 
electron density of 0.04 e Å-3 showed minimum and maximum 
values of -0.18 and 0.40, respectively. Crystal and data 
collection details together with structure refinement are 
summarized in Table 5.  
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Table 5. Crystal data and refinement of Boc-Met-Cpg-Phe-OMe. 
a
P
b
c
V
Z
F
h k l
R
F
F F
R wR
w F F
 
 
2.5.3.2 Synthesis 
 
The synthesis is reported in the Ref. 72. Needle crystals were 
obtained by slow evaporation of an ethyl acetate solution, after 
four days, at room temperature. 
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2.6 Synthesis and bioactivity of chemotactic 
tetrapeptides: fMLF-OMe analogues incorporating 
spacer amino acids at the lateral positions* 
 
Natural and synthetic chemoattractant N-formyl tripeptides 
continue to stimulate a great deal of interest due to their ability 
to bind to specific G-protein-coupled receptors (FPRs) primarily 
expressed on neutrophil and monocyte membranes. In addition 
to N-formyl tripeptides several FPR ligands of different origin 
and molecular structure have been identified over the past years. 
However, due to its simple structure and high agonistic potency 
N-formyl-Met-Leu-Phe-OH (fMLF) and its methyl ester (fMLF-
OMe) remain the reference molecules for studies on peptidic 
chemoattractants derived from cleavage of bacterial or 
mitochondrial proteins. 
Binding of N-formyl peptides to leucocyte FPRs activates a 
variety of cell functions including migration towards the 
inflammation sites, generation of free radicals and release of 
granule contents. 
In addition to the above cited biochemical events, which 
concern the role played by FPR in the host defense against 
invading microorganisms, a further relevant point has been 
recently evidenced. Studies from several groups firmly establish 
in fact that the distribution of FPR is not limited to neutrophil 
and monocytes but is widely extended to different tissues and 
                                                 
*Lucente, G.; Giordano, C.; Sansone, A.; Torino, D.; Spisani, S. 
Amino Acids 2009, 37, 285. 
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organs.39,127 Thus, it is now clear that the family of 
chemoattractant receptors, together with a variety of microbial 
and endogenous ligands, forms a complex system whose 
pathophysiological functions involve several and probably 
determinant roles in both inflammatory and immunological 
diseases. The above reported findings have enlarged the interest 
on N-formyl peptide chemoattractants well beyond the host 
defence against microbial infection and have underlined, at the 
same time, the relevance of FPRs as potential target for the 
development of new therapeutic strategies.128 However, in spite 
of these data, several aspects concerning the structural basis of 
receptor/agonists interaction and the signalling mechanisms100 
still remain to be elucidated.129  
Previous investigations based on fMLF backbone 
modification give clear evidence that the sulphur-containing N-
terminal For Met-moiety and the aromatic side chain at the C-
terminal position of the tripeptide are crucial for both binding 
and receptor activation. The central hydrophobic Leu, on the 
other hand, appears to be quite tolerant of modification70 and 
several fMLF analogues modified at position-2 with high 
activity and selectivity have been described.73,74 Finally, it is 
now well known that key interactions between ligands and FPRs 
involve in addition to the Met and Phe hydrophobic side chains 
specific hydrogen bonding established by the N-terminal 
formylic group. Relevant is the observation that modifications 
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centred at this function can modulate the neutrophil biological 
responses and open the way to FPR antagonists whose interest 
for the use in diagnostic and therapeutic applications is well 
known. In particular both urea and carbamate derivatized fMLF 
analogues, among which Boc-Met-Leu-Phe-OMe, containing 
the bulky tBuOCO (Boc) group in place the native H-CO (For), 
have been studied and found active as antagonists.67,68  
In accordance with the observed versatility towards structural 
modifications at position-2 of fMLF we reported previously 
studies on N-For and N-Boc analogues characterized by the 
presence of linear achiral ω-amino acids as spacers, in place of 
the central Leu.85 These tripeptides maintain the two native Met 
and Phe side chains but are characterized by different distances 
on the backbone between side chains at position-1 and position-
3 depending upon the ω-amino acid residue used as spacer. As 
prosecution of these studies we report here the results of a new 
approach in which N-For and N-Boc tetrapeptidic analogues of 
fMLF-OMe are examined. At variance with previous 
approaches, the here reported analogues have been designed so 
as to maintain intact all the three native residues present in the 
reference ligand and to possess a backbone sequence altered by 
the presence of a spacer amino acid inserted between the Met 
and the Leu (tetrapeptide models of the Xaa2 type) or between 
Leu and Phe (tetrapeptide models of Xaa3 type) as depicted in 
Figure 16.  
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3  
Figure 16. Structure of fMLF-OMe and its Xaa2 and Xaa3 tetrapeptide 
analogues reported in the present study. The spacer amino acid Xaa 
represents in all cases a residue of Gly, β-Ala or Pro. 
 
The aim of this study is to get preliminary information on the 
consequences that the variation of the disposition and distance, 
relating the two critical side chains present in the native ligand, 
has on the interaction with the complementary pockets of the 
FPR receptor. In order to investigate this point three different 
spacers have been used. Two of these are the achiral and side 
chain devoid residues of Gly and β-Ala while the third is the 
chiral residue of Pro. This latter shares with the achiral Gly and 
β-Ala residues the absence of the characteristic side chain 
present in all natural amino acids and, under this aspect, can be 
related to Gly of which can be considered a ring-constrained 
analogue. 
 
2.6.1 Chemistry 
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The synthesis of the N-Boc-tetrapeptides and the 
corresponding N-formyl derivatives was performed in solution 
according to the strategy reported in Schemes 6 and 7. 
 
Scheme 6.  Synthesis of N-protected tetrapeptides of the Xaa2 type (2-3: Xaa 
= Gly; 5-6: Xaa = β-Ala; 8-9: Xaa = Pro). Reagents and conditions: a) 
TFA·H2N-Leu-Phe-OMe, TEA, HOBt, EDC, dry EtOAc, 30 min 0 °C, 12h 
rt; b) TFA/CH2Cl2 1:1, 1h rt; c) Boc-Met-OH, HOBt, TEA, EDC, dry EtOAc, 
30 min 0 °C, 12h rt; d) HCOOH, overnight rt then EEDQ, CHCl3, 24h rt.  
  
Analogues of the Xaa2 type were obtained by coupling the N-
Boc-Xaa-OH derivatives with the N-terminal dipeptide fragment 
thus giving the three tripeptides Boc-Xaa-Leu-Phe-OMe (1, 4 
and 7). These were then deprotected and coupled with Boc-Met-
OH to give the three tetrapeptides Boc-Met-Xaa-Leu-Phe-OMe 
2, 5 and 8.  
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Scheme 7. Synthesis of N-protected tetrapeptides of the Xaa3 type (11-12: 
Xaa = Gly; 14-15: Xaa = β-Ala; 17-18: Xaa = Pro). Reagents and conditions: 
a) Boc-Met-Leu-OH, HOBt, TEA, EDC, dry EtOAc; b) HCOOH, overnight 
rt then EEDQ, CHCl3, 24h rt.   
 
A different strategy was adopted for the synthesis of the Xaa3 
models (see Scheme 7) where the three dipeptide derivatives 
Boc-Xaa-Phe-OMe were firstly synthesized; N-deprotection to 
10, 13 and 16 was followed by coupling with the common 
dipeptide fragment Boc-Met-Leu-OH to give the tetrapeptides 
N-Boc-Met-Leu-Xaa-Phe-OMe 11, 14 and 17. Direct 
transformation of all the N-Boc derivatives (Schemes 6, 7) into 
the corresponding N-formyl analogues 3, 6, 9, 12, 15 and 18 was 
performed by treatment of each N-Boc derivative with formic 
acid and then with EEDQ.92  
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2.6.2 Biological results 
 
The activity of the N-For and N-Boc tetrapeptide derivatives 
reported in Schemes 6 and 7 has been determined on human 
neutrophils. Directed migration (chemotaxis), superoxide anion 
production and lysozyme release have been measured. In the 
first set of experiments (see Figures 17, 18) the agonistic activity 
was measured and compared to that of the standard tripeptide 
fMLF-OMe. In the second set (see Figures 19, 20) the 
antagonistic activity of the N-Boc tetetrapeptides, which have 
been found inactive as agonists, have been examined as 
antagonists by measuring their ability to inhibit the effect 
stimulated by an optimal dose of fMLF-OMe. 
As shown in Figures 17A and 18A all the N-For tetrapeptide 
analogues maintain moderate to high capacity to induce 
chemotaxis with dose-response curves showing an optimal 
concentration value around 10-9 M. The three models of Xaa2 
type Gly2 (3), β-Ala2 (6) and Pro2 (9) (Figure 17A) exhibit 
moderate activity and very similar behaviour with the Pro2 
model 9 with about the same potency but with lower efficiency 
(peptide concentration at which maximal activity is observed) 
than the β-Ala2 (6) and Gly2 (3). The activity of the Xaa3 type 
analogues, on the other hand, is greatly influenced by the nature 
of the spacer residue (Figure 18A). Thus, while the tetrapeptide 
15, containing β-Ala as spacer, is a very potent chemotactic 
agent-nearly as active as the reference molecule-compound 12, 
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containing Gly as spacer, is only moderately active with a 
maximum value comparable to those shown by the models of 
the Xaa2 type. 
Figures 17B and 18B illustrate the ability of the Xaa2 and 
Xaa3 models, respectively, to trigger superoxide anion 
production. Also in this case all tetrapeptides maintain moderate 
to good activity with values of 50 and 53 nmoles at 10-6 M for 
β-Ala containing models 6 (Figure 17B) and 15 (Figure 18B), 
respectively. Notable is also the dose-response curve exhibited 
by the Pro3 tetrapeptide 18 (Figure 17B) with a peak value of 56 
nmoles at concentration 10-5 M. This result is opposite to that 
observed in the Xaa2 series where the Pro2 incorporation 
produces the least active model (compound 9 in Figure 17B). 
 
 
Figure 17.  Biological activity towards human neutrophils of N-For (3, 6 and 
9) and N-Boc (2, 5 and 8) tetrapeptide analogues of Xaa2 type (see Scheme 6) 
compared with the reference ligand fMLF-OMe. (A) Chemotactic index; (B) 
Superoxide anion production; (C) Release of granule enzymes evaluated by 
determining lysozyme release. Points are single representative experiments 
carried in duplicate 
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As for the enzyme secretagogue activity (Figures 17C, 18C) 
all the tetrapeptides show dose-response curves with the same 
maximum value centred at 10-5 M and lysozyme release 
moderately higher in the Xaa3 series, with values ranging 
between 46-49% and 34-42% for the Xaa3 and Xaa2 models, 
respectively. 
 
Figure 18.  Biological activity towards human neutrophils of N-For (12, 15 
and 18) and N-Boc (11, 14 and 17) tetrapeptide analogues of Xaa3 type (see 
Scheme 7) compared with the reference ligand fMLF-OMe. (A) Chemotactic 
index; (B) Superoxide anion production; (C) Release of granule enzymes 
evaluated by determining lysozyme release. Points are single representative 
experiments carried in duplicate 
 
As shown in Figures 17 and 18 the agonistic activity values 
shown by the N-Boc derivatives, regardless the nature of the 
spacer residue and its location on the backbone, are not 
statistically significant for all the three biological functions 
tested. These compounds have been examined as antagonists by 
measuring their ability to inhibit the effect stimulated by an 
optimal dose of the reference peptide fMLF-OMe. The influence 
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of increasing concentrations of N-Boc tetrapeptides of Xaa2 type 
(Gly2: 2; β-Ala2: 5; Pro2: 8) and Xaa3 type (Gly3: 11; β-Ala3: 14; 
Pro3: 17) on the three examined functional acivities are reported 
in Figures 19 and 20, respectively. It can be seen that the N-Boc 
tetrapeptides of both the series exert significant dose-dependent 
inhibition (50% ca. at 10-9 M) of the CI with a similar profile of 
activity (Figures 19A, 20A). Conversely, no significant 
inhibition is observed for the N-Boc tetrapeptides on both the 
superoxide anion production (Figures 19B, 20B) and lysozyme 
release (Figure 20C), except a very weak effect shown by the 
Xaa2 tetrapeptides on lysozyme release (Figure 19C) where a 
50% inhibition is reached only at high concentrations (10-6 to 
10-5 M). 
 
 
Figure 19. Effect of N-Boc tetrapeptides of Xaa2 type (Gly2: 2; β-Ala2: 5; 
Pro2: 8) on human neutrophil activities triggered by fMLF-OMe. (A) 
Chemotactic index; (B) Superoxide anion production; (C) Release of granule 
enzymes. 
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Figure 20. Effect of N-Boc tetrapeptides of Xaa3 type (Gly3: 11; β-Ala3: 14; 
Pro3: 17) on human neutrophil activities triggered by fMLF-OMe. (A) 
Chemotactic index; (B) Superoxide anion production; (C) Release of granule 
enzymes. 
 
2.6.3 Conclusions 
 
The results reported here give for the first time information 
on the properties of a series of tetrapeptidic fMLF-OMe 
analogues obtained by performing incorporation of spacer 
residues in the molecule of the reference ligand and leaving at 
the same time intact the original stereochemistry and succession 
on the backbone of the three native amino acid residues of the 
reference ligand. This approach differs from previously reported 
studies in which one or more residues of fMLF have been 
replaced.129 As shown in Figures 17A and 18A all N-For 
tetrapeptides maintain the ability to elicit high to moderate 
values of chemotaxis. However, when the chemotatic index of 
the two series of tetrapeptides is compared two points can be 
evidenced: (1) the incorporation of the Xaa2 spacer between the 
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Met and Leu (Figure 17A is generally more detrimental for the 
activity than the corresponding Xaa3 modification involving Leu 
and Phe (Figure 3A). Remarkable is the activity shown by the β-
Ala3 containing model 15 (Figure 18A) which reaches an 
activity comparable to that of fMLF-OMe; (2) at variance with 
Xaa3 series, the nature of the incorporated spacer does not affect 
appreciably the activity of Xaa2 models which exhibit very close 
dose-response curves (Figure 17A). Only the Pro2 analogue 9 
shows a slightly different behaviour with a peak of activity 
centred at higher concentration than the Gly2 3 and β-Ala2 6 
models. This effect can be related to the well known influence 
of the Pro residue on hydrogen bonding and backbone 
conformation. On the basis of these findings it can be speculated 
that the Met and Leu binding pockets on the receptor are more 
critically related and probably more nearly located than those 
relating Leu and Phe. The sensibly higher chemotactic activity 
of the β-Ala3 analogue 15, as compared with the corresponding 
Gly3 containing model 12 (Figure 18A), seems in accordance 
with this preliminary interpretation.  
With regard to the superoxide anion production (Figures 17B, 
18B) it can be noted the general good agonist activity shown by 
both the Xaa2 and Xaa3 series of analogues as compared with the 
only modest activity exhibited by the same models for the 
lysozyme release (Figures 17C, 18C). It can be observed here 
that the best results are obtained with the β-Ala containing 
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models in both the Xaa2 and Xaa3 series (model 6 and 15 in 
Figure 17B, 18B, respectively). Thus, the incorporation of the β-
Ala residue at position 3 leads to tetrapeptide ligands with high 
activity for both chemotaxis and generation of reactive oxygen 
species. These findings stimulate further research on fMLF-
OMe analogues obtained through incorporation of β-residues 
and in particular of achiral higher homologues of β-Ala. Models 
of this type, designed according the results reported in Figures 
17B and 18A-B, appear in fact well suited to give highly active 
new tetrapeptides as well as information on the interaction with 
receptor hydrophobic pockets. 
As shown in Figures 17 and 18 the presence of the bulky N-
Boc protecting group does not modify the expected inactivity as 
agonists of the new analogues. These compounds have been 
then tested as antagonists. Figures 19 and 20 clearly show that 
the incorporation of a spacer gives rise, almost regardless the 
nature of the incorporated amino acid residue and its position on 
the backbone, to ligands characterized by relevant inhibition 
against migratory activity (Figures 19A, 20A). A different result 
is observed in the case of the other two biological functions 
tested (Figures 19B-C, 20B-C) where all the performed 
modifications do not produce appreciable inhibitory effects at 
physiological concentrations. Thus, the elongation of the fMLF-
OMe backbone, through spacer incorporation at the two lateral 
positions, combined with the presence of a bulky N-protecting 
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group, leads to effective antagonists which can be selective for 
the chemotactic function. 
Taken together the here reported results indicate that the 
adopted approach of modification of the prototype of the family 
of chemotactic peptides gives rise to an articulate picture of data 
which represent a promising basis for the study of the FPR 
receptor and for the design of new ligands with both agonistic 
and selective antagonistic activity.  
 
2.6.4 Experimental section 
 
Materials and methods. Melting points were determined 
with a Büchi B 540 apparatus and are uncorrected. Optical 
rotations were taken at 20 °C with a Schmidt-Haensch 
Polartronic D polarimeter (1 dm cell, c 1.0 in CHCl3, unless 
otherwise specified). IR spectra were recorded in 1% CHCl3 
solution (unless otherwise specified) employing a Perkin-Elmer 
FT-IR Spectrum 1000 spectrometer. 1H NMR experiments were 
performed at 400 MHz on a Bruker AM 400 spectrometer in 
CDCl3 solution and chemical shifts (δ) are quoted in parts per 
million (ppm) and were indirectly referred to TMS. TLC (thin 
layer chromatography) were performed on silica gel Merck 60 
F254 plates. The drying agent was sodium sulphate. Elemental 
analyses were performed in the laboratories of the Servizio 
Microanalisi del CNR, Area della Ricerca di Roma, 
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Montelibretti, Italy, and were within ±0.4% of the theoretical 
values. 
Protected amino acids were purchased from Bachem and 
Fluka. Coupling and N-Boc deprotection procedures were 
performed according general protocols130 and checked for purity 
by TLC, HPLC and elemental analysis. N-Formylation was 
attained starting from the corresponding N-Boc derivatives.92  
 
2.6.4.1 Chemistry. General procedure 
A. Coupling with the carbodiimide method. To an ice-
cooled mixture containing the required N-Boc-amino 
acid (1.0 mmol), the amino-derivative salt (1.0 mmol), 
HOBt (1.2 mmol), and TEA (2.2 mmol) in anhydrous 
EtOAc (6 mL), EDC (1.2 mmol) was added and the 
reaction mixture was allowed to warm to room 
temperature. After 12 h the reaction mixture was diluted 
with EtOAc (20 mL) and washed with 1M KHSO4 (2 x 
15 mL), saturated aqueous NaHCO3 (2 x 15 mL) and 
brine (15 mL). The organic phase was dried and 
evaporated under reduced pressure. 
B. Preparation of the N-formyl derivatives. The N-Boc 
derivative (1.0 mmol) was dissolved in formic acid (3 
mL) and the mixture was allowed to stand at room 
temperature overnight. After removal of the excess 
formic acid under vacuum, the residue was dissolved in 
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dry CH2Cl2 (10 mL) or dry DMF (2 mL). EEDQ 97% 
(1.2 mmol) was added and the solution was stirred at 
room temperature for 24 h. Evaporation under reduced 
pressure afforded the crude N-formyl derivatives.92 
 
2.6.4.2 Synthesis 
Boc-Met-Gly-Leu-Phe-OMe (2). From Boc-Met-OH (0.058 
g, 0.23 mmol) and TFA·H2N-Gly-Leu-Phe-OMe (0.107 g, 0.23 
mmol)131 according to the general procedure A. Crystallization 
from hexane gave the pure product as white solid (0.100 g, 
75%); mp 134.3-136.5°C; [a]D +2.0° (c 1, CHCl3); IR (CHCl3): 
ν 3421, 1710, 1676 cm-1; 1H NMR (CDCl3): δ 0.87-0.90 [6H, m, 
Leu CH-(CH3)2], 1.45 [9H, s, C(CH3)3], 1.48-1.93 [5H, m, Met 
β-CH2 and Leu CH2-CH-(CH3)2], 2.12 (3H, s, SCH3), 2.57 (2H, 
m, Met γ-CH2), 3.01 and 3.18 (2H, A and B of an ABX, J = 6.0, 
5.6 and 14.0 Hz, Phe β-CH2), 3.71 (3H, s, COOCH3), 3.78-3.99 
(2H, m, Gly α-CH2), 3.98 (1H, m, Met α-CH), 4.44 (1H, m, Leu 
α-CH), 4.83 (1H, m, Phe α-CH), 5.37 (1H, d, J = 7.6 Hz, Met 
NH), 6.74 (2H, m, Phe NH and Leu NH), 6.96 (1H, br s, Gly 
NH), 7.12-7.29 (5H, m, aromatics). Anal. Calcd for 
C28H44N4O7S: C, 57.91; H, 7.64; N, 9.65. Found: C, 58.14; H, 
7.61; N, 9.68.  
For-Met-Gly-Leu-Phe-OMe (3). From Boc-Met-Gly-Leu 
Phe-OMe (0.1 g, 0.17 mmol) according to the general procedure 
B. Crystallization from EtOAc/Hexane. White solid (0.080 g, 
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93%); mp 175-177.9 °C; [a]D +2.0° (c 1, CHCl3); IR (CHCl3): ν 
3671, 3426, 1652 cm-1; 1H NMR (CDCl3): δ 0.87-0.90 [6H, m, 
Leu CH-(CH3)2], 1.48-1.93 [5H, m, Met β-CH2 and Leu CH2-
CH-(CH3)2], 2.12 (3H, s, SCH3)], 2.57 (2H, m, Met γ-CH2), 3.01 
and 3.18 (2H, A and B of an ABX, J = 6.3, 5.6, 13.8 Hz, Phe β-
CH2), 3.71 (3H, s, COOCH3), 3.78-3.99 (2H, m, Gly α-CH2), 
4.30 (1H, m, Met α-CH), 4.44 (1H, m, Leu α-CH), 4.83 (1H, m, 
Phe α-CH), 5.37 (1H, d, J = 8.0 Hz, Met NH), 6.74 (2H, m, Phe 
NH and Leu NH), 6.96 (1H, br s, Gly NH), 7.12-7.29 (5H, m, 
aromatics), 8.04 (1H, s, HCO). Anal. Calcd for C24H36N4O6S: C, 
56.67; H, 7.13; N, 11.02. Found: C, 56.81; H, 7.16; N, 11.05. 
Boc-β-Ala-Leu-Phe-OMe (4). From Boc-β-Ala-OH (0.080 
g, 0.42 mmol) and TFA·H2N-Leu-Phe-OMe (0.170 g, 0.42 
mmol) according to the general procedure A. The title 
compound was obtained as a white solid, pure on TLC (0.170 g, 
87%); [a]D -7.0° (c 1, CHCl3); IR (CHCl3): ν 3427, 3011, 1741, 
1631  cm-1; 1H NMR (CDCl3): δ 0.89-0.98 [6H, m, Leu CH-
(CH3)2], 1.47 [9H, s, C(CH3)3], 1.77-1.88 [5H, m, Leu CH2-CH-
(CH3)2 and β-Ala α-CH2], 2.90 and 3.15 (2H, A and B of an 
ABX, J = 6.1, 5.6 and 14.0 Hz, Phe β-CH2), 3.20-3.50 (2H, m, 
β-Ala β-CH2), 3.70 (3H, s, COOCH3), 4.50 (1H, m, Leu α-CH), 
4.75 (1H, m, Phe α-CH), 5.20 (1H, d, J = 7.2 Hz, β-Ala NH), 
6.20 (1H, d, J = 7.6 Hz, Phe NH), 6.75 (1H, d, J = 7.3 Hz, Leu 
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NH), 7.01-7.45 (5H, m, aromatics). Anal. Calcd for C24H37N3O6: 
C, 62.18; H, 8.04; N, 9.06. Found: C, 62.33; H, 8.07; N, 9.09. 
Boc-Met-β-Ala-Leu-Phe-OMe (5). From Boc-Met-OH 
(0.0645 g, 0.26 mmol) and TFA·H2N-β-Ala-Leu-Phe-OMe 
(0.123 g, 0.26 mmol), this latter obtained from deprotection of 
Boc-β-Ala-Leu-Phe-OMe, according to the general procedure A. 
Colourless oil (0.170 g, 87%); mp 133.5-135 °C; [a]D +42° (c 1, 
CHCl3); IR (CHCl3): ν 3427, 1741, 1631 cm-1; 1H NMR 
(CDCl3): δ 0.85-0.91 [6H, m, Leu CH-(CH3)2], 1.45 [9H, s, 
C(CH3)3], 1.53-1.66 [3H, m, Leu CH2-CH-(CH3)2], 1.68-1.84 
(2H, m, Met β-CH2), 2.10 (3H, s, SCH3), 2.28-2.51 (4H, m, β-
Ala α-CH2 and γ-Met CH2), 3.04-3.19 (3H, m, β-Ala β-CHH 
and Phe β-CH2), 3.75 (3H, s, COOCH3), 3.85-3.90 (2H, m, β-
Ala β-CHH and Met α-CH), 4.37 (1H, m, Leu α-CH), 4.99 (1H, 
m, Phe α-CH), 5.21 (1H, d, J = 8.0 Hz, Met NH), 6.68-6.72 (2H, 
m, Phe NH and Leu NH), 7.14-7.26 (5H, m, aromatics), 7.66 
(1H, apparent t, β-Ala NH). Anal. Calcd for C29H46N4O7S: C, 
58.56; H, 7.80; N, 9.42. Found: C, 58.79; H, 7.83; N, 9.44. 
For-Met-β-Ala-Leu-Phe-OMe (6). From Boc-Met-β-Ala-
Leu-Phe-OMe (0.1 g, 0.168 mmol) according to the general 
procedure B. Crystallized from hexane. White solid (0.050 g, 
57%); mp 157.7-161.3 °C. [a]D -16.0° (c 1, CHCl3); IR (CHCl3): 
ν 3671, 3424, 1734, 1670 cm-1; 1H NMR (CDCl3): δ 0.85-0.91 
[6H, m, Leu CH-(CH3)2], 1.53-1.66 (3H, m, Leu CH2-CH-
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(CH3)2, 1.68-1.84 (2H, m, Met β-CH2), 2.10 (3H, s, SCH3), 
2.28-2.51 (4H, m, β-Ala α-CH2 and Met γ-CH2), 3.04-3.19 (3H, 
m, β-Ala β-CHH and Phe β-CH2), 3.75 (3H, s, COOCH3), 3.85-
3.90 (2H, m, β-Ala β-CHH and Met α-CH), 4.37 (1H, m, Leu 
α-CH), 4.99 (1H, m, Phe α-CH), 5.21 (1H, d, J = 8.0 Hz, Met 
NH), 6.68-6.72 (2H, m, Phe NH and Leu NH), 7.14-7.26 (5H, 
m, aromatics), 7.66 (1H, br s, β-Ala NH), 8.01 (1H, s, HCO). 
Anal. Calcd for C25H38N4O6S: C, 57.45; H, 7.33; N, 10.72. 
Found: C, 57.58; H, 7.30; N, 10.74. 
Boc-Pro-Leu-Phe-OMe (7). From Boc-Pro-OH (0.07 g, 
0.325 mmol) and TFA·H2N-Leu-Phe-OMe (0.132 g, 0.325 
mmol) according to the general procedure A. White foam, pure 
on TLC (0.160 g, 90%); [a]D -49.05° (c 1, CHCl3); IR (CHCl3): 
ν 3422, 1760, 1676 cm-1; 1H NMR (CDCl3): δ 0.87-0.98 [6H, m, 
Leu CH-(CH3)2], 1.51 [9H, s, C(CH3)3], 1.70-2.50 [(8H, m, Pro 
β-CH2, Pro γ-CH2, Pro δ-CHH, and Leu CH2-CH-(CH3)2)], 
3.10-3.30 (2H, m, Phe β-CH2), 3.30-3.50 (1H, m, Pro δ-CHH), 
3.70 (3H, s, COOCH3), 4.30-4.60 (3H, m, Pro α-CH, Leu α-CH 
and Phe α-CH), 6.50-6.70 (2H, m, Leu NH and Phe NH), 7.01-
7.50 (5H, m, aromatics). Anal. Calcd for C26H39N3O6: C, 63.78; 
H, 8.03; N, 8.58. Found: C, 63.52; H, 8.01; N, 8.54. 
Boc-Met-Pro-Leu-Phe-OMe (8). From Boc-Met-OH 
(0.0676 g, 0.27 mmol) and TFA·HN-Pro-Leu-Phe-OMe (0.110 
g, 0.27 mmol), this latter obtained from Boc-Pro-Leu-Phe-OMe, 
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according to the general procedure A. Silica gel chromatography 
(CH2Cl2/MeOH 98:2) and crystallization from EtOAc/Hexane 
gave the pure title product as a white solid (0.120 g, 70%); mp 
112.5-114 °C; [a]D -42° (c 1, CHCl3); IR (CHCl3): ν 3419, 1741, 
1676 cm-1; 1H NMR (CDCl3): δ 0.88-0.97 [6H, m, Leu CH-
(CH3)2], 1.48 [9H, s, C(CH3)3], 1.61-1.65 (4H, m, Pro β-CH2 
and Pro γ-CH2), 1.84-2.14 [8H, m, Met β-CH2, Leu CH2-CH-
(CH3)2 and SCH3 (s at 2.13)], 2.30 (1H, m, Pro δ-CHH), 2.58 
(2H, m, Met δ-CH2), 3.10 and 3.21 (2H, A and B of an ABX, J 
= 6.0, 5.6 and 13.6 Hz, Phe β-CH2), 3.64 (1H, m, Pro δ-CHH) 
3.75 (3H, s, COOCH3), 4.35 (1H, m, Met α-CH), 4.53 (1H, m, 
Pro α-CH), 4.63 (1H, m, Leu α-CH), 4.87 (1H, m, Phe α-CH), 
5.30 (1H, d, J = 9.6 Hz, Met NH), 6.63 (1H, d, J = 6.8 Hz, Phe 
NH), 7.02 (1H, d, J = 7.6 Hz, Leu NH), 7.14-7.33 (5H, m, 
aromatics). Anal. Calcd for C31H48N4O7S: C, 59.98; H, 7.79; N, 
9.02. Found: C, 60.15; H, 7.82; N, 9.05. 
For-Met-Pro-Leu-Phe-OMe (9). From Boc-Met-Pro-Leu-
Phe-OMe (0.08 g, 0.127 mmol) according to the general 
procedure B. The mixture was purified on silica gel 
chromatography (CHCl3/MeOH 99:1). Colourless oil (0.068 g, 
95%); [a]D -13.0° (c 1, CHCl3); IR (CHCl3): ν 3417, 1743, 1677 
cm-1; 1H NMR (CDCl3): δ 0.88-0.97 [6H, m, Leu CH-(CH3)2], 
1.61-1.65 (4H, m, Pro β-CH2 and Pro γ-CH2), 1.84-2.14 [8H, m, 
Met β-CH2, Leu CH2-CH-(CH3)2 and SCH3 (s at 2.13)], 2.30 
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(1H, br s, Pro δ-CHH), 2.58 (2H, m, Met δ-CH2), 3.10 and 3.21 
(2H, A and B of an ABX, J = 6.3, 5.7 and 13.5 Hz, Phe β-CH2), 
3.64 (1H, m, Pro δ-CHH) 3.75 (3H, s, COOCH3), 4.35 (1H, m, 
Leu α-CH), 4.53 (1H, m, Pro α-CH), 4.63 (1H, m, Met α-CH), 
4.87 (1H, m, Phe α-CH), 5.30 (1H, d, J = 8.2 Hz, Met NH), 6.63 
(1H, d, J = 7.6 Hz, Phe NH), 7.02 (1H, d, J = 6.8 Hz, Leu NH), 
7.14-7.33 (5H, m, aromatics), 8.03 (1H, s, HCO). Anal. Calcd 
for C27H40N4O6S: C, 59.10; H, 7.35; N, 10.21. Found: C, 59.29; 
H, 7.38; N, 10.25. 
Boc-Met-Leu-Gly-Phe-OMe (11). From Boc-Met-Leu-OH 
(0.107 g, 0.297 mmol),132 and TFA·N2H-Gly-Phe-OMe 10 
(0.104 g, 0.297 mmol), obtained from Boc-Gly-Phe-OMe,133 
according to the general procedure A. The mixture was purified 
on silica gel chromatography (CH2Cl2/EtOAc 2:8). White foam 
(0.121 g, 70%); [a]D +1.0° (c 1, CHCl3); IR (CHCl3): ν 3419, 
1735, 1678 cm-1; 1H NMR (CDCl3): δ 0.96-0.99 [6H, m, Leu 
CH-(CH3)2], 1.45 [9H, s, C(CH3)3], 1.55-1.69 [3H, m, Leu CH2-
CH-(CH3)2], 1.88-2.11 [5H, m, Met β-CH2 and SCH3 (s, at 
2.09)], 2.55 (2H, m, Met γ-CH2), 3.05 and 3.17 (2H, A and B of 
an ABX, J = 6.0, 5.6 and 14.0 Hz, Phe β-CH2), 3.70 (3H, s, 
COOCH3), 3.86-4.03 (2H, m Gly α-CH2), 4.26 (1H, m, Met α-
CH), 4.45 (1H, m, Leu α-CH), 4.85 (1H, m, Phe α-CH), 5.45 
(1H, br s, Met NH), 6.98 (1H, d, J = 8.0 Hz, Leu NH), 7.03 (1H, 
d, J = 7.2 Hz, Phe NH), 7.12-7.29 (6H, m, aromatics and Gly 
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NH). Anal. Calcd for C28H44N4O7S: C, 57.91; H, 7.64; N, 9.65. 
Found: C, 58.14; H, 7.61; N, 9.68. 
For-Met-Leu-Gly-Phe-OMe (12). From Boc-Met-Leu-Gly-
Phe-OMe (0.07 g, 0.12 mmol) according to the general 
procedure B. The reaction mixture was purified on silica gel 
chromatography (CHCl3/MeOH 95:5). White foam (0.059 g, 
97%); [a]D +0.5° (c 0.7, CHCl3); IR (CHCl3): ν 3415, 1740, 
1670 cm-1; 1H NMR (CDCl3): δ 0.96-0.99 [6H, m, Leu CH-
(CH3)2], 1.54-1.68 [3H, m, Leu CH2-CH-(CH3)2], 1.87-2.11 
[5H, m, Met β-CH2 and SCH3 (s, at 2.06)], 2.51 (2H, m, Met γ-
CH2), 3.03 and 3.18 (2H, A and B of an ABX, J = 6.0, 5.7 and 
13.6 Hz, Phe β-CH2), 3.71 (3H, s, COOCH3), 3.96-4.20 (2H, m, 
Gly CH2), 4.94 (1H, m, Met α-CH), 4.71 (1H, m, Leu α-CH), 
4.86 (1H, m, Phe α-CH), 7.09-7.31 (6H, m, aromatics and Met 
NH), 7.42 (1H, br s, Phe NH), 7.62 (1H, br s, Gly NH), 7.75 
(1H, br s, Leu NH), 8.14 (1H, s, HCO). Anal. Calcd for 
C24H36N4O6S: C, 56.67; H, 7.13; N, 11.02. Found: C, 56.84; H, 
7.15; N, 11.05. 
Boc-Met-Leu-β-Ala-Phe-OMe (14). From Boc-Met-Leu-
OH (0.128 g, 0.354 mmol) and TFA·H2N-β-Ala-Phe-OMe 13 
(0.129 g, 0.354 mmol), this latter obtained from Boc-β-Ala-Phe-
OMe,85 according to the general procedure A. Amorphous solid, 
pure on TLC (0.155 g, 74%); [a]D +23.0° (c 1, CHCl3); IR 
(CHCl3): ν 3421, 1738, 1673 cm-1; 1H NMR (CDCl3): δ 0.93-
0.96 [6H, m, Leu CH-(CH3)2], 1.41 [9H, s, C(CH3)3], 1.48-1.70 
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[3H, m, Leu CH2-CH-(CH3)2], 1.91-2.15 [5H, m, Met β-CH2 
and SCH3 (s, at 2.12)], 2.30 (2H, m, β-Ala α-CH2), 2.63 (2H, m, 
Met γ-CH2), 2.99-3.22 (3H, m, β-Ala β-CHH and Phe β-CH2), 
3.78 (3H, s, COOCH3), 3.79-3.86 (1H, m, β-Ala β-CHH), 4.25 
(1H, m, Met α-CH), 4.27 (1H, m, Leu α-CH), 4.84 (1H, m, Phe 
α-CH), 5.18 (1H, br s, Met NH), 6.72 (1H, br s, Leu NH), 7.05 
(1H, d, J = 8.0 Hz, Phe NH), 7.22-7.33 (6H, m, aromatics and β-
Ala NH). Anal. Calcd for C29H46N4O7S: C, 58.56; H, 7.80; N, 
9.42. Found: C, 58.79; H, 7.83; N, 9.44. 
For-Met-Leu-β-Ala-Phe-OMe (15). From Boc-Met-Leu-β-
Ala-Phe-OMe (0.056 g, 0.095 mmol) according to the general 
procedure B. The mixture was purified on silica gel flash 
chromatography (CHCl3/MeOH 95:5). Amorphous solid (0.039 
g, 79%); [a]D -55.3° (c 0.38, MeOH); IR (CHCl3): ν 3421, 1743, 
1648 cm-1; 1H NMR (CDCl3): δ 0.84-0.91 [6H, Leu CH-(CH3)2], 
1.34-1.60 [3H, m, Leu CH2-CH-(CH3)2], 1.70-2.05 [5H, m, Met 
β-CH2 and SCH3 (s, at 2.02)], 2.22 (2H, m, β-Ala α-CH2), 2.42 
(2H, m, Met γ-CH2), 3.05-3.25 (2H, m, β-Ala β-CH2), 2.83-3.04 
(2H, m, Phe β-CH2), 3.58 (3H, s, COOCH3), 4.21 (1H, m, Leu 
α-CH), 4.40 (1H, m, Met α-CH), 4.46 (1H, m, Phe α-CH), 7.17-
7.30 (5H, m, aromatics), 7.87 (1H, br s, β-Ala NH), 8.00 (1H, br 
s, Leu NH), 8.01 (1H, s, HCO), 8.29 (1H, br s, Met NH), 8.39 
(1H, d, J = 7.2 Hz, Phe NH),). Anal. Calcd for C25H38N4O6S: C, 
57.45; H, 7.33; N, 10.72. Found: C, 57.30; H, 7.30; N, 10.67. 
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Boc-Met-Leu-Pro-Phe-OMe (17). From Boc-Met-Leu-OH 
(0.115 g, 0.319 mmol) and TFA·HN-Pro-Phe-OMe 16 (0.124 g, 
0.319 mmol), this latter obtained from Boc-Pro-Phe-OMe,80 
according to the general procedure A. The mixture was purified 
on silica gel chromatography (CH2Cl2/EtOAc 1:1). Colourless 
oil (0.115 g, 58%); [a]D -52.0° (c 0.94, CHCl3); IR (CHCl3): ν 
3421, 1743, 1678 cm-1; 1H NMR (CDCl3): δ 0.92-0.96 [6H, m, 
Leu CH-(CH3)2], 1.46 [9H, s, C(CH3)3], 1.56-1.72 [3H, m, Leu 
CH2-CH-(CH3)2], 1.86-2.36 [9H, m, Met β-CH2, SCH3 (s, at 
2.12) and Pro β-CH2 and Pro γ-CH2], 2.58 (2H, m, Met γ-CH2), 
3.02-3.20 (2H, m, Phe β-CH2), 3.42-3.51 (1H, m, Pro δ-HCH), 
3.61-3.69 (1H, m, Pro δ−HCH), 3.72 (3H, s, COOCH3), 4.29 
(1H, m, Met α-CH), 4.55 (1H, m, Pro α-CH), 4.73 (1H, m, Leu 
α-CH), 4.78 (1H, m, Phe α-CH), 5.17 (1H, d, J = 8.4 Hz, Met 
NH), 6.74 (1H, br s, Leu NH), 6.99 (1H, d, J = 7.6 Hz, Phe NH), 
7.11-7.33 (5H, m, aromatics). Anal. Calcd for C31H48N4O7S: C, 
59.98; H, 7.79; N, 9.02. Found: C, 59.80; H, 7.76; N, 9.00. 
For-Met-Leu-Pro-Phe-OMe (18). From Boc-Met-Leu-Pro-
Phe-OMe (0.071 g, 0.114 mmol) according to the general 
procedure B. The mixture was purified on silica gel flash 
chromatography (CHCl3/MeOH 98:2). Colourless oil (0.058 g, 
93%); [a]D -43.2° (c 0.95, CHCl3); IR (CHCl3): ν 3417, 1743, 
1673 cm-1; 1H NMR (CDCl3): δ 0.93-0.95 [6H, m, Leu CH-
(CH3)2], 1.25-1.40 [3H, m, Leu CH2-CH-(CH3)2], 1.58-2.31 
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[9H, m, Met β-CH2, SCH3 (s, at 2.11), Pro β-CH2 and Pro γ-
CH2], 2.58 (2H, m, Met γ-CH2), 3.02 and 3.15 (2H, A and B of 
an ABX, J = 6.4, 5.6 and 13.6 Hz, Phe β-CH2), 3.51 (1H, m, Pro 
δ-CHH), 3.67 (1H, m, Pro δ-CHH), 3.69 (3H, s, COOCH3), 4.62 
(1H, m, Pro α-CH), 4.76 (1H, m, Leu α-CH), 4.77 (1H, m, Phe 
α-CH), 4.85 (1H, m, Met α-CH), 6.55 (1H, d, J = 8.0 Hz, Met 
NH), 7.09 (1H, d, J = 7.2 Hz, Phe NH), 7.23 (1H, d, J = 7.6 Hz, 
Leu NH), 7.08-7.30 (5H, m, aromatics), 8.18 (1H, s, HCO). 
Anal. Calcd for C27H40N4O6S: C, 59.10; H, 7.35; N, 10.21. 
Found: C, 59.29; H, 7.38; N, 10.25. 
 
2.6.4.3 Biological assays 
 
Cell preparation 
Cells were obtained from the blood of healthy subjects, and 
human peripheral blood neutrophils were purified by using the 
standard techniques of dextran (Pharmacia, Uppsala, Sweden) 
sedimentation, centrifugation on Ficoll-Paque (Pharmacia), and 
hypotonic lysis of contaminating red cells. Cells were washed 
twice and resuspended in Krebs-Ringer phosphate (KRPG), pH 
7.4, at final concentration of 50 X 106 cells/mL and kept at room 
temperature until used. Neutrophils were 98-100% viable, as 
determined using the Trypan Blue exclusion test. The study was 
approved by the local Ethics Committee and informed consent 
was obtained from all participants.  
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Random locomotion 
Random locomotion was performed with 48-well 
microchemotaxis chamber (Bio Probe, Milan, Italy) and 
migration into the filter was evaluated by the leading-front 
method.96 The actual control random movement is 35 ± 3 µm SE 
of ten separate experiments performed in duplicate. 
 
Chemotaxis 
Each peptide was added to the lower compartment of the 
chemotaxis chamber. Peptides were diluted from a stock 
solution with KRPG containing 1 mg/mL of bovine serum 
albumin (BSA; Orha Behringwerke, Germany) and used at 
concentrations ranging from 10-12 to 10-5 M. Data were 
expressed in terms of chemotactic index (CI), which is the ratio: 
(migration towards test attractant minus migration towards the 
buffer/migration towards the buffer); the values are the mean of 
six separate experiments performed in duplicate. Standard errors 
are in the 0.02-0.09 CI range. 
 
Superoxide anion (O2-) production 
This anion was measured by the superoxide dismutase-
inhibitable reduction of ferricytochrome c (Sigma, USA) 
modified for microplate-based assays. Tests were carried out in 
a final volume of 200 µl containing 4 x 105 neutrophils, 100 
nmoles cytochrome c and KRPG. At zero time different 
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amounts (10-10 -8 x 10-5 M) of each peptide were added and the 
plates were incubated into a microplate reader (Ceres 900, Bio-
TeK Instruments, Inc.) with the compartment temperature set at 
37 °C. Absorbance was recorded at 550 and 468 nm. The 
difference in absorbance at the two wavelengths was used to 
calculate nmoles of O2- produced using a molar extinction 
coefficient for cytochrome c of 18.5 mM-1 cm-1. Neutrophils 
were incubated with 5 µg/mL cytochalasin B (Sigma) for 5 min 
prior to activation by peptides. Results were expressed as net 
nmoles of O2- per 1 x 106 cells per 5 min and are the mean of six 
separate experiments performed in duplicate. Standard errors are 
in 0.1-4 nmoles O2- range. 
 
Enzyme assay 
The release of neutrophil granule enzymes was evaluated by 
determination of lysozyme activity, modified for microplate-
based assays. Cells, 3 x 106/well, were first incubated in 
triplicate wells of microplates with 5 µg/mL cytochalasin B at 
37 °C for 15 min and then in the presence of each peptide at a 
final concentration of 10-10 -8 x 10-5 M for a further 15 min. The 
plates were then centrifuged at 400xg for 5 min and the 
lysozyme was quantified nephelometrically by the rate of lysis 
of cell wall suspension of Micrococcus lysodeikticus. The 
reaction rate was measured using a microplate reader at 465 nm. 
Enzyme release was expressed as a net percentage of total 
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enzyme content released by 0.1% Triton X-100. Total enzyme 
activity was 85 ± 1 mg per 1 x 107 cells/min. The values are the 
mean of five separate experiments done in duplicate. Standard 
errors are in the range 1-6%. 
 
Antagonist assay 
Antagonist activity was determined by measuring the ability 
of a derivative to inhibit chemotaxis, superoxide anion 
production or granule enzyme release as induced by fMLF-
OMe. Antagonist activity data (percentage of activity) were 
obtained by comparing the CI, nanomoles of O2- or percentage 
of lysozyme release in the absence (100%) and in the presence 
of the derivative. CI of 10 nM fMLF-OMe was 1.15 ± 0.10 SE. 
O2- generation produced by 1 µM fMLF-OMe was 62 ± 2 
nmol/1 x 106 cells/5 min. Enzyme activity triggered by 1 µM 
fMLF-OMe was 54 ± 5%/3 x 106 cells/min. Derivatives were 
added to neutrophils 10 min before the incubation step for 
cellular functionality. Each value represents an average of six 
separate experiments done in duplicate. Standard errors are 
within 10% of the mean value. 
 
Statistical analysis 
The non-parametric Wilcoxon test was used in the statistical 
evaluation of differences between groups. Differences were 
considered to be statistically significant at P ≤ 0.05. 
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2.7 Novel chemotactic For-Met-Leu-Phe-OMe 
(fMLF-OMe) analogues based on Met residue 
replacement by 4-amino-proline scaffold: Synthesis 
and bioactivity* 
 
Due to their key role in the body’s physiological defence 
against bacterial infections chemotactic N-formyl peptides, 
which are products of bacterial metabolism, continue to 
stimulate the interest of chemists and biochemists. They act by 
binding at highly specific G-protein-coupled formyl peptide 
receptors (FPRs) located on the membrane of neutrophils. The 
interaction triggers, in addition to a rapid movement of the 
phagocytic cells towards the sites of infections (chemotaxis), a 
series of intracellular responses, relevant among which are 
lysosomal enzyme release and superoxide anion 
production.46,50,40,129 Despite extensive studies, both the essential 
cellular mechanisms controlling the neutrophil migration and the 
structure-activity relationships regulating the N-formyl peptide-
receptor study interactions, are not completely understood and 
                                                 
*Torino, D.; Mollica, A.; Pinnen, F.; Feliciani, F.; Spisani, S.; 
Lucente, G. Bioorg. Med. Chem. 2009, 17, 251. 
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still under.100,129,134 However, since the discovery of N-formyl-
methionyl peptides as agonists at the neutrophil receptors, the 
potent chemotactic agent N-formyl-Met-Leu-Phe-OH (fMLF) 
and its methyl ester (fMLF-OMe) have been chosen as the 
reference molecules and a variety of structural modifications 
have been performed on these tripeptides for systematic studies 
on biochemical mechanism and structure activity 
relationships.58, 63, 67, 68,101 
Examination of the above cited studies indicate that both 
receptor recognition and agonistic activity of fMLF-OMe 
analogues are highly sensible to alterations centred at the N-
terminal formyl group and/or at the sulphur-containing Met side 
chain. However, both the aromatic C-terminal residue and the 
central Leu isobutyl side chain are more tolerant towards 
replacement or modification and several analogues of fMLF-
OMe modified at these two residues have been examined. Thus, 
a remarkable degree of specificity is postulated for the region of 
FPRs devoted to the accommodation of the N-terminus portion 
of fMLF-OMe ligand and its analogues.46,67 This property has 
been related to the presence in the involved receptor region of (i) 
a hydrophobic pocket containing an area of positive charge 
suitable to interact with the electron rich methylthio group of 
Met side chain and (ii) a small cavity capable to bind through a 
hydrogen bonding system the formyl H-CO-NH group. It is also 
relevant to note in this context that the replacement of the small 
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N-formyl group with the bulkier substituents such as t-
butyloxycarbonyl (Boc) transforms fMLF-OMe and several of 
its active analogues into inactive or weakly active agonists, 
generally endowed with antagonistic activity.50,67 
In order to get information on the factors responsible for the 
critical role exerted by the receptor area interacting with the N-
terminal elements of the chemotactic N-formyl tripeptide 
ligands, we reported recently results obtained by studying new 
fMLF-OMe analogues incorporating the two epimeric proline-
methionine chimera residues cis-4(S)-methylthio-(S)-proline 
(cMtp) and trans-4(R)-methylthio-(S)-proline (tMtp) at N-
terminal position (Figure 21).135 In these tripeptide analogues 
the presence of the pyrrolidine scaffold, combined with the 
different stereochemistry at position 4 of the ring, allowed the 
examination of ligands with restricted spatial orientation of the 
N-protecting groups (N-formyl or N-Boc) with respect to the S-
methyl at position 4 and the amide junction at position 2 of the 
ring. No other analogues of this type, involving the Met residue, 
have been reported so far. Examination of these new models 
showed, quite unexpectetly, that the two N-For tripeptides are 
practically inactive while the N-Boc derivatives show significant 
chemotactic activity with cMtp containing analogue almost 
equipotent with the reference ligand fMLF-OMe. It seems that 
in these models the interaction of the N-terminal functional 
groups with the involved receptor area leads to a different type 
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of accommodation as compared with usual ligands. This 
strongly suggests that studies based on conformationally 
restricted analogues of this type may shed light on a critical and 
still unclear point concerning the ligand-receptor interaction. 
Based on this consideration we decided to examine a group of 
new and unusual fMLF-OMe derivatives in which the sulfurated 
Met side chain is omitted and the 4(S) and 4(R) 4-amino-(S)-
proline (cAmp and tAmp, respectively) (Figure 21) are used as a 
quite rigid skeleton on which the N-For and N-Boc acylating 
groups can be attached in different combinations. 
 
 
Figure 21.  Chemical structure of proline scaffolds cited in the text. 
 
2.7.1 Chemistry 
 
The synthesis of the N-protected 4-amino prolines 6 and 14 
and the target tripeptides 17-19 are reported in Schemes 8-10. 
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Examination of the literature shows that efficient approaches 
can be followed to obtain different 4-substituted prolines 
starting from the commercially available trans-4-hydroxy-L-
proline. cis-isomers can be easily formed by direct Mitsunobu 
reaction136,137 or by nucleophilic SN2 displacement performed on 
trans-4-O-tosyl or 4-O-mesyl N-protected derivatives.135,138-140 
 
 
Scheme 8. Synthesis of compound 6. Reagents and conditions: a) ethereal 
diazomethane/MeOH; b) MsCl, TEA, CH2Cl2, 0 °C 3 h; c) NaN3/DMF, 55 
°C overnight; d) H2-Pd/C, MeOH, 6h rt; e) Cbz-Cl, TEA, CH2Cl2, 2h 0 °C, 
1h rt; f) 1N NaOH, MeOH, 30 min 0 °C, overnight, rt. 
 
3 2
 
Scheme 9.  Synthesis of compound 14. Reagents and conditions: a) CrO3/Py; 
b) NaBH4/H2O, MeOH; c) ethereal diazomethane/MeOH; d) MsCl, TEA, 
CH2Cl2, 30 min 0 °C; e) NaN3/DMF, 55 °C, overnight; f) H2-Pd/C, MeOH, 
6h rt,; g) Cbz-Cl,TEA,CH2Cl2, 2h 0 °C, 1h rt; h) 1N NaOH, MeOH, 30 min 0 
°C, overnight, rt. 
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An alternative synthetic strategy, based on N-protected 4-
hydroxy-L-prolines, involves the oxidation of the 4-OH group 
and the stereoselective reduction of the resultant ketone with 
NaBH4. This useful stereoselective reduction, originally 
observed by Patchett and Witkop,141 gives exclusively the cis 
isomer and is frequently used in the synthesis of peptides 
containing 4-substituted proline analogues.136,142 
According to the above reported literature data, commercially 
available N-Boc-trans-(2S,4R)-4-hydroxyproline was used as 
starting material for the synthesis of the N-Boc-cis-(2S,4S)-4-
benzyloxycarbonylamino-proline [Boc-cAmp(Cbz)-OH] 6 
(Scheme 8). Mesylation of the 4-OH, followed by inversion of 
the absolute configuration by nucleophilic substitution with 
NaN3140 gave, after reduction and amino protection, the desired 
precursor amino acid derivative 6. A more complex strategy was 
adopted for the synthesis of N-Boc-trans-(2S,4R)-4-
benzyloxycarbonylamino-proline [Boc-tAmp(Cbz)-OH] 14, the 
diastereoisomeric analogue of 6. In this case (Scheme 9) the N-
Boc-trans-(2S,4R)-4-hydroxyproline was initially oxidized to 
give the 4-oxo derivative 7. This was stereoselectively 
reduced141,142 to N-Boc-cis-(2S,4S)-4-hydroxyproline 8 and 
esterified with ethereal diazomethane to give the methyl ester 9 
as a single product on TLC. The same sequence of reactions, 
already followed to obtain compound 6, led to the final N-Boc-
tAmp(Cbz)-OH 14. 
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The above described precursors 6 and 14 were used for the 
synthesis of two series of fMLF-OMe analogues. Each series 
contains, as reported in Scheme 10, cAmp (compounds 17a-
19a) or tAmp (compounds 17b-19b) as N-terminal residue. The 
tripeptides were obtained by using the Leu-Phe-OMe dipeptide 
as common C-terminal fragment to provide the orthogonally 
protected key precursors 15a-b. Hydrogenolytic deprotection of 
the Cbz-NH- bound at the 4-amino group of the proline residue 
gave the two N-Boc tripeptides 16a-b from which the two 
couples of target substrates 17a-b and 18a-b were obtained by 
N-Boc protection or N-formylation, respectively, of the free 
proline 4-amino group. 
In order to synthesize the last couple of substrates 19a-b, 
characterized by the presence of a formyl group bound at each 
of the two amino functions of the prolinic scaffold, Boc 
deprotection followed by N-formylation of 16a-b is required. 
When the deprotection was performed with trifluoroacetic acid 
and the resulting tripeptidic bis-trifluoroacetates were used for 
the subsequent formylation reaction low yields and rather 
complex reaction mixtures were obtained. This reaction 
sequence was sensibly improved when HCOOH, instead of the 
usual trifluoroacetic acid, was used for N-Boc deprotection and 
the resulting bis-formates were formylated by adopting the 
mixed anhydride strategy. 
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Scheme 10.  Synthesis of compounds 17a,b-19a,b. Reagents and conditions: 
a) Boc-cAmp(Cbz)-OH, iBuOCOCl, NMM, CH2Cl2, 30 min -15 °C, 
overnight rt; b) Boc-tAmp(Cbz)-OH, iBuOCOCl, NMM, CH2Cl2, 30 min -15 
°C, overnight rt; c) H2-Pd/C, MeOH, 3h rt; d) Boc2O, TEA, EtOAc, 1h rt; e) 
HCOOH, iBuOCOCl, NMM, CH2Cl2, 30 min -15 °C, overnight rt; f) 
HCOOH, iBuOCOCl, NMM, CH2Cl2, 30 min -15 °C, overnight rt. 
 
2.7.2  Biological results  
 
2.7.2.1 Agonism 
The biological activity of the six models under study has 
been determined on human neutrophils and compared with that 
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of the parent tripeptide fMLF-OMe.143,144 The analogues of the 
two series (17-19a and 17-19b) were evaluated for their ability 
to activate directed migration (chemotaxis), stimulate production 
of superoxide anion radicals (O2- ) and induce lysozyme release 
from granules of human neutrophils. Results are plotted in 
Figure 22 and the activity values exhibited at the optimal 
peptide concentration are summarized in Table 6. All the four 
models containing the bulky N-Boc protecting group (i.e: 
compounds 17a, 18a and 17b, 18b) show moderate chemotactic 
activity with the highest value (0.45 C.I.) reached by the tAmp 
containing peptide 17b at the optimal concentration of 10-10M 
(Table 6 and Figure 22A). Highly active chemotactic agonists 
are the two peptides 19a and 19b, both characterized by the 
presence of a N-For acylating group at both the amino groups of 
the proline scaffold. At very low concentration (about 10-12 M) 
these models equal the activity of the reference molecule and 
reach maximal activity (0.75 C.I.) at a concentration (10-10 M), 
lower than that where the fMLF-OMe peak (10-9 M) appears 
(Table 6).  
All the models examined are practically inactive as 
superoxide anion producers (Figure 22B) and only very weak 
secretagogue agents (Figure 22C). The highest value for this 
latter function (24% of lysozyme release at concentration 10-6 
M) is shown by the peptide 19a containing two N-For acylating 
group at the cAmp residue. 
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Figure 22. Biological activities of tripeptide derivatives 17a,b-19a,b and 
fMLF-OMe. (A) Chemotactic index; (B) Superoxide anion production; (C) 
Release of neutrophil granule enzymes evaluated by determining lysozyme 
activity. 
 
Table 6. Chemotactic activity, superoxide anion production and lysozyme 
release of fMLF-OMe derivatives. 
 
± Standard errors of the mean (SEM); optimal concentration values in 
parentheses. 
a Values indicate the efficacy (activity at the optimal peptide 
concentrations). 
 
2.7.2.2 Antagonism 
All models under study were tested for their ability to inhibit 
the three biological functions, except for the chemotaxis of 
compounds 19a-b which are good agonists in this function. The 
antagonism was determined by measuring the ability to inhibit 
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the activity stimulated by fMLF-OMe on human neutrophils. 
The influence of an increasing concentration of 17a-b and 18a-b 
on chemotaxis induced by 10 nM fMLF-OMe, which is the 
optimal dose for chemotaxis activation,  is shown in Figure 23A.  
 
Figure 23.  Effect of N-Boc-protected tripeptides 17a,b-19a,b on the 
neutrophil activities triggered by fMLF-OMe. (A) Chemotactic index; (B) 
Superoxide anion production; (C) Release of neutrophil granule enzymes 
evaluated by determining the lysozyme activity. 
 
A significant dose-dependent inhibition of the chemotactic 
index, which reaches the value of 73% at the highest 
concentration, is observed for compound 18b containing the 4-
NH For substituent at the N-Boc-tAmp residue. Interestingly, 
the epimeric model 18a, containing the cAmp residue, is only a 
very modest antagonist. Good chemotactic antagonism and 
almost identical values (about 60% inhibition at the maximum 
concentration) are also shown by 17a and 17b containing two N-
Boc groups at the cAmp and tAmp residue, respectively. As can 
be deduced by Figure 23B and C, which refer to the superoxide 
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anion production and inhibition of lysozyme release, only the 
two latter mentioned analogues (17a and 17b) exhibit a modest 
activity in the superoxide anion production inhibition, with a 
maximum value of 30% at 10-5 M concentration (Figure 23B). 
None of the other tripeptides show significant antagonism 
towards both superoxide anion production and lysozyme release 
(Figures 23B and C). 
 
2.7.3 Conclusions 
 
In the present study, we tried to evaluate the functional group 
requirements of the FPRs in the critical region devoted to the 
interaction with the N-terminal residue of fMLF and related N-
formyl tripeptide ligands. Peptide models used in this effort are 
of an unusual type and contain the pyrrolidine ring of 4-amino 
L-proline in place of the native methionine. The crucial formyl 
group has been bound at either of the amino groups of the 
proline scaffold which also supports the bulky N-Boc protecting 
group. Contrary to our expectation, suggested in part by results 
obtained with fMLF-OMe analogues containing the N-Boc-4-
methylthio-proline at the N-terminal position, all the synthesized 
tripeptides characterized by the presence of the Boc group, 
including the two models 18a-b bearing a N-formylic group at 
the 4-amino-proline scaffold, display only modest chemotactic 
activity, with a maximum value of 0.45 of the chemotactic index 
(Table 6) shown by tripeptide 17b. Conversely, the derivatives 
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19a and 19b, in which both the N-terminal amino groups are 
formylated, are potent agonists with comparable potency. These 
latter models are among the first fMLF analogues which, 
although devoid of the sulfur-containing Met side chain, exhibit 
good chemotactic activity. It seems then that the absence of 
bulky groups at the N-terminal position, combined with the 
presence of the N-For groups at the rigid scaffold, may lead to a 
right fitting with the receptor even if the methylthio group of the 
Met side chain is absent. Connected with the chemotactic 
activity of 19a and 19b is the antagonism displayed by the N-
Boc-tripeptide 18b and, with reduced potency, by 17a-b (Figure 
23A). It can be seen here that the replacement of the formylic 
group with a bulky substituent leads to the same change of 
activity from agonism to antagonism, primarily observed on 
passing from fMLF-OMe to Boc-MLF-OMe. This behaviour is 
not observed in the case of the fMLF-OMe analogues containing 
proline-methionine chimera residues at the N-terminal position. 
Finally, concerning the different stereochemistry at the 4-amino-
proline residue, characterizing the three couples of the examined 
tripeptides, this feature does not influence appreciably the 
biological functions tested, regardless of the presence of N-Boc 
or N-For substituents. However, as can be seen by the values 
summarized in Table 6 the trans models are in any case slightly 
more active than the epimeric cis models.  
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A final observation concerns the agonistic activity of the 
tripeptides under study toward the superoxide anion production 
and lysozyme release (Figure 22B and C). With the exception of 
the low values observed for the secretagogue activity in the case 
of 19a (24% as maximum value at 10-6 M concentration; Table 6 
and Figure 22B) all the other compounds are practically inactive 
toward these two biological functions. Thus, the here reported 
structural modification at the N-terminal residue of fMLF-OMe 
may represent an useful basis for the design of ‘‘pure” 
chemotactic agonists. As it is well known,99,100,145 agonists of 
this type capable to select or modulate the different neutrophil 
responses (distinct from “full” agonists), are of great utility as 
probes to gain information on the complex biochemical 
mechanisms regulating the signal transduction pathways.129 
In conclusion, in this study a new type of fMLF-OMe 
tripeptide analogues, obtained by replacing the critical native 
Met residue with a 4-amino-proline scaffold bearing different 
substituents, have been described. This synthetic strategy leads 
to molecules which, depending upon the nature of the acylating 
groups at the N-terminal position, exhibit significant 
chemotactic agonism or antagonism with selectivity towards the 
neutrophil biological functions. 
 
2.7.4 Experimental section 
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Materials and methods. Optical rotations were taken at 20 
°C with a Schmidt-Haensch Polartronic D polarimeter (1 dm 
cell, c 1.0 in CHCl3 except otherwise specified). Anhydrous 
solvents were prepared by distillation over sodium metal or 
calcium hydride prior to use. TLC (thin-layer chromatography) 
and PLC (preparative layer chromatography) were performed on 
Merck 60 F254 silica gel plates. The drying agent was sodium 
sulphate. 1H NMR experiments were performed at 400 MHz on 
a Bruker AM 400 spectrometer in CDCl3 solution and chemical 
shifts (δ) are quoted in parts per million (ppm) and were 
indirectly referred to TMS. Coupling constants are in Hz. Most 
of the reactions were carried out under inert atmosphere of 
nitrogen. The reported yields are for purified materials but were 
not optimized. 
 
2.7.4.1 Chemistry. General procedure 
A. Catalytic hydrogenolysis. A solution of the compound 
in MeOH and 10% Pd on C (10%) was vigorously 
stirred at room temperature and atmospheric pressure 
for 2-6 h (TLC control) under a slow stream of 
hydrogen. The catalyst was removed by filtration and 
washed with MeOH. The filtrate was evaporated under 
reduced pressure and used for the subsequent reaction. 
B. Coupling with the mixed anhydride method. To a 
mixture cooled at -15 °C containing the required N-
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protected amino acid (1.0 mmol) in CH2Cl2 were added 
isobutyl chloroformate (IBCF; 1.0 mmol) and NMM 
(1.1 mmol). The mixture was stirred for 10 min at the 
same temperature and then the required amino-
derivative salt (1.0 mmol) and NMM (1.1 mmol) were 
added. After 15 min at -15 °C the mixture was kept at 
room temperature overnight. After removal of the 
solvent under reduced pressure, the residue was 
dissolved in EtOAc and washed with 5% citric acid (2 x 
15 mL), NaHCO3 ss (2 x 15 mL) and NaCl ss (15 mL). 
The organic layer was dried over Na2SO4 and 
evaporated under reduced pressure. 
 
2.7.4.2 Synthesis 
N-Boc-trans-(4-hydroxy)-L-proline methyl ester (1). To a 
solution of N-Boc-trans-4-hydroxy-L-proline (1 g, 4.33 mmol) 
in MeOH (10 mL) an ethereal diazomethane solution was added 
until a yellow colour persisted. The solution was evaporated 
under reduced pressure to give title compound, pure on TLC 
(quantitative yield); [a]D -65° (c 0.6, CHCl3); 1H NMR (CDCl3): 
δ 1.49 [9H, s, C(CH3)3], 2.05-2.31 (2H, m, Pro C3H2), 3.48-3.67 
(2H, m, Pro δ-C5H2), 3.75 (3H, s, COOCH3), 4.39-4.51 (2H, m, 
Pro α-CH and Pro C4H). Anal. Calcd for C11H19NO5: C, 53.87; 
H, 7.81; N, 5.71. Found: C, 53.81; H, 7.82; N, 5.75. 
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N-Boc-trans-(4-mesyloxy)-L-proline methyl ester (2). To 
an ice-cooled solution of the methyl ester 1 (1.06 g, 4.33 mmol) 
in dry CH2Cl2 (10 mL), TEA (0.73 mL, 5.2 mmol) and MsCl 
(0.4 mL, 5.2 mmol) were added. The resulting mixture was 
stirred for 3 h at 0 °C. The mixture was diluted with CH2Cl2 and 
washed with 1N HCl, NaHCO3 ss and brine. The organic layer 
was dried and evaporated under reduced pressure to yield 1.34 g 
(96%) of pure 2 as a pale yellow oil; [a]D -52° (c 1.6, CHCl3); 
1H NMR (CDCl3): δ 1.41 [9H, s, C(CH3)3], 2.21-2.67 (2H, m, 
Pro C3H2), 2.98 (3H, s, CH3SO2), 3.70-3.85 (5H, m, Pro C5H2 
and COOCH3), 4.44 (1H, m, Pro α-CH), 5.24 (1H, m, Pro C4H). 
Anal. Calcd for C12H21NO7S: C, 44.57; H, 6.55; N, 4.33. Found: 
C, 44.67; H, 6.58; N, 4.31. 
N-Boc-cis-(4-azido)-L-proline methyl ester (3). A solution 
of 2 (0.806 g, 2.49 mmol) and NaN3 (0.194 mg, 2.98 mmol) in 
dry DMF (5 mL) was stirred at 55 °C overnight. After removal 
of the solvent under reduced pressure, the residue was dissolved 
in EtOAc and washed with water and NaCl ss. The organic layer 
was dried and evaporated under reduced pressure. The residue 
was purified by silica gel chromatography (petroleum 
ether/EtOAc 5:1) to give pure 3 as a colourless oil (0.496 g, 
73%). 
N-Boc-cAmp-OMe (4). Reduction of the azido group was 
performed by adopting the general procedure above reported for 
the catalytic hydrogenolysis: 3 (0.496 g, 1.84 mmol), MeOH 
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(16.5 mL) and Pd/C (0.0496 g) gave 4 (0.34 g, 76%) after 6 h at 
room temperature. 
N-Boc-cAmp(Cbz)-OMe (5). To an ice-cooled solution of 4 
(0.359 g, 1.47 mmol) in CH2Cl2/DMF 9:1 (20 mL) TEA (0.62 
mL, 4.41 mmol) and Cbz-Cl (0.29 mL, 1.76 mmol) were added. 
The resulting mixture was stirred for 2 h at 0 °C and 1 h at room 
temperature. After removal of the solvent under reduced 
pressure, the residue was dissolved in EtOAc and washed with 
5% citric acid, NaHCO3 ss and NaCl ss. The organic layer was 
dried and evaporated under reduced pressure. The residue was 
purified by silica gel chromatography (CHCl3/EtOAc 7:3) to 
give pure 5 as a colourless oil (0.308 g, 55%); [a]D -13.9° (c 0.3, 
CHCl3); IR (CHCl3): ν 3434, 1743, 1698 cm-1; 1H NMR 
(CDCl3): δ 1.45 [9H, s, C(CH3)3], 1.89-2.03 and 2.39-2.60 (2H, 
m, Pro C3H2), 3.40-3.81 (2H, m, Pro C5H2), 3.71 (3H, s, 
COOCH3), 4.21-4.50 (2H, m, Pro α-CH, Pro C4H), 5.18 (2H, s, 
C6H5-CH2), 5.75 (1H, d, J = 8.0 Hz, Z-NH), 7.03-7.45 (5H, m, 
aromatics). Anal. Calcd for C19H26N2O6: C, 60.30; H, 6.93; N, 
7.40. Found: C, 60.47; H, 6.90; N, 7.43. 
N-Boc-cAmp(Cbz)-OH (6). To an ice-cooled solution of 
methyl ester 5 (0.145 g, 0.38 mmol) in MeOH, 1N NaOH (1.14 
mL) was added dropwise and the mixture was stirred at slow 
stream of hydrogen. The catalyst was removed by filtration and 
washed with MeOH. The filtrate was evaporated under reduced 
pressure and used for the subsequent reaction. 
        Chapter 2 
 
205 
N-Boc-(4-oxo)-L-proline (7). To a mixture of pyridine (8.8 
mL) and dry CH2Cl2 (20 mL) cooled at 0 °C, CrO3 (5.2 g, 52 
mmol) was added. Stirring was continued at 0 °C for 30 min and 
the mixture was allowed to warm at room temperature over a 
period of 30 min. A solution of N-Boc-4-trans-hydroxy-L-
proline (2 g, 8.66 mmol) in CH2Cl2 (30 mL) was added over 5 
min and stirring was continued for 1 h at room temperature. The 
mixture was taken up in diethyl ether and washed with 5% citric 
acid and brine. The organic layer was dried, filtered and 
evaporated under reduced pressure to give crude compound 7 
(0.610 g, 31%), as a pale yellow solid; [a]D +18° (c 0.5, 
acetone); 1H NMR (CDCl3): δ 1.45 [9H, s, C(CH3)3], 2.75 (2H, 
m, Pro C3H2), 3.50-3.90 (2H, m, Pro C5H2), 4.75 (1H, m, Pro α-
CH). Anal. Calcd for C10H15NO5: C, 52.40; H, 6.60; N, 6.11. 
Found: C, 52.27; H, 6.61; N, 6.09. 
N-Boc-cis-(4-hydroxy)-L-proline (8). N-Boc-4-oxo-L-
proline 7 (0.610 g, 2.66 mmol) was dissolved in MeOH (12 mL) 
and the reaction flask was cooled to 0 °C. A solution of NaBH4 
(0.328 g, 8.67 mmol) in water (1.45 mL) was added dropwise; 
after 10 min the reaction was allowed to stand at 4 °C for 15 min 
and concentrated under reduced pressure. The residue was 
diluted with water, acidified to pH 3 with 10% citric acid and 
extracted with EtOAc. The organic layer was washed with brine, 
dried and concentrated to yield 0.490 g of TLC pure derivative 8 
(80%) as a foam; [a]D -39° (c 0.66, MeOH); 1H NMR (CDCl3): 
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δ 1.45 [9H, s, C(CH3)3], 2.19-2.59 (2H, m, Pro C3H2), 3.44-3.56 
(2H, m, Pro C5H2), 4.53-4.65 (2H, m, Pro α-CH and Pro C4H). 
Anal. Calcd for C10H17NO5: C, 51.94; H, 7.41; N, 6.06. Found: 
C, 52.09; H, 7.42; N, 6.04. 
N-Boc-cis-(4-hydroxy)-L-proline methyl ester (9). To a 
solution of N-Boc-cis-4-hydroxy-L-proline (0.490 g, 2.12 mmol) 
in MeOH (4.9 mL) an ethereal diazomethane solution was added 
until a yellow colour persisted. The solution was evaporated 
under reduced pressure to give the title compound pure on TLC 
(quantitative yield); [a]D -63.9° (c 2.3, EtOH); 1H NMR 
(CDCl3): δ 1.45 [9 H, s, C(CH3)3], 2.07-2.49 (2H, m, Pro C3H2), 
3.52-3.65 (2H, m, Pro C5H2), 3.77 (3H, s, COOCH3), 4.27-4.40 
(2H, m, Pro α-CH and Pro C4H). Anal. Calcd for C11H19NO5: C, 
53.87; H, 7.81; N, 5.71. Found: C, 53.92; H, 7.79; N, 5.72. 
N-Boc-cis-(4-mesyloxy)-L-proline methyl ester (10). To an 
ice-cooled solution of the methyl ester 9 (0.519 g, 2.12 mmol) in 
dry CH2Cl2 (4.9 mL) TEA (0.385 mL, 2.76 mmol) and MsCl 
(0.215 mL, 2.76 mmol) were added. The resulting mixture was 
stirred for 30 min at 0 °C. The mixture was diluted with CH2Cl2 
and washed with 1N HCl, Na2CO3 ss and brine. The organic 
layer was dried and evaporated under reduced pressure to yield 
0.65 g (95%) of pure 10 as a pale yellow oil; 1H NMR (CDCl3): 
δ 1.44 [9H, s, C(CH3)3], 2.48-2.60 (2H, m, Pro C3H2), 3.03 (3H, 
s, CH3SO2), 3.75 and 4.45 (2H, m, Pro C5H2), 3.77 (3H, s, 
COOCH3), 4.44 and 5.29 (2H, m, Pro α-CH and Pro C4H). 
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Anal. Calcd for C12H21NO7S: C, 44.57; H, 6.55; N, 4.33; S, 
9.92. Found: C, 44.43; H, 6.53; N, 4.31. 
N-Boc-trans-(4-azido)-L-proline methyl ester (11). A 
solution of 10 (0.65 g, 2.01 mmol) and NaN3 (0.157 g, 2.41 
mmol) in dry DMF (5 mL) was stirred at 55 °C overnight. After 
removal of the solvent under reduced pressure, the residue was 
dissolved in EtOAc and washed with water and NaCl ss. The 
organic layer was dried and evaporated under reduced pressure. 
The residue was purified by silica gel chromatography 
(CH2Cl2/MeOH 99.8:0.2) to give pure 11 as a colourless oil 
(0.434 g, 80%). 
N-Boc-tAmp-OMe (12). Reduction of the azido group was 
performed by adopting the general procedure above reported for 
the catalytic hydrogenolysis: 11 (0.469 g, 1.74 mmol), MeOH 
(15.6 mL) and Pd/C (0.0469 g) gave 12 (0.22 g, 52%) after 6 h 
at room temperature. 
N-Boc-tAmp(Cbz)-OMe (13). To an ice-cooled solution of 4 
(0.22 g, 0.902 mmol) in CH2Cl2/DMF 9:1 (15 mL) TEA (0.33 
mL, 2.706 mmol) and Cbz-Cl (0.179 mL, 1.082 mmol) were 
added. The resulting mixture was stirred for 2 h at 0 °C and 1 h 
at room temperature. After removal of the solvent under reduced 
pressure, the residue was dissolved in EtOAc and washed with 
5% citric acid, NaHCO3 ss and NaCl ss. The organic layer was 
dried and evaporated under reduced pressure. The residue was 
purified by silica gel chromatography (CHCl3/EtOAc 9:1) to 
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give pure 13 as a colourless oil (0.11 g, 33%); [a]D -23.4° (c 0.4, 
CHCl3); IR (CHCl3): ν 3439, 1742, 1697 cm-1; 1H NMR 
(CDCl3): δ 1.42 [9 H, s, C(CH3)3], 2.18-2.26 (2H, m, Pro C3H2), 
3.36-3.43 and 3.76-3.81 (2H, m, Pro C5H2), 3.75 (3H, s, 
COOCH3), 4.27-4.40 (2H, m, Pro α-CH, Pro C4H), 4.92 (1H, m, 
Cbz-NH), 5.18 (2H, s, C6H5-CH2-O-), 7.10-7.47 (5H, m, 
aromatics). Anal. Calcd for C19H26N2O6: C, 60.30; H, 6.93; N, 
7.40. Found: C, 60.42; H, 6.91; N, 7.41. 
N-Boc-tAmp(Cbz)-OH (14). To an ice-cooled solution of 
methyl ester 13 (0.1 g, 0.264 mmol) in MeOH (5 mL) 1N NaOH 
(0.792 mL) was added dropwise and the mixture was stirred at 0 
°C for 15 min and at room temperature overnight. The MeOH 
was evaporated under reduced pressure, water was added and 
the solution extracted with diethyl ether (2 x 25 mL). The 
aqueous phase was then acidified with 5% citric acid and the 
product extracted with EtOAc. The organic layer was washed 
with brine, dried and evaporated to give the TLC pure title 
product 14 as white foam (0.09 g, 95%). 
N-Boc-cAmp(Cbz)-Leu-Phe-OMe (15a). Compound 6 
(0.105 g, 0.288 mmol) in CH2Cl2 (5 mL) was treated with 
TFA·H2N-Leu-Phe-OMe (0.117 g, 0.29 mmol) according to the 
general procedure B. Silica gel chromatography (CHCl3/EtOAc 
3:1) gave a pure product 15a as a white foam (0.119 g, 64%); 
[a]D -65.9° (c 0.3, CHCl3); IR (CHCl3): ν 3421, 1741, 1681     
cm-1; 1H NMR (CDCl3): δ 0.69-1.00 [6H, m, Leu CH(CH3)2], 
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1.45 [9H, s, C(CH3)3], 1.59-1.68 [3H, m, Leu CH2-CH(CH3)2], 
2.00-2.40 (2H, m, Pro C3H2), 3.00-3.21 (2H, m, Phe β-CH2) 
3.38-3.60 (2H, m, Pro C5H2), 3.71 (3H, s, COOCH3), 4.20-4.42 
(3H, m, Pro α-CH, Pro C4H and Leu α-CH), 4.84 (1H, m, Phe 
α-CH), 5.18 (2H, s, C6H5-CH2-O-), 6.50 (1H, d, J = 7.6 Hz, 
Cbz-NH), 6.67 (1H, d, J = 7.6 Hz, Phe-NH), 7.03 (10H, m, 
aromatics), 7.63 (1H, d, J = 7.6 Hz, Leu NH). Anal. Calcd for 
C34H46N4O8: C, 63.93; H, 7.26; N, 8.77. Found: C, 63.73; H, 
7.23; N, 8.74. 
N-Boc-tAmp(Cbz)-Leu-Phe-OMe (15b). Compound 14 
(0.091 g, 0.250 mmol) in CH2Cl2 (5 mL) was treated with 
TFA·H2N-Leu-Phe-OMe (0.101 g, 0.250 mmol) according to the 
general procedure B. Silica gel chromatography (CHCl3/EtOAc 
4:1) gave a pure product 15b as a white foam (0.115 g, 72%); 
[a]D -36° (c 1.0, CHCl3); IR (CHCl3): ν 436, 1722, 1682 cm-1; 
1H NMR (CDCl3): δ 0.90 [6H, m, Leu CH-(CH3)2], 1.47 [9H, s, 
C(CH3)3], 1.57 [3H, m, Leu CH2-CH-(CH3)2], 2.10-2.40 (2H, m, 
Pro C3H2), 3.10-3.18 (2H, m, Phe β-CH2), 3.25 (2H, m, Pro 
C5H2), 3.74 (3H, s, COOCH3), 4.29-4.33 (3H, m, Pro α-CH, Pro 
C4H and Leu α-CH), 4.84 (1H, m, Phe α-CH), 5.18 (2H, s, 
C6H5-CH2-O-), 6.55 (1H, m, Cbz-NH), 6.71 (1H, m, Phe NH), 
7.04-7.42 (11H, m, aromatics and Leu NH). Anal. Calcd for 
C34H46N4O8: C, 63.93; H, 7.26; N, 8.77. Found: C, 63.71; H, 
7.21; N, 8.72. 
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N-Boc-cAmp-Leu-Phe-OMe (16a). The title compound 16a 
was prepared starting from compound 15a by following the 
general procedure A: 15a (0.108 g, 0.169 mmol), MeOH (10 
mL) and Pd/C (0.047 g), 3 h at room temperature, quantitative 
yield. 
N-Boc-tAmp-Leu-Phe-OMe (16b). The title compound 16b 
was prepared starting from compound 15b by following the 
general procedure A: 15b (0.040 g, 0.063 mmol), MeOH (5 
mL), Pd/C (0.004 g), 3 h at room temperature, quantitative yield. 
N-Boc-cAmp(Boc)-Leu-Phe-OMe (17a). To a solution of 
compound 16a (0.025 g, 0.05 mmol) in EtOAc (5 mL) Boc2O 
(0.022 g, 0.10 mmol) and TEA (0.014 mL, 0.10 mmol) were 
added and the mixture was stirred 1 h at room temperature. The 
mixture was diluted with EtOAc and washed with 5% citric 
acid, NaHCO3 ss and brine. The organic layer was dried and 
evaporated under reduced pressure. The residue was purified by 
silica gel chromatography (CHCl3/EtOAc 1:1) to give pure 17a 
as a white foam (0.0185 g, 62%); [a]D -76.3° (c 0.35, CHCl3); IR 
(CHCl3): ν 3417, 1741, 1681 cm-1; 1H NMR (CDCl3): δ 0.90 [6 
H, m, Leu CH-(CH3)2], 1.47 [18H, s, 2C(CH3)3], 1.59 [3H, m, 
Leu CH2-CH-(CH3)2], 2.00-2.38 (2H, m, Pro C3H2), 3.00-3.11 
(2H, m, Phe β-CH2), 3.37-3.57 (2H, m, Pro C5H2), 3.76 (3H, s, 
COOCH3), 4.19-4.26 (3H, m, Leu α-CH, Pro α-CH, Pro C4H), 
4.83 (1H, m, Phe α-CH), 6.25 (1H, d, J = 7.6 Hz, Boc-NH), 6.61 
(1H, d, J = 7.8 Hz, Phe NH), 7.12-7.40 (5H, m, aromatics), 7.76 
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(1H, d, J = 7.6 Hz, Leu NH). Anal. Calcd for C31H48N4O8: C, 
61.57; H, 8.00; N, 9.26. Found: C, 61.69; H, 7.98; N, 9.28. 
N-Boc-tAmp(Boc)-Leu-Phe-OMe (17b). To a solution of 
compound 16b (0.032 g, 0.063 mmol) in EtOAc (6.3 mL) 
Boc2O (0.027 g, 0.126 mmol) and TEA (0.017 mL, 0.126 mmol) 
were added and the mixture was stirred 1 h at room temperature. 
The mixture was diluted with EtOAc and washed with 5% citric 
acid, NaHCO3 ss and brine. The organic layer was dried and 
evaporated under reduced pressure. The residue was purified by 
silica gel chromatography (CHCl3/EtOAc 4:1) to give pure 17b 
as a white foam (0.021 g, 55%); [a]D -34.2° (c 0.6, CHCl3); IR 
(CHCl3): ν 3439, 1741, 1683 cm-1; 1H NMR (CDCl3): δ 0.89 
[6H, m, Leu CH-(CH3)2], 1.47 [18H, s, 2 C(CH3)3], 1.60 [3H, m, 
Leu CH2-CH-(CH3)2], 2.03-2.35 (2H, m, Pro C3H2), 3.08-3.14 
(2H, m, Phe β-CH2), 3.31 and 3.53 (2H, m, Pro C5H2), 3.70 (3H, 
s, COOCH3), 4.19-4.26 (3H, m, Leu α-CH, Pro α-CH, Pro 
C4H), 4.83 (1H, m, Phe α-CH), 6.30 (1H, m, Boc-NH), 7.08-
7.35 (7H, m, Phe NH, Leu NH and aromatics). Anal. Calcd for 
C31H48N4O8: C, 61.57; H, 8.00; N, 9.26. Found: C, 61.63; H, 
8.01; N, 9.25. 
N-Boc-cAmp(For)-Leu-Phe-OMe (18a). To a solution of 
HCOOH (0.018 g, 0.40 mmol) in CH2Cl2 (5 mL) cooled at -15 
°C, iBuOCOCl (0.052 mL, 0.40 mmol) and NMM (0.044 mL, 
0.40 mmol) were added. The mixture was stirred for 10 min at 
the same temperature and then a solution in CH2Cl2 of 16a (0.02 
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g, 0.0396 mmol) and NMM (0.044 mL, 0.40 mmol) was added. 
Work up according to general procedure B was then followed. 
Preparative layer chromatography (CHCl3/EtOAc 1:2) gave a 
pure product 18a as a amorphous solid (0.0125 g, 59%); [a]D -
75.9° (c 0.5, CHCl3); IR (CHCl3) ν: 3419, 1741, 1675 cm-1; 1H 
NMR (CDCl3): δ 0.86 [6H, m, Leu CH-(CH3)2], 1.47 [9H, s, 
C(CH3)3], 1.58 [3H, m, Leu CH2-CH-(CH3)2], 2.06-2.32 (2H, m, 
Pro C3H2), 3.07-3.23 (2H, m, Phe β-CH2), 3.42-3.57 (2H, m, Pro 
C5H2), 3.76 (3H, s, COOCH3), 4.32 (1H, m, Leu α-CH), 4.40 
(1H, m, Pro α-CH), 4.57 (1H, m, Pro C4H), 4.86 (1H, m, Phe α-
CH), 6.58 (1H, d, J = 8.0 Hz, Phe NH), 7.09-7.31 (5H, m, 
aromatics), 7.76 (2H, m, Leu NH and For NH), 8.11 (1H, s, 
HCO). Anal. Calcd for C27H40N4O7: C, 60.88; H, 7.57; N, 10.52. 
Found: C, 61.00; H, 7.55; N, 10.54. 
N-Boc-tAmp(For)-Leu-Phe-OMe (18b). To a solution of 
HCOOH (0.029 g, 0.63 mmol) in CH2Cl2 (5 mL) cooled at -15 
°C, iBuOCOCl (0.082 mL, 0.63 mmol) and NMM (0.069 mL, 
0.63 mmol) were added. The mixture was stirred for 10 min at 
the same temperature and then a solution in CH2Cl2 of 16b 
(0.032 g, 0.063 mmol) and NMM (0.069 mL, 0.63 mmol) was 
added. Work up according to general procedure B was then 
followed. Silica gel chromatography (CHCl3/EtOAc 1:2) gave a 
pure product 18b as a white foam (0.024 g, 73%); [a]D -32.1° (c 
0.65, CHCl3); IR (CHCl3): ν 3429, 1742, 1686 cm-1; 1H NMR 
(CDCl3): δ 0.91 [6H, m, Leu CH-(CH3)2] 1.47 [9H, s, C(CH3)3], 
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1.62 [3H, m, Leu CH2-CH-(CH3)2], 2.00-2.30 (2H, m, Pro 
C3H2), 3.07-3.15 (2H, m, Phe β-CH2) 3.25 and 3.77 (2H, m, Pro 
C5H2), 3.74 (3H, s, COOCH3), 4.35 (2H, m, Leu α-CH and Pro 
α-CH), 4.53 (1H, m, Pro C4H), 4.83 (1H, m, Phe α-CH), 7.06-
7.32 (8H, m, Leu NH, Phe NH, For NH and aromatics), 8.15 
(1H, s, HCO). Anal. Calcd for C27H40N4O7: C, 60.88; H, 7.57; 
N, 10.52. Found: C, 61.01; H, 7.56; N, 10.56. 
N-For-cAmp(For)-Leu-Phe-OMe (19a). HCOOH (0.066 g, 
1.44 mmol) in CH2Cl2 (5 mL) was treated with 2HCOOH·HN-
cAmp-Leu-Phe-OMe (0.024 g, 0.048 mmol) according to the 
general procedure B. Preparative layer chromatography (EtOAc) 
gave a pure product 19a as a white foam (0.008 g, 36%); [a]D -
71.9° (c 0.5, CHCl3); IR (CHCl3): ν 3427, 1740, 1687 cm-1; 1H 
NMR (CDCl3): δ 0.91 [6H, m, Leu CH-(CH3)2], 1.62 [3H, m, 
Leu CH2-CH-(CH3)2], 2.16-2.31 (2H, m, Pro C3H2), 3.10-3.24 
(2H, m, Phe β-CH2), 3.60 and 3.77 (2H, m, Pro C5H2), 3.73 (3H, 
s, COOCH3), 4.29 (1H, m, Leu α-CH), 4.52 (1H, m, Pro α-CH), 
4.55 (1H, m, Pro C4H), 4.86 (1H, m, Phe α-CH), 6.52 (1H, d, J 
= 7.6 Hz, Phe NH), 7.12-7.40 (5H, m, aromatics), 7.50 (1H, d, J 
= 7.4 Hz, Leu NH), 7.75 (1H, d, J = 7.8 Hz, For-NH), 8.15 (1H, 
s, HCO), 8.25 (1H, s, HCO). Anal. Calcd for C23H32N4O6: C, 
59.99; H, 7.00; N, 12.17. Found: C, 59.75; H, 6.97; N, 12.21. 
N-For-tAmp(For)-Leu-Phe-OMe (19b). HCOOH (0.0566 
g, 1.23 mmol) in CH2Cl2 (5 mL) was treated with 
2HCOOH·HN-tAmp-Leu-Phe-OMe (0.029 g, 0.059 mmol) 
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according to the general procedure B. Preparative layer 
chromatography (EtOAc/MeOH 9:1) gave the pure product 19b 
as a white foam (0.005 g, 26%); [a]D -35° (c 0.5, CHCl3); IR 
(CHCl3): ν 3425, 1742, 1685 cm-1; 1H NMR (CDCl3): δ 0.89 
[6H, m, Leu CH-(CH3)2], 1.27 [3H, m, Leu CH2-CH-(CH3)2], 
2.10-2.40 (2H, m, Pro C3H2), 3.11-3.27 (2H, m, Phe β-CH2), 
3.60 and 3.77 (2H, m, Pro C5H2), 3.72 (3H, s, COOCH3), 4.36 
(1H, m, Leu α-CH), 4.58 (2H, m, Pro α-CH and Pro C4H), 4.80 
(1H, m, Phe α-CH), 6.53 (1H, d, J = 7.6 Hz, Phe NH), 7.00-7.50 
(7H, m, Leu NH, For NH and aromatics), 8.13 (1H, s, HCO), 
8.21 (1H, s, HCO). Anal. Calcd for C23H32N4O6: C, 59.99; H, 
7.00; N, 12.17. Found: C, 59.76; H, 6.98; N, 12.20. 
 
2.7.4.3 Biological assays 
 
Cell preparation 
Cells were obtained from the blood of healthy subjects, and 
human peripheral blood neutrophils were purified by using the 
standard techniques of dextran (Pharmacia, Uppsala, Sweden) 
sedimentation, centrifugation on Ficoll-Paque (Pharmacia), and 
hypotonic lysis of contaminating red cells. Cells were washed 
twice and resuspended in Krebs-Ringer phosphate (KRPG), pH 
7.4, at final concentration of 50 x 106 cells/mL and kept at room 
temperature until used. Neutrophils were 98-100% viable, as 
determined using the Trypan Blue exclusion test. The study was 
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approved by the local Ethics Committee and informed consent 
was obtained from all participants. 
 
Random locomotion 
Random locomotion was performed with 48-well 
microchemotaxis chamber (Bio Probe, Milan, Italy) and 
migration into the filter was evaluated by the leading-front 
method.96 The actual control random movement is 35 ± 3 µm SE 
of 10 separate experiments performed in duplicate. 
 
Chemotaxis 
Each peptide was added to the lower compartment of the 
chemotaxis chamber. Peptides were diluted from a stock 
solution with KRPG containing 1 mg/mL of bovine serum 
albumin (BSA; Orha Behringwerke, Germany) and used at 
concentrations ranging from 10–13 to 10–5 M. Data were 
expressed in terms of chemotactic index (C.I.), which is the 
ratio: (migration toward test attractant minus migration toward 
the buffer/migration toward the buffer); the values are the mean 
of six separate experiments performed in duplicate. Standard 
errors are in the 0.02-0.09 C.I. range. 
 
Superoxide anion (O2- ) production 
This anion was measured by the superoxide dismutase 
inhibitable reduction of ferricytochrome c (Sigma, USA) 
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modified for microplate-based assays. Tests were carried out in 
a final volume of 200 µL containing 4 x 105 neutrophils, 100 
nmol cytochrome c and KRPG. At zero time different amounts 
(10–10 -5 x 10–5M) of each peptide were added and the plates 
were incubated into a microplate reader (Ceres 900, Bio-TeK 
Instruments, Inc.) with the compartment temperature set at 37 
°C. Absorbance was recorded at 550 and 468 nm. The difference 
in absorbance at the two wavelengths was used to calculate 
nmol of O2- produced using an absorptivity for cytochrome c of 
18.5 mmol-1 cm-1. Neutrophils were incubated with 5 µg/mL 
cytochalasin B (Sigma) for 5 min prior to activation by peptides. 
Results were expressed as net nmol of O2- per 1 x 106 cells per 5 
min and are the mean of six separate experiments performed in 
duplicate. Standard errors are in 0.1-4 nmol O2- range. 
 
Enzyme assay 
The release of neutrophil granule enzymes was evaluated by 
determination of lysozyme activity, modified for microplate 
based assays. Cells, 3 x 106/well, were first incubated in 
triplicate wells of microplates with 5 µg/mL cytochalasin B at 
37 °C for 15 min and then in the presence of each peptide at a 
final concentration of 10-10 -5 x 10-5 M for a further 15 min. The 
plates were then centrifuged at 400g for 5 min and the lysozyme 
was quantified nephelometrically by the rate of lysis of cell wall 
suspension of Micrococcus lysodeikticus. The reaction rate was 
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measured using a microplate reader at 465 nm. Enzyme release 
was expressed as a net percentage of total enzyme content 
released by 0.1% Triton X-100. Total enzyme activity was 85 ± 
1 µg per 1 x 107 cells/min. The values are the mean of five 
separate experiments done in duplicate. Standard errors are in 
the range 1-6%. 
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 CHAPTER 3 
 
(S)-Aziridine-2-carboxylic acid. A 
constrained and reactive amino acid unit for 
the synthesis of bioactive peptide analogues 
 
3.1 Reactivity of aziridine system 
 
 
The aziridine functionality, or alternatively named the 
azaethylene or ethylenimine unit, represents one of the most 
valuable three membered ring systems, because of its widely 
recognized versatility as a significant building block in organic 
synthesis for its ability to function as reactive electrofilic 
substrates. Aziridines are saturated three-membered 
heterocycles containing one nitrogen atom (Figure 1). 
 
 
Figure 1.  Structure of aziridine. 
 
Like other three membered rings such as cyclopropanes and 
epoxides, aziridines are highly strained. Aziridines have a 
significantly higher barrier to pyramidal inversion of the 
nitrogen atom than acyclic amines (18.9 kcal/mol for the parent, 
unsubstituted aziridine, compared to 5-6 kcal/mol for most 
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amines).1 This gives rise to two distinguishable invertomers: one 
with the nitrogen substituent cis to the carbon substituent and 
another with a trans relationship between the two substituents 
(Figure 2).2 
 
 
Figure 2. Due to the high nitrogen inversion barrier of aziridines, the cis and 
trans invertomers are two distinct species at low temperatures. 
 
The inherent reactivity of aziridines is due, in large part, to 
ring strain energy which is similar to that of cyclopropane (27 
kcal mol-1), reflecting high bond-angle strain.3 Ring strain 
renders aziridines susceptible to the ring-opening reactions. 
Nucleophilic ring opening (NRO) is the most thoroughly studied 
manipulation of aziridines.4 Where an aziridine is 
unsymmetrically-substituted, reaction with a nucleophile can 
lead to two products of ring-opening (Scheme 1). As would be 
expected, most nucleophiles preferentially direct their attack to 
the site of lesser substitution, though electronic considerations 
(for instance in the ring-opening of 2-arylaziridines) may 
perturb this preference. 
The nitrogen substituent plays a crucial role in the NRO of 
aziridines. In general, two types of aziridine can be considered: 
activated and unactivated. The former contain substituents 
capable of stabilising the developing negative charge on 
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nitrogen during NOR. The latter, also known as simple 
aziridines, are generally unsubstituted or with alkyl substitution 
on nitrogen. 
 
 
Scheme 1.  Regioselective nucleophilic attack at the C-2 or C-3 positions. 
 
Despite high ring strain energy, unactivated aziridines are 
generally not extremely susceptible to ring opening via 
nucleophilic attack. Activation by protonation, formation of a 
Lewis acid adduct, or replacement of the N hydrogen with an 
electron-withdrawing substituent (e.g. acyl, carbamoyl, sulfonyl) 
increases susceptibility to ring opening through nucleophilic 
attack.5 
 
3.2 (S)-Aziridine-2-carboxylic acid containing 
peptides 
 
(S)-aziridine-2-carboxylic acid (Azy) is the lowest cyclic 
homologue of (S)-proline. Among cyclic imino acids that mimic 
proline we can cite (S)-azetidin-2-carboxylic acid and (S)-
piperidin-2-carboxylic acid. The former is a lower homologue of 
proline, containing a four-membered ring, the latter is a higher 
homologue of proline, containing a six-membered ring, in place 
of the five-membered ring of proline (Figure 3). Proline is 
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unique among naturally occurring amino acids whose Cα-N is a 
part of pyrrolidine ring. This cyclic side chain imposes strong 
restraints on peptide conformation, since the nitrogen is 
consequently unable to act as a hydrogen bond donor.  
 
 
Figure 3. Structure of (S)-proline and its homologues. 
 
The replacement of  Pro with its homologues is of particular 
interest to compare the structural effect on conformation of  non 
proteinic cyclic amino acids with that of proline which is a 
natural residue.  
For both the structural features and chemical reactivity of 
aziridine system, (S)-aziridine-2-carboxylic acid (Azy) 
represents a very challenging research subject in the field of 
peptide chemistry. Azy, as well as Azy containing peptides, 
have found useful application as intermediates in the synthesis 
of various amino acid and peptide derivatives. They are useful 
for the indirect introduction into the backbone of different 
residues and fragments derived from Azy ring opening or 
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rearrangement.6,7 This latter property of Azy containing peptides 
has been successfully followed for the synthesis of irreversible 
protease inhibitors.8  
The acylation of the Azy nitrogen atom (i.e. the incorporation 
into the peptide backbone) leads to an amide bond with very 
peculiar structure and reactivity.  
Amide bonds in peptides and proteins typically adopt planar 
cis or trans conformations by a partial π-electron delocalization 
between carbonyl and amine units which causes the four 
adjacent bonded atoms of the peptide linkage to become a 
coplanar, rigid unit (Figure 4). This produces a high barrier (16-
22 kcal mol-1) to rotation about the bonds within the linkage9,10 
which is required for cis-trans isomerization.  
 
 
Figure 4. Cis-trans isomerization in a peptide bond. Left, a cis amide bond; 
right, a trans amide bond. The amide torsion angle ω (Cα-C-N-Cα) is 0° for 
the cis form and 180° for the trans form. 
 
Amide bond isomerization is important in many processes that 
require alteration to protein structure, among them the transport 
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of polypeptides through membranes and oligomerization and 
folding of proteins.11-13 
Usual amides are strongly stabilized by mesomeric effect 
involving an sp2 hybridized N-atom; in the highly constrained 3-
membered ring the amide nitrogen is practically sp3 hybridized 
with high loss of the usual stability. The conjugation is 
maintained, but weaker than a normal amide bond. This feature 
deeply affects the structural and chemical properties of the R-
CO-Azy- fragment as well as the conformation of Azy 
containing peptides: a) lengthening of the CO-N bond; b) higher 
reactivity toward ring opening by nucleophiles; c) higher lability 
of the peptide bond; d) alteration of the usual 1H- and 13C-NMR 
values. Concerning 13C-NMR, the spectra are diagnostic for the 
presence of an acylated Azy residue. Generally, chemical shifts 
of amide peptide carbonyl groups are in the range 167-175 ppm. 
The carbonyl group attached to the aziridine nitrogen is more 
ketone-like. As a consequence of the acquired ketone character, 
the Azy amide carbonyl group appears in the range 180-184 
ppm.  
In order to acquire more information on the incorporation of 
the Azy residue into peptide backbones we chose as suitable 
models two bioactive oligopeptides: a) the chemotactic 
tripeptide For-Met-Leu-Phe-OMe with the Azy residue in place 
of the central Leu; b) the opioid tetrapeptide Tyr-Pro-Phe-Phe-
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NH2 (endomorphin-2) with the Azy residue replacing the native 
Pro at position 2 (Figure 5). 
 
 
Figure 5.  Structure of  a) N-acylated Azy residue, b) Tyr-Azy-Phe-Phe-
OMe, c) R-NH-Met-Azy-Phe-OMe. 
 
3.3 On the synthesis of (S)-Aziridine-2-carboxylic 
acid containing bioactive peptides 
 
For both the structural features and chemical reactivity, 
synthesis of Azy containing peptides require special attention. 
Concerning the synthesis of Azy residue, several methods have 
been considered in the past.14-16 We chose an efficient one-pot 
synthesis, recently reported in literature,17 in which N-trityl-
aziridine-2-carboxylic acid 5 was prepared from L-serine methyl 
ester hydrochloride 1 (Scheme 2). The choice of trityl group as 
N-protecting alkyl group was made both to protect the α-center 
of amino acid from base-promoted racemization and to protect 
N-acylated serine from elimination to give didehydroalanine. 
The replacement of Leu at position 2 in chemotactic 
tripeptide For-Met-Leu-Phe-OMe with Azy was unsuccessfull. 
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Synthesis of Trt-Azy-Phe-OMe and the subsequent trityl 
deprotection were performed following standard literature 
methods of solution phase synthesis of peptides (Scheme 3)18 
and compounds 6 and 7 were obtained in high yield. 
 
 
 
Scheme 2.  Synthesis of N-trityl-aziridine-2-carboxylic acid 5. Reagents and 
conditions: a) Trt-Cl, TEA, CHCl3, 24h 0 °C; b) MsCl, TEA, THF, 30 min 0 
°C, 48h reflux; c) 1.5N NaOH, THF, 30 min 0 °C, overnight rt. 
 
 
 
 
Scheme 3.  Attempted synthesis of 8. Reagents and conditions: a) HCl·H2N-
Phe-OMe, EDC, HOBt, NMM, CH2Cl2, 30 min 0 °C, 12h rt; b) TFA, 
CH2Cl2, MeOH, 0°C, overnight; c) Boc-Met-OH, BOP, DIPEA, CHCl3, 30 
min 0 °C, 12h rt. 
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Coupling of the HN-Azy-Phe-OMe with Boc-Met-OH leads 
to two main products instead of the expected tripeptide 8 
(Scheme 3). Available spectral data suggested ring expansion of 
the Azy residue to an oxazoline6 system and opening of the 3-
membered ring. Then, coupling by using Boc-Nle-OH in place 
of Boc-Met-OH was designed (see product 9 in Scheme 4). 
However, notwithstanding the adoption of Boc-Nle-OH as 
acylating agent, the same products isolated in the reaction with 
Boc-Met-OH were identified. 
 
 
Scheme 4.  Attempted synthesis of 9. Reagents and conditions: a) Boc-Nle-
OH, BOP, DIPEA, CHCl3, 30 min 0 °C, 12h rt. 
 
The replacement of Pro at position 2 of Boc-derivative 12 of 
EM-2 was performed following standard literature methods of 
solution phase synthesis of peptides (Scheme 5).19  
Boc-tetrapeptide 12 was synthesized, although with low 
yields, without difficulty. Synthesis of EM-2 containing Azy 
residue in place of Pro2 was difficult. Due to the presence of the 
N-acylated -Azy-fragment, the removal conditions usually 
adopted for the N-Boc protecting group, cannot be used in the 
case of Azy containing peptides. Deprotection mediated by 
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tetrabutyl-ammonium fluoride (TBAF)20 was then considered. 
Despite the mild conditions adopted the desired Azy containing 
peptide H2N-Tyr-Azy-Phe-Phe-NH2 was not formed. The main 
product of the reaction was identified as the didehydroalanine 
(∆Ala) containing tetrapeptide Boc-Tyr-∆Ala-Phe-Phe-NH2 (13, 
Scheme 5). 
 
 
Scheme 5.  Attempted synthesis of H2N-Tyr-Azy-Phe-Phe-NH2. Reagents 
and conditions: a) HCl·H2N-Phe-Phe-OMe, EDC, HOBt, NMM, CH2Cl2, 30 
min 0 °C, 12h rt; b) MeOH 0 °C/NH3 sat., 24h rt; c) TFA, CH2Cl2, MeOH, 
0°C overnight; d) Boc-Tyr-OH, BOP, DIPEA, CHCl3, 30 min, 0 °C, 12h rt; 
e) TBAF, THF, 4h, reflux. 
 
Then, we chose to adopt the carboxybenzyl (Cbz) as 
protecting group. Literature data21 demonstrate in fact the 
compatibility of Azy containing peptides with catalytic 
hydrogenolysis. Contrary to the expectation, the catalytic 
hydrogenolysis of Z-Tyr-Azy-Phe-Phe-NH2 led to a Tyr 
deprived tripeptide (Scheme 6). A reasonable explanation of this 
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result points toward an intermolecular deacylation. The 
concurrent intramolecular reaction, leading to a 
diketopiperazine, cannot take place since the starting 
tetrapeptide lacks a residue preceding the N-terminal Tyr. 
 
 
Scheme 6.  Attempted synthesis of H2N-Tyr-Azy-Phe-Phe-NH2. Reagents 
and conditions: a) TFA, CH2Cl2, MeOH, 0°C overnight; b) Z-Tyr-OH, BOP, 
DIPEA, CHCl3, 30 min 0 °C, 12h rt; c) H2-Pd/C, MeOH, 5h rt. 
 
In order to circumvent the above reported unexpected result, 
use of fluorenylmethoxycarbonyl (Fmoc) as protecting group 
appeared convenient. It has been in fact previously reported that 
the Fmoc removal, which is usually performed with piperidine, 
can be also advantageously achieved by replacing secondary 
amines (not compatible with the N-acyl-Azy moiety) with the 
non nucleophilic base 1,8-diazabicyclo[5.4.0]undec-7-ene 
(DBU).22 This approach was then considered suitable and 
adopted in the case of the tetrapeptide model Fmoc-Tyr-Azy-
Phe-Phe-OMe (16, Scheme 7). Furthermore, adoption of the C-
terminal methyl ester, instead of the CO-NH2 group, was 
imposed by the high insolubility shown by the tetrapeptide 
amide. 
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Scheme 7.  Synthesis of H2N-Tyr-Azy-Phe-Phe-OCH3 17. Reagents and 
conditions: a) TFA, CH2Cl2, MeOH, 0°C, overnight; b) Fmoc-Tyr-OH, BOP, 
DIPEA, CHCl3, 30 min 0 °C, 12h rt; c) DBU, CH2Cl2, 5 min rt. 
 
3.3.1 X-ray crystal structure of tripeptide Trt-Azy-Phe-
Phe-NH2 
 
 
Suitable X-ray crystal of the tripeptide 11 were obtained  
from MeOH solution.  
Crystallographic analysis showed the conformation reperted 
in Figure 6 was studied. Table 1 reports the main torsion angles 
of the molecule. 
 
 
Figure 6.  Crystal structure of Trt-Azy-Phe-Phe-NH2 (11). N4 is 0.603(4) Å 
out of the plain defined by C4, C10 and C20. 
 
This shows an highly pyramidalized Azy nitrogen atom and 
adopts an extended conformation which can be described by two 
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consecutive enlarged inverse γ-turns centered at the two Phe 
residues. 
 
Table 1.  Main torsion angles (°) of N-Trt-Azy-Phe-Phe-NH2. 
 
 
3.4 Conclusions 
 
A study of the Azy containing peptides synthesis, 
protection/deprotection conditions and reactivity has been 
reported. As previously reported, during the synthesis of the 
chemotactic tripeptide containing a central Azy residue opening 
and rearrangement of the Azy ring was observed. The failure of 
the desired reaction was initially attributed to an anchimeric 
assistance by the sulphur containing Met side chain.  
In order to clarify this point, coupling by using Boc-Nle-OH 
in place of Boc-Met-OH was designed (see product 9 in Scheme 
4). However, notwithstanding the adoption of Boc-Nle-OH as 
acylating agent, the same products isolated in the reaction with 
Boc-Met-OH were identified. It has been then evidenced an 
inherent instability to the adopted deprotection conditions of the 
dipeptide Trt-Azy-Phe-OMe not observed in the case of the 
analogue deprotection on tripeptide Trt-Azy-Phe-Phe-OMe. 
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Finally, a previously not known rearrangement, leading from 
Azy to ∆Ala residues, has been evidenced and this result 
represents an interesting starting point for further research. 
Thus, it has been shown that a proper choice of N-protection and 
deprotection conditions (i.e. Fmoc/DBU) can lead to the 
synthesis of endomorphin-2 analogues, containing the 
conformationally restricted Azy residue in place of the native 
Pro at position 2.  
In addition to this the X-ray chrystallographic analysis of the 
N-Trt-Azy-Phe-Phe-NH2 11 gives the first information on the 
conformation adopted in the crystal by an Azy containing EM-2 
analogue.  
 
3.5 Experimental section 
 
Materials and methods. Melting points were determined 
with a Büchi B 540 apparatus and are uncorrected. 1H NMR 
experiments were performed at 400 MHz on a Bruker AM 400 
spectrometer in CDCl3 solution (unless otherwise specified) and 
chemical shifts (δ) are quoted in parts per million (ppm) and 
were indirectly referred to TMS. TLC (thin layer 
chromatography) and PLC (preparative layer chromatography) 
were performed on silica gel Merck 60 F254 plates. The drying 
agent was sodium sulphate.  
 
3.5.1 Chemistry. General procedures 
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A. Coupling with the carbodiimide method. To an ice-
cooled mixture containing the required N-protected- 
amino acid (1.1 mmol), HOBt (1.1 mmol), EDC (1.1 
mmol) in anhydrous CH2Cl2, the amino-derivative salt 
(1.0 mmol), and NMM (2.2 mmol), was added and the 
reaction mixture was allowed to warm to room 
temperature. After 12 h the reaction mixture was diluted 
with EtOAc (20 mL) and washed with 5% citric acid (2 
x 15 mL), saturated aqueous NaHCO3 (2 x 15 mL) and 
brine (15 mL). The organic phase was dried over 
Na2SO4 and evaporated under reduced pressure. 
B. Coupling with BOP. To solution of amino acid (1.5 
mmol), amino- peptide-derivative salt (1.0 mmol) and 
BOP (1.5 mmol) in CH2Cl2, DIPEA (2.0 mmol) was 
added dropwise and the reaction mixture was allowed to 
warm to room temperature. After 12 h the reaction 
mixture was diluted with CH2Cl2 (20 mL) and washed 
with 5% citric acid (15 mL), saturated aqueous NaHCO3 
(15 mL) and brine (15 mL). The organic phase was 
dried over Na2SO4 and evaporated under reduced 
pressure. 
 
3.5.2 Synthesis 
Trt-Ser-OMe (2). TEA (6.13 mL, 44 mmol) was added 
dropwise to a stirred suspension of L-serine methyl ester 
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hydrochloride 1 in CHCl3 at room temperature. On dissolution, 
the solution was cooled to 0 °C and then triphenylmethyl 
chloride (5.57 g, 20 mmol) was added. The solution was stirred 
at 0 °C for 24 h and then washed with 10% citric acid (2 x 20 
mL) and water (20 mL). The combined organic extracts were 
dried and evaporated in vacuo to give the title compound as 
white solid pure on TLC (7.01 g, 97%) that was used without 
further purification.   
Trt-Azy-OMe (4). TEA (1.6 mL, 11.4 mmol) was added 
dropwise to a stirred solution of 2 (1.375 g, 3.80 mmol) in 
anhydrous THF (10 mL) at 0 °C. Methanesulfonyl chloride 
(0.44 mL, 5.7 mmol) was added dropwise and the solution was 
stirred at 0 °C for 30 min and then at reflux for 48 h. The solvent 
was removed in vacuo to give a residue which was taken up in 
ethyl acetate (20 mL) and washed with 5% citric acid (3 x 15 
mL), NaHCO3 ss (2 x 15 mL) and NaCl ss (15 mL). The 
combined organic extracts were dried and evaporated in vacuo. 
Silica gel chromatography (CH2Cl2) gave the title compound as 
white foam (1.042 g, 80%); 1H NMR (CDCl3): δ 1.45 (1H, m, β-
HCH), 1.91 (1H, m, α-CH), 2.29 (1H, m, β-HCH), 3.79 (3H, s, 
COOCH3), 7.18-7.61 (15 H, m, aromatics). 
Trt-Azy-OH (5). To solution of 4 (1.0 g, 2.92 mmol) in THF 
(3 mL) was added 1.5N NaOH (2.92 mL) at 0 °C. The solution 
was stirred at 0 °C for 12 h. Then was evaporated under reduced 
pressure, diluted with water and washed with Et2O (2 x 15 mL). 
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The aqueous phase was then acidified with 5% citric acid and 
extracted with EtOAc (3 x 20 mL). The combined organic 
phases were washed with brine, dried and evaporated. A white 
foam (0.92 g, 96%), was obtained and used without further 
purification.   
N-Boc-Phe-Phe-OMe. N-Boc-Phe-OH (0.895 g, 3.71 mmol) 
in CH2Cl2 (60 mL) was treated with HCl·H2N-Phe-OMe (0.727 
g, 3.37 mmol) according to the general procedure A. The title 
compound was obtained as a white solid, pure on TLC (1.246 g, 
87%); [a]D +34.28° (c 1, CHCl3); IR (CHCl3): ν 3423, 1742, 
1677 cm-1; 1H NMR (CDCl3): δ 1.42 [9H, s, C(CH3)3], 3.07 (4H, 
m, Phe3 and Phe4 β-CH2), 3.70 (3H, s, COOCH3), 4.35 (1H, m, 
Phe3 α-CH), 4.81 (1H, m, Phe4 α-CH), 4.93 (1H, br s, Phe3 
NH), 6.29 (1H, br s, Phe4 NH), 7.00-7.30 (10H, m, aromatics). 
Anal. Calcd for C24H30N2O5: C, 67.59; H, 7.09; N, 6.57. Found: 
C, 67.86; H, 7.11; N, 6.59. 
TFA·H2N-Phe-Phe-OMe. The Boc group was removed by 
treatment of N-Boc-Phe-Phe-OMe (0.381 g, 0.89 mmol) with 
TFA in CH2Cl2 (1:1, 6 mL) for 1 h at room temperature. 
Removal of solvent and precipitation of the residue with diethyl 
ether gave TFA·H2N-Phe-Phe-OMe (0.392 g, quantitative yield) 
that was used in the next step without further purification. 
Trt-Azy-Phe-Phe-OMe (10). Trt-Azy-OH (0.322 g, 0.979 
mmol) in CH2Cl2 (10 mL) was treated with TFA·Η2Ν-Phe-Phe-
OMe (0.392 g, 0.89 mmol) according to the general procedure 
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A. Silica gel chromatography (CHCl3/EtOAc 95:5) gave a pure 
product as a white foam (0.397 g, 70%); 1H NMR (CDCl3): 
δ 1.32 (1H, m, Azy β-HCH), 1.47 (1H, m, Azy α-CH), 1.93 
(1H, m, Azy β-HCH), 3.03-3.21 (4H, m, Phe3 β-CH2 and Phe4 
β-CH2), 3.70 (3H, s, COOCH3), 4.62 (1H, m, Phe α-CH), 4.84 
(1H, m, Phe α-CH), 6.50 (1H, d, J = 7.6 Hz, Phe NH), 7.18 (1H, 
m, Phe NH), 7.01-7.48 (25 H, m, aromatics).   
Trt-Azy-Phe-Phe-NH2 (11). The peptide methyl ester 9 
(0.200 g, 0.314 mmol) is allowed to stand in a pressure bottle at 
room temperature for 48 h in anhydrous MeOH (9.25 mL) 
previously saturated with ammonia gas at 0 °C for 24 h. The 
solution is then concentrated to dryness in vacuo at a 
temperature not exceeding 40 °C. The title compound was 
obtained as white crystal (0.18 g, 93%); mp 245.7-247.6 °C;      
1H NMR (CDCl3): δ 1.34 (1H, m, Azy β-HCH), 1.48 (1H, m, 
Azy α-CH), 1.93 (1H, m, Azy β-HCH), 3.03-3.21 (4H, m, Phe3 
β-CH2 and Phe4 β-CH2), 4.53 (1H, m, Phe α-CH), 4.75 (1H, m, 
Phe α-CH), 5.31 (1H, br s, CONHH), 5.95 (1H, br s, CONHH), 
6.55 (1H, d, J = 8.0 Hz, Phe NH), 7.23 (1H, m, Phe NH), 7.14-
7.51 (25 H, m, aromatics). 
HN-Azy-Phe-Phe-NH2. To an ice cooled solution of 11 
(0.226 g, 0.363 mmol) in CHCl3 (0.72 mL) and absolute MeOH 
(0.5 mL, used as a scavenger of trityl group), TFA (0.15 mL) 
was added. The solution was stirred for 12 h at 0 °C. Then the 
solvent was removed in vacuo and the residue was partitioned 
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between diethyl ether and water. NaHCO3 was added to aqueous 
layer. The aqueous phase was extracted with EtOAc (3 x 20 
mL). The combined organic phases were washed with brine, 
dried and evaporated. The obtained product (0.124 g, 90%), was 
used for the next step.  
Boc-Tyr-Azy-Phe-Phe-NH2 (12). Boc-Tyr-OH (0.100 g, 
0.355 mmol) in THF (5.8 mL), was treated with HN-Azy-Phe-
Phe-NH2 (0.090 g, 0.237 mmol) according to the general 
procedure B. PLC (EtOAc) gave a pure product as a white foam 
(0.061 g, 40%); 1H NMR (DMSO-d6): δ 1.39 [9H, s, C(CH3)3], 
2.19 (1H, m, Azy β-HCH), 2.51 (1H, m, Azy α-CH), 2.60-3.03 
(6H, m, Tyr β-CH2, Phe3 β-CH2 and Phe4 β-CH2), 3.05 (1H, m, 
Azy β-HCH), 4.09 (1H, m, Tyr α-CH), 4.38 (1H, m, Phe α-CH), 
4.51 (1H, m, Phe α-CH), 6.94 (1H, d, J = 8.0 Hz, Tyr NH), 
6.63-7.28 (16H, m, aromatics and COONH2), 8.17 (1H, d, J = 
8.4 Hz, Phe NH), 8.39 (1H, d, J = 8.0 Hz, Phe NH), 9.24 (1H, s, 
Tyr OH).  
Attempted synthesis of H2N-Tyr-Azy-Phe-Phe-NH2. To a 
THF (5 mL) solution of 12 (0.023 g, 0.036 mmol) a solution of 
tetrabutylammonium fluoride (TBAF, 1M in THF, 0.072 mL) 
was added, and the mixture was stirred under reflux for 4 h. 
Then the solvent was evaporated, the residue was dissolved in 
EtOAc and washed with 2M NaHCO3 and water. The organic 
layer was dried and evaporated under reduced pressure. PLC 
(CHCl3/MeOH 9:1) gave a pure product 13 (0.013 g, 67%); 1H 
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NMR (DMSO-d6): δ 1.39 [9H, s, C(CH3)3], 2.60-3.03 (6H, m, 
Tyr β-CH2, Phe3 β-CH2 and Phe4 β-CH2), 4.09 (1H, m, Tyr α-
CH), 4.38 (1H, m, Phe α-CH), 4.51 (1H, m, Phe α-CH), 6.94 
(1H, d, J = 8.0 Hz, Tyr NH), 5.48 (1H, s, ∆Ala CHH), 6.17 (1H, 
s, ∆Ala CHH), 6.62-7.38 (17H, m, aromatics, Tyr NH and 
COONH2), 8.08 (1H, d, J = 8.0 Hz, Phe NH), 8.49 (1H, d, J = 
8.4 Hz, Phe NH), 9.16 (1H, s, Tyr OH).  
Z-Tyr-Azy-Phe-Phe-NH2 (14). Z-Tyr-OH (0.092 g, 0.292 
mmol) in CH2Cl2 (4.7 mL), was treated with HN-Azy-Phe-Phe-
NH2 (0.074 g, 0.195 mmol) according to the general procedure 
B. PLC (EtOAc) gave a pure product as an amorfous solid 
(0.035 g, 26%); 1H NMR (DMSO-d6): δ 2.22 (1H, m, Azy β-
HCH), 2.52 (1H, m, Azy α-CH), 2.60-3.05 (6H, m, Tyr β-CH2, 
Phe3 β-CH2 and Phe4 β-CH2), 3.14 (1H, m, Azy β-HCH), 4.19 
(1H, m, Tyr α-CH), 4.43 (1H, m, Phe α-CH), 4.53 (1H, m, Phe 
α-CH), 5.15 (m, 2H, C6H5-CH2-O), 6.61-7.35 (16H, m, 
aromatics and COONH2), 7.53 (1H, d, J = 8.4 Hz, Tyr NH), 
8.17 (1H, d, J = 8.0 Hz, Phe NH), 8.43 (1H, d, J = 8.4 Hz, Phe 
NH), 9.22 (1H, s, Tyr OH).  
Attempted synthesis of H2N-Tyr-Azy-Phe-Phe-NH2. A  
solution of 14 (0.018 g, 0.026 mmol) in MeOH and 10% Pd on 
C (10%) was vigorously stirred at room temperature and 
atmospheric pressure for 5 h  under a slow stream of hydrogen. 
The catalyst was removed by filtration and washed with MeOH. 
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The filtrate was evaporated under reduced pressure. To this 
compound the structure 15 was assigned.  
Fmoc-Tyr-Azy-Phe-Phe-OCH3 (16). Fmoc-Tyr-OH (0.092 
g, 0.228 mmol) in CH2Cl2 (5 mL), was treated with HN-Azy-
Phe-Phe-NH2 (0.045 g, 0.114 mmol) according to the general 
procedure B. PLC (CHCl3/EtOAc 8:2) gave a pure product as an 
amorfous solid (0.027 g, 31%); 1H NMR (CDCl3): δ 1.36 (1H, 
m, Azy β-HCH), 2.48 (1H, m, Azy α-CH), 2.75-3.25 (7H, m, 
Tyr β-CH2, Phe3 β-CH2, Phe4 β-CH2 and Azy β-HCH), 3.76 
(3H, s, COOCH3), 4.18 (1H, m, Fmoc CH), 4.32 (1H, m, Tyr α-
CH), 4.36 (2H, m, Fmoc OCH2), 4.49 (1H, m, Phe α-CH), 4.82 
(1H, m, Phe α-CH), 5.39 (1H, d, J = 7.6 Hz, Tyr NH), 5.49 (1H, 
d, J = 8.4 Hz, Phe NH), 6.74 (1H, d, J = 7.6 Hz, Phe NH), 6.69-
7.88 (24H, m, aromatics).  
H2N-Tyr-Azy-Phe-Phe-OCH3 (17). To a solution of 16 
(0.050 g, 0.064 mmol) in CH2Cl2 (0.44 mL), DBU (0.039 g, 
0.07 mmol) was added at room temperature. After 20 min the 
solution was evaporated to dryness. Silica gel chromatography 
(EtOAc/MeOH 97:3) gave a pure product 17 (0.021 g, 59%); 1H 
NMR (DMSO-d6): δ 1.80 (2H, br s, Tyr NH2), 2.21 (1H, m, Azy 
β-HCH), 2.37 (1H, m, Azy α-CH), 2.63-3.11 (7H, m, Tyr β-
CH2, Phe3 β-CH2, Phe4 β-CH2 and Azy β-HCH), 3.61 (3H, s, 
COOCH3), 4.49 (3H, m, Tyr α-CH, Phe3 α-CH and Phe4 α-CH), 
6.50-7.38 (15H, m, aromatics and Phe NH), 8.50 (1H, br s, Phe 
NH). 
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Trt-Azy-Phe-OMe (6). Compound 5 (0.281 g, 0.853 mmol) 
in CH2Cl2 (10 mL) was treated with HCl·Η2Ν-Phe-OMe (0.153 
g, 0.711 mmol) according to the general procedure A. Silica gel 
chromatography (Hexane/EtOAc 8:2) gave a pure product 6 as a 
white foam (0.327 g, 94%); 1H NMR (CDCl3): δ 1.40 (1H, m, 
Azy β-HCH), 1.71 (1H, m, Azy α-CH), 1.97 (1H, m, Azy β-
HCH), 3.22-3.24 (2H, m, Phe β-CH2), 3.84 (3H, s, COOCH3), 
4.96 (1H, m, Phe α-CH), 7.33 (1H, br s, Phe NH), 7.19-7.46 (20 
H, m, aromatics). 
HN-Azy-Phe-OMe (7). To an ice cooled solution of 6 (0.267 
g, 0.546 mmol) in CHCl3 (9.44 mL) and absolute MeOH (6.55 
mL, used as a scavenger of trityl group), TFA (1.7 mL) was 
added. The solution was stirred for 12 h at 0 °C. Then the 
solvent was removed in vacuo and the residue was partitioned 
between diethyl ether and water. NaHCO3 was added to aqueous 
layer. The aqueous phase was extracted with EtOAc (3 x 20 
mL). The combined organic phases were washed with brine, 
dried and evaporated. The obtained product was used for the 
next step. 
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